Antigen binding molecules specifically binding to PSMA and CD28 and medical uses thereof

CN118922449APending Publication Date: 2024-11-08JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030018.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-11
Filing Date
2023-04-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing technology makes it difficult to effectively utilize PSMA and CD28 antigen-binding molecules in the treatment of tumors, especially in providing targeted therapy for prostate cancer and other types of tumors.

Method used

An antibody that specifically binds CD28 and PSMA antigens was developed, including an antigen-binding module that specifically binds CD28 and an antigen-binding module of PSMA. The heavy chain and light chain variable regions of these modules are used to achieve efficient binding and enhance the targeting of tumor cells. targeting ability.

Benefits of technology

Through specific binding, the ability to identify and attack tumor cells is significantly improved, providing a potentially effective means of treating prostate cancer and other types of tumors, especially in malignant tumors with increased expression of PSMA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000191_0000
    Figure 00000191_0000
  • Figure 00000191_0001
    Figure 00000191_0001
  • Figure 00000192_0000
    Figure 00000192_0000
Patent Text Reader

Abstract

The present disclosure relates to antigen binding molecules that specifically bind PSMA and CD28 and medical uses thereof. The antigen binding molecules can be used to treat tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Antigen-binding molecules that specifically bind to PSMA and CD28 and their pharmaceutical applications This disclosure claims priority to Chinese patent application 202210371696.3, filed on April 11, 2022. Technical Field This disclosure pertains to the field of biotechnology, and more specifically, to the PSMA / CD28 antigen-binding molecule and its applications. Background Technology The statements herein are provided only as background information in connection with this disclosure and do not necessarily constitute prior art. PSMA belongs to Glutamate carboxypeptidase II (GCPII) and is composed of 750 amino acids. The extracellular portion of PSMA consists of three domains: a protease-like domain, an apical domain, and a C-terminus. All three domains are involved in substrate binding. The protease-like domain and the apical domain bind directly to the substrate, while the C-terminus causes PSMA to form a dimer and exert its function. In prostate cancer patients, PSMA expression levels in tumor tissues are 100-1000 times higher than in normal prostate tissues, especially in poorly differentiated, metastatic, and hormone-resistant cancers, where PSMA expression is significantly increased. PSMA is also expressed in the endothelial cells of capillaries in the peripheral and intratumoral regions of some malignant tumors, but not in the blood vessels of normal tissues. In addition, PSMA is associated with tumor angiogenesis (Silver DA (1997) Clinical Cancer Research 3: 81-85). Recently, PSMA has been shown to be expressed in the endothelial cells of the tumor-associated neovascularization system in colon cancer, breast cancer, bladder cancer, pancreatic cancer, kidney cancer, and melanoma (Chang, SS (2004) Curr Opin Investig Drugs 5: 611-5). Therefore, PSMA may be applicable not only to prostate cancer but also to other types of tumors. Normally, T cell activation depends on a first signal provided by the TCR activated by the MHC-peptide complex on the surface of APC cells or other cells, and a second signal provided by co-stimulatory factors is also required for complete T cell activation. CD28, as one of the major co-stimulatory molecules on the T cell surface, is a member of the immunoglobulin superfamily. In humans, CD28 is mainly expressed on the surface of T cells, and also expressed in small amounts in other cells such as bone marrow stromal cells, plasma cells, neutrophils, and eosinophils. CD28 molecules can further activate downstream NFAT, NF-κB, and AP-1 signaling pathways by binding to CD80 / CD86 molecules expressed on the surface of activated APC cells, promoting T cell activation and proliferation. Therefore, providing bispecific antibodies targeting PSMA / CD28 is an effective means of treating diseases such as tumors. Summary of the Invention This disclosure provides a specific binding to CD28 and PSMA antigen-binding molecules and an antibody that specifically binds to CD28. In one aspect, this disclosure provides an antigen-binding molecule comprising at least one specific binding The CD28 antigen-binding module and at least one PSMA-specific antigen-binding module, wherein the CD28-specific antigen-binding module comprises a heavy chain variable region CD28-VH and a light chain variable region CD28-VL, and the PSMA-specific antigen-binding module comprises a heavy chain variable region PSMA-VH and a light chain variable region PSMA-VL. In some embodiments, the antigen-binding molecule as described above, wherein: (i) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 35, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 36, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, or 115, or (ii) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 33, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 34, 72, 73, 74, 75, 76, 77, 78, 79, or 80, or (iii) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 37, 129, or 132, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 38, 138, 139, 141, 142, or 143, or (iv) CD28-HCDR1, CD28-HCDR2 and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2 and CD28-HCDR3 in SEQ ID NO: 31, 46, 47, 48 or 49, and CD28-LCDR1, CD28-LCDR2 and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2 and CD28-LCDR3 in SEQ ID NO: 32 or 52. In some embodiments, the antigen-binding molecule as described above, wherein: (i) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 35, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 36, or (ii) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 33, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 80. amino acid sequence, or The CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 33, and the CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 34, or (iii) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 37, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 38, or (iv) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 31, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 32; or The CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 31, and the CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 52. In some implementations, CD28-HCDR1, CD28-HCDR2, CD28-HCDR3, CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 are defined according to Kabat, IMGT, Chothia, AbM, or Contact numbering rules. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 19, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 20, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 22, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 23, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 24; or (ii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 13, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 14, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 15, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 16, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 17, 54, 55, 56, 57, 58, 59, 60, 61, or 62, and CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 18. CD28-LCDR3; or (iii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25 or 117, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26 or 116, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or (iv) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, 39, 40, 41, or 42, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 11 or 43, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 116, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 117, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 117, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 116, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, 39, 40, 41, or 42; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 11, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12; or The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, 39, 40, 41, or 42, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 43, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 19, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 20, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 22, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 23, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 24; or (ii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 13, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 14, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 15, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 16, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 62, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 18; or (iii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or (iv) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 43, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 19, CD28-HCDR2 as shown in SEQ ID NO: 20, and CD28-HCDR3 as shown in SEQ ID NO: 21, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 22, and CD28-LCDR3 as shown in SEQ ID NO: 23, 81, 81, 81, 81, 82, 83, 84, 85, 86, 87, 88, 88, 89 ... CD28-LCDR2 as shown in 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92 or 93 and CD28-LCDR3 as shown in SEQ ID NO: 24; or (ii) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 13, CD28-HCDR2 as shown in SEQ ID NO: 14, and CD28-HCDR3 as shown in SEQ ID NO: 15, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 16, CD28-LCDR2 as shown in SEQ ID NO: 17, 54, 55, 56, 57, 58, 59, 60, 61, or 62, and CD28-LCDR3 as shown in SEQ ID NO: 18; or (iii) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 25 or 117, CD28-HCDR2 as shown in SEQ ID NO: 26 or 116, and CD28-HCDR3 as shown in SEQ ID NO: 27, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 28, CD28-LCDR2 as shown in SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 as shown in SEQ ID NO: 30; or (iv) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 7, CD28-HCDR2 as shown in SEQ ID NO: 8, and CD28-HCDR3 as shown in SEQ ID NO: 9, 39, 40, 41, or 42, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 10, CD28-LCDR2 as shown in SEQ ID NO: 11 or 43, and CD28-LCDR3 as shown in SEQ ID NO: 12. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 25, CD28-HCDR2 as shown in SEQ ID NO: 26, and CD28-HCDR3 as shown in SEQ ID NO: 27, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 28, CD28-LCDR2 as shown in SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 as shown in SEQ ID NO: 30; or The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 25, CD28-HCDR2 as shown in SEQ ID NO: 116, and CD28-HCDR3 as shown in SEQ ID NO: 27, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 28, CD28-LCDR2 as shown in SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 as shown in SEQ ID NO: 30; or The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 117, CD28-HCDR2 as shown in SEQ ID NO: 26, and CD28-HCDR3 as shown in SEQ ID NO: 27, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 28, CD28-LCDR2 as shown in SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 as shown in SEQ ID NO: 30; or The CD28-VH includes CD28-HCDR1 as shown in SEQ ID NO: 117, CD28-HCDR2 as shown in SEQ ID NO: 116, and CD28-HCDR3 as shown in SEQ ID NO: 27, and the CD28-VL includes CD28-LCDR1 as shown in SEQ ID NO: 28, CD28-LCDR2 as shown in SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 as shown in SEQ ID NO: 30. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 7, CD28-HCDR2 as shown in SEQ ID NO: 8, and CD28-HCDR3 as shown in SEQ ID NO: 9, 39, 40, 41, or 42, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 10, CD28-LCDR2 as shown in SEQ ID NO: 11, and CD28-LCDR3 as shown in SEQ ID NO: 12; or The CD28-VH includes CD28-HCDR1 as shown in SEQ ID NO: 7, CD28-HCDR2 as shown in SEQ ID NO: 8, and CD28-HCDR3 as shown in SEQ ID NO: 9, 39, 40, 41, or 42, and the CD28-VL includes CD28-LCDR1 as shown in SEQ ID NO: 10, CD28-LCDR2 as shown in SEQ ID NO: 43, and CD28-LCDR3 as shown in SEQ ID NO: 12. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 19, CD28-HCDR2 as shown in SEQ ID NO: 20, and CD28-HCDR3 as shown in SEQ ID NO: 21, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 22, CD28-LCDR2 as shown in SEQ ID NO: 23, and CD28-LCDR3 as shown in SEQ ID NO: 24; or (ii) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 13, CD28-HCDR2 as shown in SEQ ID NO: 14, and CD28-HCDR3 as shown in SEQ ID NO: 15, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 16, CD28-LCDR2 as shown in SEQ ID NO: 62, and CD28-LCDR3 as shown in SEQ ID NO: 18; or (iii) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 25, CD28-HCDR2 as shown in SEQ ID NO: 26, and CD28-HCDR3 as shown in SEQ ID NO: 27, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 28, CD28-LCDR2 as shown in SEQ ID NO: 29, and CD28-LCDR3 as shown in SEQ ID NO: 30; or (iv) The CD28-VH includes CD28-HCDR1 as shown in SEQ ID NO: 7, CD28-HCDR2 as shown in SEQ ID NO: 8, and CD28-HCDR3 as shown in SEQ ID NO: 9, and the CD28-VL includes CD28-LCDR1 as shown in SEQ ID NO: 10, CD28-LCDR2 as shown in SEQ ID NO: 43, and CD28-LCDR3 as shown in SEQ ID NO: 12. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The CD28-VH includes CD28-HCDR1 as shown in SEQ ID NO: 19, CD28-HCDR2 as shown in SEQ ID NO: 20, and CD28-HCDR3 as shown in SEQ ID NO: 21, and the CD28-VL includes CD28-LCDR1 as shown in SEQ ID NO: 22, CD28-LCDR2 as shown in SEQ ID NO: 23, and CD28-LCDR3 as shown in SEQ ID NO: 24. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The CD28-VH includes CD28-HCDR1 as shown in SEQ ID NO: 13, CD28-HCDR2 as shown in SEQ ID NO: 14, and CD28-HCDR3 as shown in SEQ ID NO: 15, and the CD28-VL includes CD28-LCDR1 as shown in SEQ ID NO: 16, CD28-LCDR2 as shown in SEQ ID NO: 62, and CD28-LCDR3 as shown in SEQ ID NO: 18. In some embodiments, the antigen-binding molecules as described in any of the preceding claims, wherein CD28-HCDR1, CD28-HCDR2, CD28-HCDR3, CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 are defined according to the Kabat numbering rules. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the CD28-VH and CD28-VL are humanized and each contains the FR region of a human antibody. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 19, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 20, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 26A, 29L, 69L, 71V, 78A, and 93S; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 22, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 23, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21. CD28-LCDR3 comprising the amino acid sequence of SEQ ID NO: 24, and the FR region of the CD28-VL comprising one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44I, and 71Y; or (ii) the CD28-VH comprising: CD28-HCDR1 comprising the amino acid sequence of SEQ ID NO: 13, CD28-HCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and CD28-HCDR3 comprising the amino acid sequence of SEQ ID NO: 15, and the FR region of the CD28-VH comprising one or more amino acid substitutions selected from the group consisting of 1E, 28S, 69L, 71V, 73K, and 94S; and the CD28-VL comprising: CD28-LCDR1 comprising the amino acid sequence of SEQ ID NO: 16, CD28-LCDR2 comprising the amino acid sequence of SEQ ID NO: 17, 54, 55, 56, 57, 58, 59, 60, 61, or 62, and comprising SEQ ID NO: 15. The CD28-LCDR3 has an amino acid sequence of NO: 18, and the FR region of the CD28-VL contains one or more amino acid substitutions selected from the group consisting of 43S and 70K; or (iii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25 or 117, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26 or 116, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 25P, 71V, and 78A; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30, and the FR region of the CD28-VL comprises one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44V, and 73L; or (iv) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, 39, 40, 41, or 42, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 69L, 71V, 73K, 78A, and 94S; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 11 or 43, and the amino acid sequence of SEQ ID NO: 12. The CD28-LCDR3 of the column; and the FR region of the CD28-VL contains one or more amino acid substitutions selected from the group consisting of 43S and 73F. In some embodiments, the antigen-binding molecule as described in any of the preceding claims has a capacitance of less than 2 × 10⁻⁶ at 25°C. -8 M, 8×10 -9 M or 5×10 -9 M binds to human CD28 via KD, which is measured by surface plasmon resonance. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 19, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 20, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 26A, 29L, 69L, 71V, 78A, and 93S; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 22, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 23, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 24, and the FR region of the CD28-VL comprises one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44I, and 71Y; or (ii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 13, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 14, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 15, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 28S, 69L, 71V, 73K, and 94S; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 16, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 62, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 18, and the FR region of the CD28-VL comprises one or more amino acid substitutions selected from the group consisting of 43S and 70K; or (iii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 25P, 71V, and 78A; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30, and the FR region of the CD28-VL comprises one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44V, and 73L; or (iv) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 69L, 71V, 73K, 78A, and 94S; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 43, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12; and the The FR region of CD28-VL contains one or more amino acid substitutions selected from the group consisting of 43S and 73F. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: i) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 164, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 165, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 166; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 167, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 168, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 169; or ii) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 170, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 171, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 172; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 173, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 174, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 175; or iii) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 158, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 159, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 160; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 161, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 162, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 163; or iv) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 176, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 177, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 178; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 179, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 180, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 181; or v) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 213, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 214, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 215; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 216, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 217, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 218. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 170, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 171, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 172; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 173, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 174, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 175. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 164, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 165, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 166; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 167, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 168, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 169. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: i) The PSMA-VH comprises PSMA-HCDR1 as shown in SEQ ID NO: 164, PSMA-HCDR2 as shown in SEQ ID NO: 165, and PSMA-HCDR3 as shown in SEQ ID NO: 166; and the PSMA-VL comprises PSMA-LCDR1 as shown in SEQ ID NO: 167, PSMA-LCDR2 as shown in SEQ ID NO: 168, and PSMA-LCDR3 as shown in SEQ ID NO: 169; or ii) The PSMA-VH comprises PSMA-HCDR1 as shown in SEQ ID NO: 170, PSMA-HCDR2 as shown in SEQ ID NO: 171, and PSMA-HCDR3 as shown in SEQ ID NO: 172; and the PSMA-VL comprises PSMA-LCDR1 as shown in SEQ ID NO: 173, PSMA-LCDR2 as shown in SEQ ID NO: 174, and PSMA-LCDR3 as shown in SEQ ID NO: 175; or iii) The PSMA-VH comprises PSMA-HCDR1 as shown in SEQ ID NO: 158, PSMA-HCDR2 as shown in SEQ ID NO: 159, and PSMA-HCDR3 as shown in SEQ ID NO: 160; and the PSMA-VL comprises PSMA-LCDR1 as shown in SEQ ID NO: 161, PSMA-LCDR2 as shown in SEQ ID NO: 162, and PSMA-LCDR3 as shown in SEQ ID NO: 163; or iv) The PSMA-VH comprises PSMA-HCDR1 as shown in SEQ ID NO: 176, PSMA-HCDR2 as shown in SEQ ID NO: 177, and PSMA-HCDR3 as shown in SEQ ID NO: 178; and the PSMA-VL comprises PSMA-LCDR1 as shown in SEQ ID NO: 179, PSMA-LCDR2 as shown in SEQ ID NO: 180, and PSMA-LCDR3 as shown in SEQ ID NO: 181; or v) The PSMA-VH includes PSMA-HCDR1 as shown in SEQ ID NO: 213, PSMA-HCDR2 as shown in SEQ ID NO: 214, and PSMA-HCDR3 as shown in SEQ ID NO: 215; and the PSMA-VL includes PSMA-LCDR1 as shown in SEQ ID NO: 216, PSMA-LCDR2 as shown in SEQ ID NO: 217, and PSMA-LCDR3 as shown in SEQ ID NO: 218. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The PSMA-VH includes PSMA-HCDR1 as shown in SEQ ID NO: 170, PSMA-HCDR2 as shown in SEQ ID NO: 171, and PSMA-HCDR3 as shown in SEQ ID NO: 172; and the PSMA-VL includes PSMA-LCDR1 as shown in SEQ ID NO: 173, PSMA-LCDR2 as shown in SEQ ID NO: 174, and PSMA-LCDR3 as shown in SEQ ID NO: 175. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The PSMA-VH includes PSMA-HCDR1 as shown in SEQ ID NO: 164, PSMA-HCDR2 as shown in SEQ ID NO: 165, and PSMA-HCDR3 as shown in SEQ ID NO: 166; and the The PSMA-VL includes PSMA-LCDR1 as shown in SEQ ID NO: 167, PSMA-LCDR2 as shown in SEQ ID NO: 168, and PSMA-LCDR3 as shown in SEQ ID NO: 169. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 98 or a variant thereof, the variant comprising one or more amino acid substitutions selected from the group consisting of 26A, 29L, 69L, 71V, 78A, and 93S in the FR region of SEQ ID NO: 98, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 102 or a variant thereof, the variant comprising one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44I, and 71Y in the FR region of SEQ ID NO: 102; or (ii) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 69 or a variant thereof, the variant comprising one or more amino acid substitutions selected from the group consisting of 28S, 69L, 71V, 73K, and 94S in the FR region of SEQ ID NO: 69, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 70 or a variant thereof, the variant comprising one or more amino acid substitutions selected from the group consisting of 43S and 70K in the FR region of SEQ ID NO: 70; or (iii) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 133 or a variant thereof, wherein the variant comprises one or more amino acid substitutions selected from the group consisting of 25P, 71V, and 78A in the FR region of SEQ ID NO: 133, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 137 or a variant thereof, wherein the variant comprises one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44V, and 73L in the FR region of SEQ ID NO: 137; or (iv) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 53 or a variant thereof, the variant comprising one or more amino acid substitutions selected from the group consisting of 1E, 69L, 71V, 73K, 78A and 94S in the FR region of SEQ ID NO: 53, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 52 or a variant thereof, the variant comprising one or more amino acid substitutions selected from the group consisting of 43S and 73F in the FR region of SEQ ID NO: 52. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, 35, 94, 96, 97 or 98, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101, 36, 99, 100, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 or 115; or (ii) The CD28-VH comprises the amino acid sequence SEQ ID NO: 68, 33, 63, 64, 65, 66, 67 or 69, and the CD28-VL comprises the amino acid sequence SEQ ID NO: 80, 34, 70, 71, 72, 73, 74, 75, 76, 77, 78 or 79; or (iii) The CD28-VH contains the amino acid sequence SEQ ID NO: 126, 37, 123, 124, 125, 127, 128, 129, 130, 131, 132 or 133, and the CD28-VL contains the amino acid sequence SEQ ID NO: 134, 38, 135, 136, 137, 138, 139, 140, 141, 142 or 143; or (iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, 31, 45, 46, 47, 48, 49 or 53, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52, 32, 50 or 51. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, 94, 96, 97 or 98, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101, 99, 100, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 or 115; or (ii) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 68, 63, 64, 65, 66, 67 or 69, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 80, 70, 71, 72, 73, 74, 75, 76, 77, 78 or 79; or (iii) The CD28-VH contains the amino acid sequence SEQ ID NO: 126, 123, 124, 125, 127, 128, 129, 130, 131, 132 or 133, and the CD28-VL contains the amino acid sequence SEQ ID NO: 134, 135, 136, 137, 138, 139, 140, 141, 142 or 143; or (iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, 45, 46, 47, 48, 49 or 53, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52, 50 or 51. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, 94, 96, 97 or 98, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101, 99, 100 or 102, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101, 99, 100, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 or 115, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 94, and the CD28-VL contains the amino acid sequences of SEQ ID NO: 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, or 115, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 96, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 99 or 100, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 97, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 99, 100, or 101, or ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80, 72, 73, 74, 75, 76, 77, 78, or 79, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 63, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70 or 71, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 64, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70, 71, or 72, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 65, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70, 71, or 72, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 66, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70, 71, 72, 74, 75, 76, or 79, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 67, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 72, 74, 75, 76, or 79, or iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 135, 136, 137, 138, or 139, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 123, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 135, or 136, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 124, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 135; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 125, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134 or 135, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 127, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 137, 138, or 139; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 128, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 137, 138, 139, or 142; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 129, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 138, 139, 140, 141, 142, or 143, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 130, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 138, 140, 141, 142, or 143, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 131, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 138, 140, 141, 142, or 143, or iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52, 50, or 51, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 45, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 52, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 47, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 48, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 35, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 36; or (ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 33, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 34; or (iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 37, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 38; or (iv) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 31, and the CD28-VL contains... The amino acid sequence containing SEQ ID NO: 32. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; or (ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 65, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 71; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 78; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; or (iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 94, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; or (iv) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 126, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 134; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 125, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 135; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 128, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 142; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 129, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 138. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The amino acid sequence of CD28-VH is shown in SEQ ID NO: 44, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 50; or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 44, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 52; or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 46, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 52; or (ii) The amino acid sequence of CD28-VH is shown in SEQ ID NO: 65, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 65. The amino acid sequence is shown in SEQ ID NO: 71; or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 68, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 78; or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 68, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 80; or (iii) The amino acid sequence of CD28-VH is shown in SEQ ID NO: 95, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 101; or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 95, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 106; or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 94, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 101; or (iv) The amino acid sequence of CD28-VH is shown in SEQ ID NO: 126, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 134; or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 125, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 135; or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 128, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 142; or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 129, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 138. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50, 51, or 52, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 45, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 52, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 47, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 48, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51, or (ii) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 63, 64, 65 or 66, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 70; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 63, 64, 65 or 66, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 71; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 64 or 65, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 72; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 66, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 71, 72, 74, 75, 76, or 79; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 67, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 72, 74, 75, 76, or 79; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 72, 73, 74, 75, 76, 78, 79, or 80; or (iii) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 94, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, or 115; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, or 115; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 96, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 99 or 100; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 97, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 99, 100, or 101; or (iv) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 123, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 134, 135, or 136; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 124, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 135; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 125, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134 or 135, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 135, 136, 137, 138, or 139; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 127, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 137, 138, or 139; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 128, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 137, 138, 139, or 142; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 129, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 138, 139, 140, 141, 142, or 143; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 130, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 138, 140, 141, 142, or 143; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 131, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 138, 140, 141, 142 or 143. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains... The amino acid sequence containing SEQ ID NO: 101; or (ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; or (iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; or (iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: (i) The amino acid sequence of CD28-VH is shown in SEQ ID NO: 95, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 101; or (ii) The amino acid sequence of CD28-VH is shown in SEQ ID NO: 68, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 80; or (iii) The amino acid sequence of CD28-VH is shown in SEQ ID NO: 126, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 134; or (iv) The amino acid sequence of CD28-VH is shown in SEQ ID NO: 44, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 52. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the amino acid sequence of CD28-VH is as shown in SEQ ID NO: 95, and the amino acid sequence of CD28-VL is as shown in SEQ ID NO: 101. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the amino acid sequence of CD28-VH is as shown in SEQ ID NO: 68, and the amino acid sequence of CD28-VL is as shown in SEQ ID NO: 80. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: i) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, 199, 332, 194, 195, 196 or 198, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201, 202, 333 or 200; or ii) The PSMA-VH comprises the amino acid sequence of SEQ ID NO: 204, 184 or 203, and the PSMA-VL comprises the amino acid sequence of SEQ ID NO: 206, 185 or 205; or iii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, 182, 189 or 190, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191, 183, 192 or 193; or iv) The PSMA-VH comprises the amino acid sequence of SEQ ID NO: 207 or 186, and the PSMA-VL comprises the amino acid sequence of SEQ ID NO: 208, 187, 209, or 210; or v) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: i) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or ii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The PSMA-VH contains the amino acid sequence of SEQ ID NO: 199, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 202; or iii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or iv) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 208. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The PSMA-VH contains the amino acid sequence of SEQ ID NO: 199, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 202. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: i) The amino acid sequence of PSMA-VH is shown in SEQ ID NO: 204, and the amino acid sequence of PSMA-VL is shown in SEQ ID NO: 206; or ii) The amino acid sequence of PSMA-VH is shown in SEQ ID NO: 197, and the amino acid sequence of PSMA-VL is shown in SEQ ID NO: 201; or The amino acid sequence of PSMA-VH is shown in SEQ ID NO: 199, and the amino acid sequence of PSMA-VL is shown in SEQ ID NO: 202; or iii) The amino acid sequence of PSMA-VH is shown in SEQ ID NO: 188, and the amino acid sequence of PSMA-VL is shown in SEQ ID NO: 191; or iv) The amino acid sequence of the PSMA-VH is shown in SEQ ID NO: 207, and the amino acid sequence of the PSMA-VL is shown in SEQ ID NO: 208. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The amino acid sequence of the PSMA-VH is shown in SEQ ID NO: 204, and the amino acid sequence of the PSMA-VL is shown in SEQ ID NO: 206. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The amino acid sequence of the PSMA-VH is shown in SEQ ID NO: 197, and the amino acid sequence of the PSMA-VL is shown in SEQ ID NO: 201. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The amino acid sequence of the PSMA-VH is shown in SEQ ID NO: 199, and the amino acid sequence of the PSMA-VL is shown in SEQ ID NO: 202. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding module that specifically binds to CD28 or the antigen-binding module that specifically binds to PSMA comprises a Titin chain and an Obscurin chain capable of forming a dimer. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the CD28-specific antigen-binding module comprises a Titin chain and an Obscurin chain capable of forming a dimer. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding module that specifically binds to PSMA comprises a Titin chain and an Obscurin chain capable of forming a dimer. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the Titin chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 334 to SEQ ID NO: 352, and the Obscurin chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 353 to SEQ ID NO: 393. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the titin chain comprises the amino acid sequence of SEQ ID NO: 350. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the Obscurin chain comprises the amino acid sequence of SEQ ID NO: 388. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the Titin chain comprises the amino acid sequence of SEQ ID NO: 350, and the Obscurin chain comprises the amino acid sequence of SEQ ID NO: 388. In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an Fc region. In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an IgG Fc region. In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an IgG1Fc region. In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an Fc region containing one or more amino acid substitutions that reduce the binding of the Fc region to the Fcγ receptor. In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an Fc region, the Fc region being the human IgG1 Fc region, and the amino acids at positions 234 and 235 being A, numbered according to the EU index. In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an Fc region comprising a first subunit Fc1 and a second subunit Fc2 capable of associating with each other, wherein each of Fc1 and Fc2 independently has one or more amino acid substitutions that reduce homodimerization of the Fc region. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule... The sub-sub ... In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an Fc region comprising a first subunit Fc1 and a second subunit Fc2 capable of associating with each other, the Fc1 having a protruding structure according to the mortar and pestle technique, and the Fc2 having a porous structure according to the mortar and pestle technique, wherein the amino acid at position 366 of the Fc1 is W; and the amino acid at position 366 of the Fc2 is S, the amino acid at position 368 is A, and the amino acid at position 407 is V, numbered according to the EU index. In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an Fc region comprising a first subunit Fc1 and a second subunit Fc2 capable of associating with each other, the Fc1 having a protruding structure according to the mortar and pestle technique, and the Fc2 having a porous structure according to the mortar and pestle technique, wherein the amino acid at position 354 of the Fc1 is C and the amino acid at position 366 is W; and the amino acid at position 349 of the Fc2 is C, the amino acid at position 366 is S, the amino acid at position 368 is A, and the amino acid at position 407 is V, numbered according to the EU index. In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an Fc region comprising a first subunit Fc1 and a second subunit Fc2 capable of associating with each other, wherein Fc1 comprises the amino acid sequence of SEQ ID NO: 220; and Fc2 comprises the amino acid sequence of SEQ ID NO: 221 or 222. In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an Fc region comprising a first subunit Fc1 and a second subunit Fc2 capable of associating with each other, wherein Fc1 comprises the amino acid sequence of SEQ ID NO: 220; and Fc2 comprises the amino acid sequence of SEQ ID NO: 221. In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an antigen-binding module that specifically binds to CD28 and an antigen-binding module that specifically binds to PSMA. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule comprises an antigen-binding module that specifically binds to CD28 and an antigen-binding module that specifically binds to PSMA, wherein: The antigen-binding module that specifically binds to CD28 is a Fab, and the antigen-binding module that specifically binds to PSMA is a replaced Fab containing a Titin chain and an Obscurin chain capable of forming a dimer. In some embodiments, the antigen-binding molecule as described in any of the preceding claims comprises a first chain having the structure shown in formula (a), a second chain having the structure shown in formula (b), a third chain having the structure shown in formula (c), and a fourth chain having the structure shown in formula (d). (a)[CD28-VH]-[CH1]-[Fc1], (b)[CD28-VL]-[CL] (c)[PSMA-VH]-[Connector 1]-[Titin Chain]-[Fc2], (d) [PSMA-VL]-[Connector 2]-[Obscurin Chain] Wherein: linker 1 and linker 2 are the same or different peptide linkers; the structures shown in formulas (a), (b), (c) and (d) are arranged from the N-terminus to the C-terminus. In some embodiments, the antigen-binding molecule as described in any of the preceding claims comprises a first chain having the structure shown in formula (a), a second chain having the structure shown in formula (b), a third chain having the structure shown in formula (c), and a fourth chain having the structure shown in formula (d). (a)[CD28-VH]-[CH1]-[Fc1], (b)[CD28-VL]-[CL] (c)[PSMA-VH]-[Connector 1]-[Titin Chain]-[Fc2], (d) [PSMA-VL]-[Connector 2]-[Obscurin Chain] Wherein: connector 1 and connector 2 do not exist, that is, connector 1 and connector 2 are both bonds; the structures shown in equations (a), (b), (c) and (d) are arranged from the N end to the C end. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 33, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 34; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 65, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 71; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 78; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 208; or ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 31, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 32; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 208; or iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 208; or iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 37, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 38; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The amino acid sequence of CD28-VH is shown in SEQ ID NO: 68, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 80; and the amino acid sequence of PSMA-VH is shown in SEQ ID NO: 204, and the amino acid sequence of PSMA-VL is shown in SEQ ID NO: 206. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the titin chain and obscurin chain are selected from any titin chain and obscurin chain capable of forming a dimer as shown in Tables 3-1 and 3-2 of this disclosure. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the titin chain comprises an amino acid sequence as shown in SEQ ID NO: 350. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the obscurin chain comprises an amino acid sequence as shown in SEQ ID NO: 388. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein linker 1 and linker 2 are peptide linkers known in the art, provided that the antigen-binding molecule can exhibit the desired antigen-binding activity. For example, the peptide linker may be a flexible peptide having 1-50 or 3-20 amino acid residues. In some embodiments, the peptide linker is 3-15 amino acid residues in length. In some embodiments, each peptide linker independently has a (GGGGS)n structure, where n is 1, 2, or 3. In some embodiments, the sequences of linker 1 and linker 2 are GGGGS (SEQ ID NO: 223). In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the CH1 is IgG. The CH1 sequence. In some embodiments, the CH1 is the CH1 of IgG1. In some embodiments, the CH1 contains the amino acid sequence of SEQ ID NO: 219. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the CL is a light chain constant region of an antibody. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the CL is a light chain constant region of kappa or lambda. In some embodiments, wherein the CL comprises the amino acid sequence of SEQ ID NO: 145. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule has: A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 239, a third strand containing the amino acid sequence SEQ ID NO: 249, and a fourth strand containing the amino acid sequence SEQ ID NO: 250; or A first strand containing the amino acid sequence SEQ ID NO: 226, a second strand containing the amino acid sequence SEQ ID NO: 227, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence of SEQ ID NO: 230, a second strand containing the amino acid sequence of SEQ ID NO: 231, a third strand containing the amino acid sequence of SEQ ID NO: 228, and a fourth strand containing the amino acid sequence of SEQ ID NO: 229; or A first strand containing the amino acid sequence of SEQ ID NO: 230, a second strand containing the amino acid sequence of SEQ ID NO: 232, a third strand containing the amino acid sequence of SEQ ID NO: 228, and a fourth strand containing the amino acid sequence of SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 233, a second strand containing the amino acid sequence SEQ ID NO: 234, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 235, a second strand containing the amino acid sequence SEQ ID NO: 236, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 238, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 239, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 240, a second strand containing the amino acid sequence SEQ ID NO: 241, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 240, and a strand containing the amino acid sequence SEQ ID NO: A second strand containing the amino acid sequence 242, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 243, a second strand containing the amino acid sequence SEQ ID NO: 244, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 245, a second strand containing the amino acid sequence SEQ ID NO: 246, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence of SEQ ID NO: 230, a second strand containing the amino acid sequence of SEQ ID NO: 232, a third strand containing the amino acid sequence of SEQ ID NO: 247, and a fourth strand containing the amino acid sequence of SEQ ID NO: 248; or A first strand containing the amino acid sequence SEQ ID NO: 230, a second strand containing the amino acid sequence SEQ ID NO: 232, a third strand containing the amino acid sequence SEQ ID NO: 249, and a fourth strand containing the amino acid sequence SEQ ID NO: 250; or A first strand containing the amino acid sequence SEQ ID NO: 251, a second strand containing the amino acid sequence SEQ ID NO: 232, a third strand containing the amino acid sequence SEQ ID NO: 247, and a fourth strand containing the amino acid sequence SEQ ID NO: 248; or A first strand containing the amino acid sequence SEQ ID NO: 251, a second strand containing the amino acid sequence SEQ ID NO: 232, a third strand containing the amino acid sequence SEQ ID NO: 249, and a fourth strand containing the amino acid sequence SEQ ID NO: 250; or A first strand containing the amino acid sequence SEQ ID NO: 251, a second strand containing the amino acid sequence SEQ ID NO: 232, a third strand containing the amino acid sequence SEQ ID NO: 252, and a fourth strand containing the amino acid sequence SEQ ID NO: 253; or A first strand containing the amino acid sequence SEQ ID NO: 251, a second strand containing the amino acid sequence SEQ ID NO: 232, a third strand containing the amino acid sequence SEQ ID NO: 254, and a fourth strand containing the amino acid sequence SEQ ID NO: 255; or A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 239, a third strand containing the amino acid sequence SEQ ID NO: 247, and a fourth strand containing the amino acid sequence SEQ ID NO: 248; or A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 239, a third strand containing the amino acid sequence SEQ ID NO: 252, and a fourth strand containing the amino acid sequence SEQ ID NO: 253; or A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 239, a third strand containing the amino acid sequence SEQ ID NO: 254, and a fourth strand containing the amino acid sequence SEQ ID NO: 255; or A first strand containing the amino acid sequence SEQ ID NO: 240, and a strand containing the amino acid sequence SEQ ID NO: A second strand containing the amino acid sequence of SEQ ID NO: 242, a third strand containing the amino acid sequence of SEQ ID NO: 247, and a fourth strand containing the amino acid sequence of SEQ ID NO: 248; or A first strand containing the amino acid sequence SEQ ID NO: 240, a second strand containing the amino acid sequence SEQ ID NO: 242, a third strand containing the amino acid sequence SEQ ID NO: 249, and a fourth strand containing the amino acid sequence SEQ ID NO: 250; or A first strand containing the amino acid sequence SEQ ID NO: 240, a second strand containing the amino acid sequence SEQ ID NO: 242, a third strand containing the amino acid sequence SEQ ID NO: 252, and a fourth strand containing the amino acid sequence SEQ ID NO: 253; or A first strand containing the amino acid sequence of SEQ ID NO: 240, a second strand containing the amino acid sequence of SEQ ID NO: 242, a third strand containing the amino acid sequence of SEQ ID NO: 254, and a fourth strand containing the amino acid sequence of SEQ ID NO: 255. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule has: A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 239, a third strand containing the amino acid sequence SEQ ID NO: 249, and a fourth strand containing the amino acid sequence SEQ ID NO: 250. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule has: A first chain as shown in SEQ ID NO: 237, a second chain as shown in SEQ ID NO: 239, a third chain as shown in SEQ ID NO: 249, and a fourth chain as shown in SEQ ID NO: 250. In some embodiments, the antigen-binding molecule as described in any of the preceding claims includes an antigen-binding module that specifically binds to CD28 and an antigen-binding module that specifically binds to PSMA, wherein the antigen-binding module that specifically binds to PSMA is a Fab; and the antigen-binding module that specifically binds to CD28 is a replaced Fab comprising a Titin chain and an Obscurin chain capable of forming a dimer. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule comprises a first chain having the structure shown in formula (e), a second chain having the structure shown in formula (f), a third chain having the structure shown in formula (g), and a fourth chain having the structure shown in formula (h). (e)[CD28-VH]-[Connector 3]-[Titin Chain]-[Fc1], (f) [CD28-VL]-[Connector 4]-[Obscurin Chain] (g)[PSMA-VH]-[CH1]-[Fc2], (h)[PSMA-VL]-[CL], Wherein: linker 3 and linker 4 are the same or different peptide linkers; the structures shown in formulas (e), (f), (g) and (h) are arranged from the N-terminus to the C-terminus. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule comprises a first chain having the structure shown in formula (e), a second chain having the structure shown in formula (f), and a... A third chain having the structure shown in equation (g) and a fourth chain having the structure shown in equation (h), (e)[CD28-VH]-[Connector 3]-[Titin Chain]-[Fc1], (f) [CD28-VL]-[Connector 4]-[Obscurin Chain] (g)[PSMA-VH]-[CH1]-[Fc2], (h)[PSMA-VL]-[CL], Wherein: connectors 3 and 4 are not present, that is, connectors 3 and 4 are both bonds; the structures shown in equations (e), (f), (g) and (h) are arranged from the N end to the C end. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 94, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 208; or ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 37, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 38; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL The PSMA-VH contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 211; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 129, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 138; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 208. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The amino acid sequence of CD28-VH is shown in SEQ ID NO: 95, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 101; and the amino acid sequence of PSMA-VH is shown in SEQ ID NO: 197, and the amino acid sequence of PSMA-VL is shown in SEQ ID NO: 201. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein: The amino acid sequence of CD28-VH is shown in SEQ ID NO: 95, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 101; and the amino acid sequence of PSMA-VH is shown in SEQ ID NO: 204, and the amino acid sequence of PSMA-VL is shown in SEQ ID NO: 206. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the titin chain and The obscurin chain can be selected from any of the dimeric titin and obscurin chains listed in Tables 3-1 and 3-2 of this disclosure. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the titin chain comprises an amino acid sequence such as SEQ ID NO: 350. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the obscurin chain comprises an amino acid sequence such as SEQ ID NO: 388. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein linkers 3 and 4 are peptide linkers known in the art, provided that the antigen-binding molecule can exhibit the desired antigen-binding activity. For example, the peptide linker may be a flexible peptide containing 1-50 or 3-20 amino acid residues. In some embodiments, the peptide linker is 3-15 amino acid residues in length. In some embodiments, each peptide linker independently has a (GGGGS)n structure, where n is 1, 2, or 3. In some embodiments, the sequences of linkers 3 and 4 are GGGGS (SEQ ID NO: 223). In some embodiments, the antigen-binding molecule as described in any of the preceding embodiments, wherein the CH1 is the CH1 sequence of IgG. In some embodiments, the CH1 is the CH1 of IgG1. In some embodiments, the CH1 comprises the amino acid sequence of SEQ ID NO: 219. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the CL is a light chain constant region of an antibody. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the CL is a light chain constant region of kappa or lambda. In some embodiments, wherein the CL comprises the amino acid sequence of SEQ ID NO: 145. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule has: A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 274, and a fourth strand containing the amino acid sequence SEQ ID NO: 275; or A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 272, and a fourth strand containing the amino acid sequence SEQ ID NO: 273; or A first strand containing the amino acid sequence SEQ ID NO: 257, a second strand containing the amino acid sequence SEQ ID NO: 258, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 263, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 264, and a second strand containing the amino acid sequence SEQ ID NO: A second strand containing the amino acid sequence of SEQ ID NO: 265, a third strand containing the amino acid sequence of SEQ ID NO: 259, and a fourth strand containing the amino acid sequence of SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 266, a second strand containing the amino acid sequence SEQ ID NO: 267, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 268, a second strand containing the amino acid sequence SEQ ID NO: 269, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 270, a second strand containing the amino acid sequence SEQ ID NO: 271, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 276, and a fourth strand containing the amino acid sequence SEQ ID NO: 277; or A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 278, and a fourth strand containing the amino acid sequence SEQ ID NO: 279; or A first strand containing the amino acid sequence SEQ ID NO: 268, a second strand containing the amino acid sequence SEQ ID NO: 269, a third strand containing the amino acid sequence SEQ ID NO: 272, and a fourth strand containing the amino acid sequence SEQ ID NO: 273; or A first strand containing the amino acid sequence SEQ ID NO: 268, a second strand containing the amino acid sequence SEQ ID NO: 269, a third strand containing the amino acid sequence SEQ ID NO: 274, and a fourth strand containing the amino acid sequence SEQ ID NO: 275; or A first strand containing the amino acid sequence SEQ ID NO: 268, a second strand containing the amino acid sequence SEQ ID NO: 269, a third strand containing the amino acid sequence SEQ ID NO: 276, and a fourth strand containing the amino acid sequence SEQ ID NO: 277; or A first strand containing the amino acid sequence SEQ ID NO: 268, a second strand containing the amino acid sequence SEQ ID NO: 269, a third strand containing the amino acid sequence SEQ ID NO: 278, and a fourth strand containing the amino acid sequence SEQ ID NO: 279. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule has: A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 272, and a fourth strand containing the amino acid sequence SEQ ID NO: 273. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule has: A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 274, and a fourth strand containing the amino acid sequence SEQ ID NO: 275. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule has: A first chain as shown in SEQ ID NO: 261, a second chain as shown in SEQ ID NO: 262, a third chain as shown in SEQ ID NO: 272, and a fourth chain as shown in SEQ ID NO: 273. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the antigen-binding molecule has: A first chain as shown in SEQ ID NO: 261, a second chain as shown in SEQ ID NO: 262, a third chain as shown in SEQ ID NO: 274, and a fourth chain as shown in SEQ ID NO: 275. On the other hand, this disclosure also provides an anti-CD28 antibody that specifically binds to CD28, said anti-CD28 antibody comprising a heavy chain variable region CD28-VH and a light chain variable region CD28-VL, wherein: (i) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 35, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 36, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, or 115, or (ii) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 33, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 34, 73, 74, 75, 76, 77, 78, 79, or 80, or (iii) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 37, 129, or 132, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 38, 139, 141, 142, or 143, or (iv) CD28-HCDR1, CD28-HCDR2 and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2 and CD28-HCDR3 in SEQ ID NO: 31, and CD28-LCDR1, CD28-LCDR2 and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2 and CD28-LCDR3 in SEQ ID NO: 32, 46, 47, 48 or 49. In some embodiments, the anti-CD28 antibody as described above, wherein: (i) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 35, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 36, or (ii) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 33, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 80, or The CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 33, and the CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 34, or (iii) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 37, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 38, or (iv) CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 31, and CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 32; or The CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in CD28-VH respectively contain the amino acid sequences of CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3 in SEQ ID NO: 31, and the CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in CD28-VL respectively contain the amino acid sequences of CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 in SEQ ID NO: 52. In some implementations, CD28-HCDR1, CD28-HCDR2, CD28-HCDR3, CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 are defined according to Kabat, IMGT, Chothia, AbM, or Contact numbering rules. In some embodiments, the anti-CD28 antibody as described above, wherein: (i) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 19. CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 20 and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21, and said CD28-VL having: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 22, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 23, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92 or 93 and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 24; or (ii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 13, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 14, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 15, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 16, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 17, 54, 55, 56, 57, 58, 59, 60, 61, or 62, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 18; or (iii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25 or 117, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26 or 116, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or (iv) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, 39, 40, 41, or 42, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 11 or 43, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12. In some implementations, such as the anti-CD28 antibody described in the preceding one, wherein: The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 116, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 117. CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26 and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27, and said CD28-VL having: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121 or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 117, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 116, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30. In some implementations, such as the anti-CD28 antibody described in the preceding one, wherein: (i) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 19, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 20, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 22, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 23, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 24; or (ii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 13, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 14, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 15, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 16, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 62, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 18; or (iii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or (iv) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 43, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12. In some implementations, such as the anti-CD28 antibody described in the preceding one, wherein: (i) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 19, CD28-HCDR2 as shown in SEQ ID NO: 20, and CD28-HCDR3 as shown in SEQ ID NO: 21, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 22, CD28-LCDR2 as shown in SEQ ID NO: 23, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93, and CD28-LCDR2 as shown in SEQ ID NO: 23, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93, and CD28-HCDR3 as shown in SEQ ID NO: 21. CD28-LCDR3 as shown in SEQ ID NO: 24; or (ii) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 13, CD28-HCDR2 as shown in SEQ ID NO: 14, and CD28-HCDR3 as shown in SEQ ID NO: 15, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 16, CD28-LCDR2 as shown in SEQ ID NO: 17, 54, 55, 56, 57, 58, 59, 60, 61, or 62, and CD28-LCDR3 as shown in SEQ ID NO: 18; or (iii) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 25 or 117, CD28-HCDR2 as shown in SEQ ID NO: 26 or 116, and CD28-HCDR3 as shown in SEQ ID NO: 27, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 28, CD28-LCDR2 as shown in SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 as shown in SEQ ID NO: 30; or (iv) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 7, CD28-HCDR2 as shown in SEQ ID NO: 8, and CD28-HCDR3 as shown in SEQ ID NO: 9, 39, 40, 41, or 42, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 10, CD28-LCDR2 as shown in SEQ ID NO: 11 or 43, and CD28-LCDR3 as shown in SEQ ID NO: 12. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein: The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 116, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 117, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 117, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 116, and amino acid sequence of SEQ ID NO: 27. The CD28-HCDR3 and CD28-VL have the following amino acid sequences: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121 or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein: The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, 39, 40, 41, or 42; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 11, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12; or The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, 39, 40, 41, or 42, and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 43, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12. In some implementations, such as the anti-CD28 antibody described in the preceding one, wherein: (i) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 19, CD28-HCDR2 as shown in SEQ ID NO: 20, and CD28-HCDR3 as shown in SEQ ID NO: 21, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 22, CD28-LCDR2 as shown in SEQ ID NO: 23, and CD28-LCDR3 as shown in SEQ ID NO: 24; or (ii) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 13, CD28-HCDR2 as shown in SEQ ID NO: 14, and CD28-HCDR3 as shown in SEQ ID NO: 15, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 16, CD28-LCDR2 as shown in SEQ ID NO: 62, and CD28-LCDR3 as shown in SEQ ID NO: 18; or (iii) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 25, CD28-HCDR2 as shown in SEQ ID NO: 26, and CD28-HCDR3 as shown in SEQ ID NO: 27, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 28, CD28-LCDR2 as shown in SEQ ID NO: 29, and CD28-LCDR3 as shown in SEQ ID NO: 30; or (iv) The CD28-VH includes CD28-HCDR1 as shown in SEQ ID NO: 7, CD28-HCDR2 as shown in SEQ ID NO: 8, and CD28-HCDR3 as shown in SEQ ID NO: 9, and the CD28-VL includes CD28-LCDR1 as shown in SEQ ID NO: 10, CD28-LCDR2 as shown in SEQ ID NO: 43, and CD28-LCDR3 as shown in SEQ ID NO: 12. In some implementations, such as the anti-CD28 antibody described in the preceding one, wherein: The CD28-VH includes CD28-HCDR1 as shown in SEQ ID NO: 19, CD28-HCDR2 as shown in SEQ ID NO: 20, and CD28-HCDR3 as shown in SEQ ID NO: 21, and the CD28-VL includes CD28-LCDR1 as shown in SEQ ID NO: 22, CD28-LCDR2 as shown in SEQ ID NO: 23, and CD28-LCDR3 as shown in SEQ ID NO: 24. In some implementations, such as the anti-CD28 antibody described in the preceding one, wherein: The CD28-VH includes CD28-HCDR1 as shown in SEQ ID NO: 13, CD28-HCDR2 as shown in SEQ ID NO: 14, and CD28-HCDR3 as shown in SEQ ID NO: 15, and the CD28-VL includes CD28-LCDR1 as shown in SEQ ID NO: 16, CD28-LCDR2 as shown in SEQ ID NO: 62, and CD28-LCDR3 as shown in SEQ ID NO: 18. In some embodiments, the anti-CD28 antibodies as described in any of the preceding claims, wherein CD28-HCDR1, CD28-HCDR2, CD28-HCDR3, CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3 are defined according to the Kabat numbering rules. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein the CD28-VH and CD28-VL are humanized and each contains the FR region of a human antibody. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein: (i) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 19, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 20, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 26A, 29L, 69L, 71V, 78A, and 93S; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 22, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 23, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21. The CD28-LCDR3 of the amino acid sequence NO: 24, wherein the FR region of the CD28-VL contains one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44I, and 71Y; or (ii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 13, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 14, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 15, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 28S, 69L, 71V, 73K, and 94S; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 16, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 17, 54, 55, 56, 57, 58, 59, 60, 61, or 62, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 18, and the FR region of the CD28-VL comprises one or more amino acid substitutions selected from the group consisting of 43S and 70K; or (iii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25 or 117, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26 or 116, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 25P, 71V, and 78A; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30, and the FR region of the CD28-VL comprises one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44V, and 73L; or (iv) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7. The CD28-HCDR2 comprising the amino acid sequence of SEQ ID NO: 8 and the CD28-HCDR3 comprising the amino acid sequence of SEQ ID NO: 9, 39, 40, 41 or 42, wherein the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 69L, 71V, 73K, 78A and 94S; and the CD28-VL comprises: CD28-LCDR1 comprising the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 comprising the amino acid sequence of SEQ ID NO: 11 or 43 and CD28-LCDR3 comprising the amino acid sequence of SEQ ID NO: 12; wherein the FR region of the CD28-VL comprises one or more amino acid substitutions selected from the group consisting of 43S and 73F. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein: (i) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 19, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 20, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 26A, 29L, 69L, 71V, 78A, and 93S; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 22, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 23, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 24, and the FR region of the CD28-VL comprises one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44I, and 71Y; or (ii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 13, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 14, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 15, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 28S, 69L, 71V, 73K, and 94S; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 16, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 62, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 18, and the FR region of the CD28-VL comprises one or more amino acid substitutions selected from the group consisting of 43S and 70K; or (iii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 25P, 71V, and 78A; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30, and the FR region of the CD28-VL comprises one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44V, and 73L; or (iv) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, and the FR region of the CD28-VH comprises one or more amino acid substitutions selected from the group consisting of 1E, 69L, 71V, 73K, 78A, and 94S; and the CD28-VL comprises: containing the amino acid sequence of SEQ ID NO: 7. CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 43, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12; and the FR region of the CD28-VL contains one or more amino acid substitutions selected from the group consisting of 43S and 73F. In some embodiments, the anti-CD28 antibody, as described in any of the preceding claims, has a yield of less than 2 × 10⁻⁶ at 25°C. -8 M, 8×10 -9 M or 5×10 -9 M binds to human CD28 via KD, which is measured by surface plasmon resonance. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein: (i) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 98 or a variant thereof, the variant being one or more amino acid substitutions in the FR region of SEQ ID NO: 98 and the FR region of the CD28-VH comprising one or more amino acid substitutions selected from the group consisting of 26A, 29L, 69L, 71V, 78A, and 93S; and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 102 or a variant thereof, the variant being one or more amino acid substitutions in the FR region of SEQ ID NO: 102 comprising one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44I, and 71Y; or (ii) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 69 or a variant thereof, the variant comprising one or more amino acid substitutions selected from the group consisting of 28S, 69L, 71V, 73K, and 94S in the FR region of SEQ ID NO: 69, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 70 or a variant thereof, the variant comprising one or more amino acid substitutions selected from the group consisting of 43S and 70K in the FR region of SEQ ID NO: 70; or (iii) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 133 or a variant thereof, wherein the variant comprises one or more amino acid substitutions selected from the group consisting of 25P, 71V, and 78A in the FR region of SEQ ID NO: 133, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 137 or a variant thereof, wherein the variant comprises one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44V, and 73L in the FR region of SEQ ID NO: 137; or (iv) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 53 or a variant thereof, wherein the variant comprises one or more amino acid substitutions selected from the group consisting of 1E, 69L, 71V, 73K, 78A, and 94S in the FR region of SEQ ID NO: 53, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 50 or a variant thereof, wherein the variant comprises one or more amino acid substitutions selected from the group consisting of 43S and 73F in the FR region of SEQ ID NO: 50; or The CD28-VH comprises the amino acid sequence of SEQ ID NO: 53 or a variant thereof, wherein the variant comprises one or more amino acid substitutions selected from the group consisting of 1E, 69L, 71V, 73K, 78A and 94S in the FR region of SEQ ID NO: 53, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 52 or a variant thereof, wherein the variant comprises one or more amino acid substitutions selected from the group consisting of 43S and 73F in the FR region of SEQ ID NO: 52. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein: (i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, 35, 94, 96, 97 or 98, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101, 36, 99, 100, 102, 103, 104, 105, The amino acid sequence of 106, 107, 108, 109, 110, 111, 112, 113, 114 or 115; or (ii) The CD28-VH comprises the amino acid sequence SEQ ID NO: 68, 33, 63, 64, 65, 66, 67 or 69, and the CD28-VL comprises the amino acid sequence SEQ ID NO: 80, 34, 70, 71, 72, 73, 74, 75, 76, 77, 78 or 79; or (iii) The CD28-VH contains the amino acid sequence SEQ ID NO: 126, 37, 123, 124, 125, 127, 128, 129, 130, 131, 132 or 133, and the CD28-VL contains the amino acid sequence SEQ ID NO: 134, 38, 135, 136, 137, 138, 139, 140, 141, 142 or 143; or (iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, 31, 45, 46, 47, 48, 49 or 53, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52, 32, 50 or 51. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein: (i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, 94, 96, 97 or 98, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101, 99, 100, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 or 115; or (ii) The CD28-VH comprises the amino acid sequence of SEQ ID NO: 68, 63, 64, 65, 66, 67 or 69, and the CD28-VL comprises the amino acid sequence of SEQ ID NO: 80, 70, 71, 72, 73, 74, 75, 76, 77, 78 or 79; or (iii) The CD28-VH contains the amino acid sequence SEQ ID NO: 126, 123, 124, 125, 127, 128, 129, 130, 131, 132 or 133, and the CD28-VL contains the amino acid sequence SEQ ID NO: 134, 135, 136, 137, 138, 139, 140, 141, 142 or 143; or (iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, 45, 46, 47, 48 or 49, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52, 50, 51 or 53. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein: (i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 35, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 36; or (ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 33, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 34; or (iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 37, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 38; or (iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 31, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 32. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein: (i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, 94, 96, 97 or 98, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101, 99, 100 or 102, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 94, and the CD28-VL contains the amino acid sequences of SEQ ID NO: 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, or 115, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequences of SEQ ID NO: 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, or 115, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 96, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 99 or 100, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 97, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 99, 100, or 101, or (ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 63, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70 or 71, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 64, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70, 71, or 72, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 65, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70, 71, or 72, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 66, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70, 71, 72, 74, 75, 76, or 79, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 67, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 72, 74, 75, 76, or 79, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 72, 73, 74, 75, 76, 77, 78, 79, or 80, or (iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 123, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 135, or 136, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 124, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 135; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 125, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134 or 135, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 135, 136, 137, 138, or 139, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 127, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 137, 138, or 139; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 128, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 137, 138, 139, or 142; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 129, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 138, 139, 140, 141, 142, or 143, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 130, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 138, 140, 141, 142, or 143, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 131, and the CD28-VL contains... The amino acid sequence of SEQ ID NO: 138, 140, 141, 142 or 143, or (iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50, 51, or 52, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 45, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 52, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 47, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 48, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein: (i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; or (ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; or (iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; or (iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein the amino acid sequence of CD28-VH is as shown in SEQ ID NO: 95, and the amino acid sequence of CD28-VL is as shown in SEQ ID NO: 101. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein the amino acid sequence of CD28-VH is as shown in SEQ ID NO: 68, and the amino acid sequence of CD28-VL is as shown in SEQ ID NO: 80. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein the amino acid sequence of CD28-VH is shown as SEQ ID NO: 126, and the amino acid sequence of CD28-VL is shown as SEQ ID NO: 134. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein the amino acid sequence of CD28-VH is as shown in SEQ ID NO: 44, and the amino acid sequence of CD28-VL is as shown in SEQ ID NO: 52. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims comprises a heavy chain constant region and a light chain constant region. In some embodiments, such as the anti-CD28 antibody described in any of the preceding claims, wherein the heavy chain constant region is the human IgG1 constant region. In some embodiments, such as the anti-CD28 antibody described in any of the preceding claims, the heavy chain constant region comprises an amino acid sequence such as SEQ ID NO: 144. In some embodiments, such as the anti-CD28 antibody described in any of the preceding claims, the light chain constant region comprises an amino acid sequence such as SEQ ID NO: 145. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein the anti-CD28 antibody comprises a heavy chain and a light chain, wherein: The heavy chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 146, and the light chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 147; or The heavy chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 148, and the light chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 149; or The heavy chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 150, and the light chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 151; or The heavy chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 152, and the light chain comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 153. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims, wherein the anti-CD28 antibody comprises a heavy chain and a light chain, wherein: The heavy chain contains the amino acid sequence of SEQ ID NO: 146, and the light chain contains the amino acid sequence of SEQ ID NO: 147; The heavy chain comprises the amino acid sequence of SEQ ID NO: 148, and the light chain comprises the amino acid sequence of SEQ ID NO: 149; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 150, and the light chain comprises the amino acid sequence of SEQ ID NO: 151; or The heavy chain contains the amino acid sequence of SEQ ID NO: 152, and the light chain contains the amino acid sequence of SEQ ID NO: 153. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 150, and the light chain comprises the amino acid sequence of SEQ ID NO: 151. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 148, and the light chain comprises the amino acid sequence of SEQ ID NO: 149. In some embodiments, the anti-CD28 antibody, as described in any of the preceding claims, is an antibody fragment. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims is an antibody fragment, wherein the antibody fragment is Fab, Fab', F(ab')2, Fd, Fv, scFv, dsFv or dAb. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims is a bispecific antibody. In some embodiments, the anti-CD28 antibody as described in any of the preceding claims is a bispecific antibody that specifically binds to CD28 and PSMA. In another aspect, this disclosure provides a pharmaceutical composition comprising (e.g., a therapeutically effective amount) of the antigen-binding molecule or the anti-CD28 antibody described in any of the preceding claims, and one or more pharmaceutically acceptable carriers, diluents, buffers, or excipients. In some embodiments, the pharmaceutical composition further comprises at least one (e.g., one) second therapeutic agent. In one embodiment, the second therapeutic agent is any agent advantageously combined with the PSMA / CD28 bispecific antigen-binding molecule (including antitumor agents, radiotherapy, antibody-drug conjugates, bispecific antibodies, bispecific antibodies conjugated to antitumor agents, immune checkpoint inhibitors, or combinations thereof). In some embodiments, the second therapeutic agent is an antibody capable of specifically binding to CD3; preferably, the second therapeutic agent is a bispecific antibody capable of specifically binding to CD3; more preferably, the second therapeutic agent is a bispecific antibody capable of specifically binding to CD3 and tumor cell surface antigen (TAA); most preferably, the second therapeutic agent is a bispecific antibody capable of specifically binding to CD3 and PSMA. In some embodiments, the second therapeutic agent is an immune checkpoint inhibitor that targets PD-1 or CTLA4; preferably, the immune checkpoint inhibitor is an anti-PD-1 antibody. In another aspect, this disclosure also provides isolated nucleic acids encoding the antigen-binding molecules described in any of the foregoing claims or the anti-CD28 antibodies described in any of the foregoing claims. In another aspect, this disclosure also provides a vector containing the aforementioned isolated nucleic acid. In another aspect, this disclosure also provides a host cell comprising the aforementioned vector. In another aspect, this disclosure also provides a method of treating a disease, the method comprising administering to a subject (e.g., a therapeutically effective amount) an antigen-binding molecule as described in any of the preceding claims, an anti-CD28 antibody as described in any of the preceding claims, or a composition as described in any of the preceding claims. In another aspect, this disclosure also provides the antigen-binding molecule described in any of the foregoing claims or any of the foregoing claims. The use of the antibody or a combination thereof in the preparation of a medicament for treating diseases. In another aspect, this disclosure also provides the antigen-binding molecule or the anti-CD28 antibody or composition as described in any of the preceding claims for use as a medicament. In some embodiments, the medicament is used to treat a disease. In some embodiments, the disease described in any of the preceding claims is a tumor. In some embodiments, the tumor described in any of the preceding claims is prostate cancer, kidney cancer, urothelial carcinoma, breast cancer, bladder cancer, primary liver cancer, pancreatic cancer, melanoma, glioblastoma (e.g., glioblastoma multiforme), osteosarcoma, ovarian cancer, esophageal cancer, cervical squamous cell carcinoma, lung cancer (non-small cell lung cancer, small cell lung cancer, squamous cell carcinoma of the lung, adenocarcinoma of the lung), colorectal cancer (including colon cancer and rectal cancer), endometrial cancer, skin cancer, head and neck squamous cell carcinoma, brain cancer, gastroesophageal cancer (gastroesophageal adenocarcinoma), metastatic liver cancer, multiple myeloma, lymphoma, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or B-cell lymphoma. In some implementations, PSMA is expressed in tumor cells or vascular endothelial cells near the tumor, as described above. In some implementations, the tumor, as described above, is a solid tumor. In some embodiments, the tumor as described above is a solid tumor, such as prostate cancer, kidney cancer, urothelial carcinoma, breast cancer, bladder cancer, primary liver cancer, pancreatic cancer, melanoma, glioblastoma (e.g., glioblastoma multiforme), osteosarcoma, ovarian cancer, esophageal cancer, cervical squamous cell carcinoma, lung cancer (non-small cell lung cancer, small cell lung cancer, squamous cell carcinoma of the lung, adenocarcinoma of the lung), colorectal cancer (including colon cancer and rectal cancer), endometrial cancer, skin cancer, head and neck squamous cell carcinoma, brain cancer, gastroesophageal cancer (gastroesophageal adenocarcinoma), and metastatic liver cancer. In some implementations, the tumor as described above is prostate cancer. In some implementations, the tumor, as described above, is a non-solid tumor. In some embodiments, the tumor as described above is a non-solid tumor, such as multiple myeloma, lymphoma, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or B-cell lymphoma. In some implementations, the prostate cancer described above is refractory prostate cancer, prostate intraepithelial neoplasia, androgen-independent prostate cancer, malignant prostate cancer, recurrent prostate cancer, or castration-resistant prostate cancer. In some implementations, the aforementioned disease is a PSMA-related disease; in other implementations, the aforementioned disease is a disease that expresses PSMA. In some embodiments, the method of treating a disease as described above further includes the use of a second therapeutic agent. In some embodiments, the second therapeutic agent includes an antitumor agent, radiotherapy, an antibody-drug conjugate, a bispecific antibody, a bispecific antibody conjugated to an antitumor agent, an immune checkpoint inhibitor, or a combination thereof. In some embodiments, the second therapeutic agent is an antibody capable of specifically binding to CD3; preferably, the second therapeutic agent is a bispecific antibody capable of specifically binding to CD3; more preferably, The second therapeutic agent is a bispecific antibody capable of specifically binding to CD3 and tumor cell surface antigen (TAA); most preferably, the second therapeutic agent is a bispecific antibody capable of specifically binding to CD3 and PSMA. In some embodiments, the second therapeutic agent is an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor targets PD-1 or CTLA4; preferably, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody. In some implementations, the second therapeutic agent, as described in any of the preceding claims, may be administered simultaneously, sequentially, or separately from the antigen-binding molecule described in any of the present disclosures. In some implementations, the second therapeutic agent, as described in the preceding one, is a bispecific antibody that specifically binds to PSMA and CD3. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, comprising at least one antigen-binding module that specifically binds to PSMA and at least one antigen-binding module that specifically binds to CD3. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds PSMA and CD3, comprising at least one antigen-binding module that specifically binds PSMA and at least one antigen-binding module that specifically binds CD3, wherein the antigen-binding module that specifically binds PSMA binds to an epitope different from the antigen-binding module that binds PSMA in an antigen-binding molecule that specifically binds CD28 and PSMA. In some embodiments, the second therapeutic agent as described in any of the preceding claims is a bispecific antibody that specifically binds to PSMA and CD3, comprising at least one antigen-binding module that specifically binds to PSMA and at least one antigen-binding module that specifically binds to CD3, wherein the antigen-binding module that specifically binds to PSMA comprises a heavy chain variable region PSMA-VH and a light chain variable region PSMA-VL, and the antigen-binding module that specifically binds to CD3 comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: i) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 164, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 165, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 166; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 167, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 168, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 169; or ii) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 170, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 171, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 172; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 173, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 174, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 175; or iii) The PSMA-VH has: an amino acid sequence comprising SEQ ID NO: 158. PSMA-HCDR1, PSMA-HCDR2 comprising the amino acid sequence of SEQ ID NO: 159, and PSMA-HCDR3 comprising the amino acid sequence of SEQ ID NO: 160; and the PSMA-VL comprising: PSMA-LCDR1 comprising the amino acid sequence of SEQ ID NO: 161, PSMA-LCDR2 comprising the amino acid sequence of SEQ ID NO: 162, and PSMA-LCDR3 comprising the amino acid sequence of SEQ ID NO: 163; or iv) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 176, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 177, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 178; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 179, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 180, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 181; or v) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 301, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 302, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 303; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 304, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 305, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 306. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 170, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 171, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 172; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 173, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 174, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 175. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 164, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 165, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 166; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 167, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 168, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 169. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: i) The PSMA-VH includes PSMA-HCDR1 as shown in SEQ ID NO: 164, PSMA-HCDR2 as shown in SEQ ID NO: 165, and PSMA-HCDR3 as shown in SEQ ID NO: 166; and the PSMA-VL includes PSMA-LCDR1 as shown in SEQ ID NO: 167. PSMA-LCDR2 as shown in SEQ ID NO: 168, and PSMA-LCDR3 as shown in SEQ ID NO: 169; or ii) The PSMA-VH comprises PSMA-HCDR1 as shown in SEQ ID NO: 170, PSMA-HCDR2 as shown in SEQ ID NO: 171, and PSMA-HCDR3 as shown in SEQ ID NO: 172; and the PSMA-VL comprises PSMA-LCDR1 as shown in SEQ ID NO: 173, PSMA-LCDR2 as shown in SEQ ID NO: 174, and PSMA-LCDR3 as shown in SEQ ID NO: 175; or iii) The PSMA-VH comprises PSMA-HCDR1 as shown in SEQ ID NO: 158, PSMA-HCDR2 as shown in SEQ ID NO: 159, and PSMA-HCDR3 as shown in SEQ ID NO: 160; and the PSMA-VL comprises PSMA-LCDR1 as shown in SEQ ID NO: 161, PSMA-LCDR2 as shown in SEQ ID NO: 162, and PSMA-LCDR3 as shown in SEQ ID NO: 163; or iv) The PSMA-VH comprises PSMA-HCDR1 as shown in SEQ ID NO: 176, PSMA-HCDR2 as shown in SEQ ID NO: 177, and PSMA-HCDR3 as shown in SEQ ID NO: 178; and the PSMA-VL comprises PSMA-LCDR1 as shown in SEQ ID NO: 179, PSMA-LCDR2 as shown in SEQ ID NO: 180, and PSMA-LCDR3 as shown in SEQ ID NO: 181; or v) The PSMA-VH includes PSMA-HCDR1 as shown in SEQ ID NO: 301, PSMA-HCDR2 as shown in SEQ ID NO: 302, and PSMA-HCDR3 as shown in SEQ ID NO: 303; and the PSMA-VL includes PSMA-LCDR1 as shown in SEQ ID NO: 304, PSMA-LCDR2 as shown in SEQ ID NO: 305, and PSMA-LCDR3 as shown in SEQ ID NO: 306. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: The PSMA-VH includes PSMA-HCDR1 as shown in SEQ ID NO: 170, PSMA-HCDR2 as shown in SEQ ID NO: 171, and PSMA-HCDR3 as shown in SEQ ID NO: 172; and the PSMA-VL includes PSMA-LCDR1 as shown in SEQ ID NO: 173, PSMA-LCDR2 as shown in SEQ ID NO: 174, and PSMA-LCDR3 as shown in SEQ ID NO: 175. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: The PSMA-VH includes PSMA-HCDR1 as shown in SEQ ID NO: 164, PSMA-HCDR2 as shown in SEQ ID NO: 165, and PSMA-HCDR3 as shown in SEQ ID NO: 166; and the PSMA-VL includes PSMA-LCDR1 as shown in SEQ ID NO: 167, PSMA-LCDR2 as shown in SEQ ID NO: 168, and PSMA-LCDR3 as shown in SEQ ID NO: 169. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: i) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, 199, 332, 194, 195, 196 or 198, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201, 202, 333 or 200; or ii) The PSMA-VH comprises the amino acid sequence of SEQ ID NO: 204, 184 or 203, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206, 185, or 205; or iii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, 182, 189 or 190, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191, 183, 192 or 193; or iv) The PSMA-VH comprises the amino acid sequence of SEQ ID NO: 207 or 186, and the PSMA-VL comprises the amino acid sequence of SEQ ID NO: 208, 187, 209, or 210; or v) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 313, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 314. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: i) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or ii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or iii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or iv) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 199, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 202; or v) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 208. In some embodiments, the second therapeutic agent as described in any of the preceding claims is a bispecific antibody that specifically binds to PSMA and CD3, wherein the PSMA-VH comprises the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL comprises the amino acid sequence of SEQ ID NO: 206. In some embodiments, the second therapeutic agent as described in any of the preceding claims is a bispecific antibody that specifically binds to PSMA and CD3, wherein the PSMA-VH comprises the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL comprises the amino acid sequence of SEQ ID NO: 201. In some embodiments, the second therapeutic agent as described in any of the preceding claims is a bispecific antibody that specifically binds to PSMA and CD3, wherein the PSMA-VH comprises the amino acid sequence of SEQ ID NO: 199, and the PSMA-VL comprises the amino acid sequence of SEQ ID NO: 202. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, wherein the antigen-binding module that specifically binds to CD3 comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL, wherein: i) The CD3-VH comprises: CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 283, CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 284, and CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 285; and the CD3-VL comprises: CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 286, and CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 287. and CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 288; or ii) The CD3-VH comprises: CD3-HCDR1 comprising the amino acid sequence of SEQ ID NO: 307, CD3-HCDR2 comprising the amino acid sequence of SEQ ID NO: 308, and CD3-HCDR3 comprising the amino acid sequence of SEQ ID NO: 309; and the CD3-VL comprises: CD3-LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, CD3-LCDR2 comprising the amino acid sequence of SEQ ID NO: 311, and CD3-LCDR3 comprising the amino acid sequence of SEQ ID NO: 312. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, wherein the antigen-binding module that specifically binds to CD3 comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL, wherein: The CD3-VH comprises: CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 283, CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 284, and CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 285; and the CD3-VL comprises: CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 286, CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 287, and CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 288. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, wherein the antigen-binding module that specifically binds to CD3 comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL, wherein: i) The CD3-VH comprises CD3-HCDR1 as shown in SEQ ID NO: 283, CD3-HCDR2 as shown in SEQ ID NO: 284, and CD3-HCDR3 as shown in SEQ ID NO: 285; and the CD3-VL comprises CD3-LCDR1 as shown in SEQ ID NO: 286, CD3-LCDR2 as shown in SEQ ID NO: 287, and CD3-LCDR3 as shown in SEQ ID NO: 288; or ii) The CD3-VH includes CD3-HCDR1 as shown in SEQ ID NO: 307, CD3-HCDR2 as shown in SEQ ID NO: 308, and CD3-HCDR3 as shown in SEQ ID NO: 309; and the CD3-VL includes CD3-LCDR1 as shown in SEQ ID NO: 310, CD3-LCDR2 as shown in SEQ ID NO: 311, and CD3-LCDR3 as shown in SEQ ID NO: 312. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, wherein the antigen-binding module that specifically binds to CD3 comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL, wherein: The CD3-VH includes CD3-HCDR1 as shown in SEQ ID NO: 283, CD3-HCDR2 as shown in SEQ ID NO: 284, and CD3-HCDR3 as shown in SEQ ID NO: 285; and the CD3-VL includes CD3-LCDR1 as shown in SEQ ID NO: 286, CD3-LCDR2 as shown in SEQ ID NO: 287, and CD3-LCDR3 as shown in SEQ ID NO: 288. In some embodiments, the second therapeutic agent as described in any of the preceding claims is a bispecific antibody that specifically binds to PSMA and CD3, wherein CD3-VH comprises the amino acid sequence of SEQ ID NO: 289 and CD3-VL comprises the amino acid sequence of SEQ ID NO: 290; or The CD3-VH contains the amino acid sequence of SEQ ID NO: 315, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 315. The amino acid sequence of ID NO: 316. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: The PSMA-VH includes PSMA-HCDR1 as shown in SEQ ID NO: 170, PSMA-HCDR2 as shown in SEQ ID NO: 171, and PSMA-HCDR3 as shown in SEQ ID NO: 172; and the PSMA-VL includes PSMA-LCDR1 as shown in SEQ ID NO: 173, PSMA-LCDR2 as shown in SEQ ID NO: 174, and PSMA-LCDR3 as shown in SEQ ID NO: 175; and The CD3-VH includes CD3-HCDR1 as shown in SEQ ID NO: 283, CD3-HCDR2 as shown in SEQ ID NO: 284, and CD3-HCDR3 as shown in SEQ ID NO: 285; and the CD3-VL includes CD3-LCDR1 as shown in SEQ ID NO: 286, CD3-LCDR2 as shown in SEQ ID NO: 287, and CD3-LCDR3 as shown in SEQ ID NO: 288. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: The PSMA-VH includes PSMA-HCDR1 as shown in SEQ ID NO: 164, PSMA-HCDR2 as shown in SEQ ID NO: 165, and PSMA-HCDR3 as shown in SEQ ID NO: 166; and the PSMA-VL includes PSMA-LCDR1 as shown in SEQ ID NO: 167, PSMA-LCDR2 as shown in SEQ ID NO: 168, and PSMA-LCDR3 as shown in SEQ ID NO: 169; and The CD3-VH includes CD3-HCDR1 as shown in SEQ ID NO: 283, CD3-HCDR2 as shown in SEQ ID NO: 284, and CD3-HCDR3 as shown in SEQ ID NO: 285; and the CD3-VL includes CD3-LCDR1 as shown in SEQ ID NO: 286, CD3-LCDR2 as shown in SEQ ID NO: 287, and CD3-LCDR3 as shown in SEQ ID NO: 288. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: The PSMA-VH includes PSMA-HCDR1 as shown in SEQ ID NO: 301, PSMA-HCDR2 as shown in SEQ ID NO: 302, and PSMA-HCDR3 as shown in SEQ ID NO: 303; and the PSMA-VL includes PSMA-LCDR1 as shown in SEQ ID NO: 304, PSMA-LCDR2 as shown in SEQ ID NO: 305, and PSMA-LCDR3 as shown in SEQ ID NO: 306; and The CD3-VH comprises: CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 307, CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 308, and CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 309; and the CD3-VL comprises: CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 310, CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 311, and CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 312. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: The PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; and The CD3-VH contains the amino acid sequence of SEQ ID NO: 289, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 290. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: The PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; and The CD3-VH contains the amino acid sequence of SEQ ID NO: 289, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 290. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: The PSMA-VH contains the amino acid sequence of SEQ ID NO: 199, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 202; and The CD3-VH contains the amino acid sequence of SEQ ID NO: 289, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 290. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein: The PSMA-VH contains the amino acid sequence of SEQ ID NO: 313, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 314; and The CD3-VH contains the amino acid sequence of SEQ ID NO: 315, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 316. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, and includes an Fc region. In some embodiments, the Fc region is an IgG Fc region. In some embodiments, the Fc region is an IgG1 Fc region. In some embodiments, the Fc region includes one or more amino acid substitutions capable of reducing the binding of the Fc region to the Fcγ receptor. In some embodiments, the Fc region is a human IgG1 Fc region, and the amino acids at positions 234 and 235 are A, numbered according to the EU index. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, comprising an Fc region containing a first subunit Fc1 and a second subunit Fc2 capable of associating with each other, wherein Fc1 and Fc2 each independently have one or more amino acid substitutions that reduce homodimerization of the Fc region. In some embodiments, Fc1 has a protruding structure according to a mortar and pestle technique, and Fc2 has a porous structure according to a mortar and pestle technique. In some embodiments, the amino acid at position 366 of Fc1 is W; and the amino acid at position 366 of Fc2 is S, the amino acid at position 368 is A, and the amino acid at position 407 is V, numbered according to the EU index. In some embodiments, Fc1 has amino acid C at position 354 and amino acid W at position 366; and Fc2 has amino acid C at position 349, amino acid S at position 366, amino acid A at position 368, and amino acid V at position 407, numbered according to the EU index. In some embodiments, Fc1 contains The amino acid sequence of SEQ ID NO: 220; Fc2 contains the amino acid sequence of SEQ ID NO: 221. In some embodiments, Fc1 contains the amino acid sequence of SEQ ID NO: 220; and Fc2 contains the amino acid sequence of SEQ ID NO: 222. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, comprising an antigen-binding module that specifically binds to PSMA and an antigen-binding module that specifically binds to CD3, wherein both the antigen-binding module that specifically binds to PSMA and the antigen-binding module that specifically binds to CD3 are scFv. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, comprising a first chain having the structure shown in formula (a) and a second chain having the structure shown in formula (b). (a)[PSMA-VH]-[Connector 6]-[PSMA-VL]-[Connector 7]-[CD3-VH]-[Connector 8]-[CD3-VL]-[Connector 9]-[Fc2], (b)[Fc1], The structures shown in formulas (a) and (b) are arranged from the N-terminus to the C-terminus, and the linkers 6, 7, 8 and / or 9 are the same or different peptide linkers. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, comprising a first chain having the structure shown in formula (a) and a second chain having the structure shown in formula (b). (a)[PSMA-VH]-[Connector 6]-[PSMA-VL]-[Connector 7]-[CD3-VH]-[Connector 8]-[CD3-VL]-[Connector 9]-[Fc2], (b)[Fc1], The structures shown in formulas (a) and (b) are arranged from the N-terminus to the C-terminus, and the linkers 6, 7, 8, and / or 9 are the same or different peptide linkers; wherein: The PSMA-VH contains the amino acid sequence of SEQ ID NO: 197; and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; and the CD3-VH contains the amino acid sequence of SEQ ID NO: 289; and the CD3-VL contains the amino acid sequence of SEQ ID NO: 290. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, comprising a first chain having the structure shown in formula (a) and a second chain having the structure shown in formula (b). (a)[PSMA-VH]-[Connector 6]-[PSMA-VL]-[Connector 7]-[CD3-VH]-[Connector 8]-[CD3-VL]-[Connector 9]-[Fc2], (b)[Fc1], The structures shown in formulas (a) and (b) are arranged from the N-terminus to the C-terminus, and the linkers 6, 7, 8, and / or 9 are the same or different peptide linkers; wherein: The PSMA-VH contains the amino acid sequence of SEQ ID NO: 199; and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; and the CD3-VH contains the amino acid sequence of SEQ ID NO: 289. Amino acid sequence; and the CD3-V L containing the amino acid sequence of SEQ ID NO: 290. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, comprising a first chain having the structure shown in formula (a) and a second chain having the structure shown in formula (b). (a)[PSMA-VH]-[Connector 6]-[PSMA-VL]-[Connector 7]-[CD3-VH]-[Connector 8]-[CD3-VL]-[Connector 9]-[Fc2], (b)[Fc1], The structures shown in formulas (a) and (b) are arranged from the N-terminus to the C-terminus, wherein linkers 6 and 8 are peptide linkers with the same sequence; and linkers 7 and 9 are peptide linkers with different sequences. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, and the linkers 6, 7, 8, and 9 can be any suitable peptide linker, provided that the antigen-binding molecule can exhibit the desired antigen-binding activity. For example, the peptide linker can be a flexible peptide containing 1-50 or 3-20 amino acid residues. In some embodiments, each of the peptide linkers independently has an L1-(GGGGS)n-L2 structure, wherein L1 is a bond, S, GS, GGS (SEQ ID NO: 399) or GGGS (SEQ ID NO: 400), n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, L2 is a bond, G, GG, GGG (SEQ ID NO: 295) or GGGG (SEQ ID NO: 256), and the peptide linker is not a bond. In some embodiments, the length of the peptide linker is 3-15 amino acid residues. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, wherein linkers 6 and 8 comprise the amino acid sequence of SEQ ID NO: 293 (GGGGSGGGGSGGGGS). In some embodiments, wherein linker 7 comprises the amino acid sequence of SEQ ID NO: 294 (SGGGGS). In some embodiments, wherein linker 9 comprises the amino acid sequence of SEQ ID NO: 295 (GGG). In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein the Fc1 comprises the amino acid sequence of SEQ ID NO: 220. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein the Fc2 comprises the amino acid sequence of SEQ ID NO: 221. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, wherein the bispecific antibody that specifically binds to PSMA and CD3 has: a first chain containing the amino acid sequence of SEQ ID NO: 296 and a second chain containing the amino acid sequence of SEQ ID NO: 220. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, wherein the bispecific antibody that specifically binds to PSMA and CD3 has: A first strand containing the amino acid sequence of SEQ ID NO: 297 and a second strand containing the amino acid sequence of SEQ ID NO: 220. In some implementations, the second therapeutic agent, as described in the preceding one, specifically binds to PSMA and A bispecific antibody against CD3, comprising an antigen-binding module that specifically binds to PSMA and an antigen-binding module that specifically binds to CD3, wherein the antigen-binding module that specifically binds to PSMA or the antigen-binding module that specifically binds to CD3 comprises a Titin chain and an Obscurin chain capable of forming a dimer. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, comprising an antigen-binding module that specifically binds to PSMA and an antigen-binding module that specifically binds to CD3, wherein the antigen-binding module that specifically binds to PSMA is a Fab; and the antigen-binding module that specifically binds to CD3 is a replaced Fab comprising a Titin chain and an Obscurin chain capable of forming a dimer. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, wherein the antigen-binding module that specifically binds to CD3 is a Fab; and the antigen-binding module that specifically binds to PSMA is a replaced Fab comprising a Titin chain and an Obscurin chain capable of forming a dimer. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, comprising a first chain having the structure shown in formula (c), a second chain having the structure shown in formula (d), a third chain having the structure shown in formula (e), and a fourth chain having the structure shown in formula (f). (c)[PSMA-VH]-[CH1]-[Fc1], (d)[PSMA-VL]-[CL], (e)[CD3-VH]-[Connector 10]-[Obscurin Chain]-[Fc2], (f) [CD3-VL]-[Connector 11]-[Titin Chain] The structures shown in formulas (c), (d), (e) and (f) are arranged from the N-terminus to the C-terminus, and the linkers 10 and 11 are the same or different peptide linkers. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, comprising a first chain having the structure shown in formula (c), a second chain having the structure shown in formula (d), a third chain having the structure shown in formula (e), and a fourth chain having the structure shown in formula (f). (c)[PSMA-VH]-[CH1]-[Fc1], (d)[PSMA-VL]-[CL], (e)[CD3-VH]-[Connector 10]-[Obscurin Chain]-[Fc2], (f) [CD3-VL]-[Connector 11]-[Titin Chain] The structures shown in formulas (c), (d), (e), and (f) are arranged from the N-terminus to the C-terminus, and linkers 10 and 11 are the same or different peptide linkers; wherein: The PSMA-VH contains the amino acid sequence of SEQ ID NO: 204; and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; and the CD3-VH contains the amino acid sequence of SEQ ID NO: 289; and the CD3-VL contains the amino acid sequence of SEQ ID NO: 290. In some implementations, the second therapeutic agent, as described in the preceding one, specifically binds to PSMA and A bispecific antibody against CD3, wherein the titin chain and obscurin chain are any titin chain and obscurin chain that can form a dimer as listed in Tables 3-1 and 3-2 of this disclosure. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the titin chain comprises an amino acid sequence as shown in SEQ ID NO: 350. In some embodiments, the antigen-binding molecule as described in any of the preceding claims, wherein the obscurin chain comprises an amino acid sequence as shown in SEQ ID NO: 388. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, wherein the linkers 10 and 11 can be any suitable peptide linker, provided that the antigen-binding molecule can exhibit the desired antigen-binding activity. For example, the peptide linker can be a flexible peptide containing 1-50 or 3-20 amino acid residues. In some embodiments, each of the peptide linkers independently has an L1-(GGGGS)n-L2 structure, wherein L1 is a bond, S, GS, GGS (SEQ ID NO: 399) or GGGS (SEQ ID NO: 400), n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, L2 is a bond, G, GG, GGG (SEQ ID NO: 295) or GGGG (SEQ ID NO: 256), and the peptide linker is not a bond. In some embodiments, the length of the peptide linker is 3-15 amino acid residues. In some embodiments, linkers 10 and 11 comprise an amino acid sequence as shown in SEQ ID NO: 223. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, wherein the CH1 is the CH1 sequence of IgG. In some embodiments, the CH1 is the CH1 of IgG1. In some embodiments, the CH1 comprises the amino acid sequence of SEQ ID NO: 219. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is a bispecific antibody that specifically binds to PSMA and CD3, wherein the CL is a light chain constant region of kappa or lambda. In some embodiments, wherein the CL comprises the amino acid sequence of SEQ ID NO: 145. In some embodiments, the second therapeutic agent as described in any of the preceding claims is a bispecific antibody that specifically binds to PSMA and CD3, having: a first chain containing the amino acid sequence of SEQ ID NO: 298, a second chain containing the amino acid sequence of SEQ ID NO: 275, a third chain containing the amino acid sequence of SEQ ID NO: 291, and a fourth chain containing the amino acid sequence of SEQ ID NO: 292. In some implementations, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3 and has an IgG-scFv structure. In some embodiments, the second therapeutic agent, as described in any of the preceding embodiments, is a bispecific antibody that specifically binds to PSMA and CD3, comprising two first chains of the structure shown in formula (a) and two second chains of the structure shown in formula (b): (a) [PSMA-VH]-[IgG constant region]-[linker 12]-[CD3-VL]-[linker 13]-[CD3-VH]; (b)[PSMA-VL]-CL; The structures shown in formulas (a) and (b) are arranged from the N-terminus to the C-terminus, and the linkers 12 and 13 are the same or different peptide linkers. In some implementations, the second therapeutic agent, as described in the preceding one, specifically binds to PSMA and A bispecific antibody against CD3, having an IgG-scFv structure comprising two first strands of the structure shown in formula (a) and two second strands of the structure shown in formula (b): (a) [PSMA-VH]-[IgG constant region]-[linker 12]-[CD3-VL]-[linker 13]-[CD3-VH]; (b)[PSMA-VL]-CL; The structures shown in formulas (a) and (b) are arranged from the N-terminus to the C-terminus, and linkers 12 and 13 are the same or different peptide linkers; wherein: The PSMA-VH contains the amino acid sequence of SEQ ID NO: 313; the PSMA-VL contains the amino acid sequence of SEQ ID NO: 314; the CD3-VH contains the amino acid sequence of SEQ ID NO: 315; and the CD3-VL contains the amino acid sequence of SEQ ID NO: 316. In some embodiments, the bispecific antibody that specifically binds to PSMA and CD3 comprises two amino acid sequences of SEQ ID NO: 299 and two amino acid sequences of SEQ ID NO: 300. In some implementations, the second therapeutic agent, as described in any of the preceding embodiments, is an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor targets PD-1 or CTLA4. In some implementations, the second therapeutic agent, as described in any of the preceding embodiments, is an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is an anti-PD-1 antibody, which includes any known anti-PD-1 antibody with therapeutic activity, including but not limited to Camrelizumab, Keytruda, Opdivo, and cemiplimab. In some embodiments, the second therapeutic agent as described in any of the preceding embodiments is an anti-PD-1 antibody comprising a heavy chain variable region PD-1-VH and a light chain variable region PD-1-VL, wherein: The PD-1-VH comprises: PD-1-HCDR1 containing the amino acid sequence of SEQ ID NO: 319, PD-1-HCDR2 containing the amino acid sequence of SEQ ID NO: 320, and PD-1-HCDR3 containing the amino acid sequence of SEQ ID NO: 321, and the PD-1-VL comprises: PD-1-LCDR1 containing the amino acid sequence of SEQ ID NO: 322, PD-1-LCDR2 containing the amino acid sequence of SEQ ID NO: 323, and PD-1-LCDR3 containing the amino acid sequence of SEQ ID NO: 324. In some embodiments, the second therapeutic agent, as described in any one of them, is an anti-PD-1 antibody comprising a heavy chain variable region PD-1-VH and a light chain variable region PD-1-VL, wherein: The PD-1-VH contains the amino acid sequence of SEQ ID NO: 325, and the PD-1-VL contains the amino acid sequence of SEQ ID NO: 326. In some embodiments, the second therapeutic agent as described in any of the preceding claims is an anti-PD-1 antibody comprising a heavy chain of the amino acid sequence of SEQ ID NO: 328 and a light chain of the amino acid sequence of SEQ ID NO: 329. The antigen-binding molecules disclosed herein possess good therapeutic activity, safety, pharmacokinetic properties, and drug-likeness (such as stability). Attached Figure Description Figure 1A: Schematic diagram of the structure of Formula 1 of the PSMA / CD28 bispecific antibody; Figure 1B: Schematic diagram of the structure of Formula 2 of the PSMA / CD28 bispecific antibody; Figure 1C: Schematic diagram of the structure of Formula 1 of the PSMA / CD3 bispecific antibody; Figure 1D: Schematic diagram of Formula 5 of PSMA / CD3 bispecific antibody; where Ob represents Obscurin. Figure 2: Killing effect of different concentrations of PSMA / CD28 bispecific antibody on CHO-huPSMA cells with fixed concentration of PSMA / CD3 bispecific antibody CC-1. Figure 3: Changes in IFN-γ secretion in PBMCs under the combined action of PSMA / CD3 double antibody, PSMA / CD28 double antibody and CHO-huPSMA cells. Figure 4: Changes in IL-6 secretion in PBMCs under the combined action of PSMA / CD3 double antibody, PSMA / CD28 double antibody and CHO-huPSMA cells. Detailed Implementation the term The terminology used herein is for descriptive purposes only and is not intended to be limiting. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Unless the context clearly requires otherwise, throughout the specification and claims, the words “comprising,” “having,” “including,” etc., should be understood to have an inclusive meaning, rather than an exclusive or exhaustive meaning; that is, the meaning of “including but not limited to.” Unless otherwise stated, “comprising” includes “consisting of…”. For example, PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 1 explicitly covers the amino acid sequence PSMA-HCDR1 as shown in SEQ ID NO: 1. The three-letter and single-letter codes for amino acids used in this disclosure are as described in J. Biol. Chem., 243, p3558 (1968). The term “and / or”, such as “X and / or Y”, should be understood to mean “X and Y” or “X or Y” and should be used to provide clear support for both meanings or either meaning. The term "CD28" (differentiation cluster 28, Tp44) refers to any CD28 protein from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). CD28 is expressed on T cells and provides the co-stimulatory signal required for T cell activation and survival. In addition to the T cell receptor (TCR), stimulation of T cells via CD28 can also provide an effective signal for the production of various interleukins. CD28 is the receptor for both CD80 (B7.1) and CD86 (B7.2) proteins and is the only B7 receptor constitutively expressed on naive T cells. The amino acid sequence of human CD28 is shown in UniProt (www.uniprot.org) accession number P10747. The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimics that function in a similar manner to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those that have been modified, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs are those that have the same basic chemical structure as naturally occurring amino acids. Compounds that are α-carbons (i.e., bound to hydrogen, carboxyl, amino, and R groups), such as homoserine, ortholeucine, methionine sulfoxide, and methionine methylsulfonium. These analogues have modified R groups (e.g., ortholeucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimics are chemical compounds that have a structure different from the general chemical structure of amino acids, but function in a manner similar to naturally occurring amino acids. The term "amino acid mutation" includes amino acid substitution, deletion, insertion, and modification. Any combination of substitution, deletion, insertion, and modification can be performed to achieve the final construct, provided that the final construct possesses the desired properties, such as reduced or absent binding to Fc receptors. Amino acid sequence deletions and insertions include deletions and insertions at the amino and / or carboxyl ends of the polypeptide chain. A specific amino acid mutation can be an amino acid substitution. In one embodiment, an amino acid mutation is a non-conservative amino acid substitution, i.e., replacing one amino acid with another amino acid that has a different structure and / or chemical properties. Amino acid substitution includes substitution by non-naturally occurring amino acids or by derivatives of 20 naturally occurring amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods known in the art. Genetic methods can include site-directed mutagenesis, PCR, gene synthesis, etc. Methods other than genetic engineering that alter amino acid side chain groups, such as chemical modification, are also expected to be available. Various names may be used herein to refer to the same amino acid mutation. In this paper, the amino acid residue at a specific site can be represented by the format of position + amino acid residue. For example, 366W indicates that the amino acid residue at position 366 is W. T366W indicates that the amino acid residue at position 366 has mutated from T to W. The term "antigen-binding molecule" is used in the broadest sense to encompass molecules that specifically bind antigens, including but not limited to antibodies, other peptides with antigen-binding activity, and antibody fusion proteins formed by the fusion of both, provided they exhibit the desired antigen-binding activity. The antigen-binding molecules described herein comprise a variable region (VH) and a variable region (VL), which together constitute the antigen-binding domain. Exemplarily, the antigen-binding molecules described herein are bispecific antigen-binding molecules (e.g., bispecific antibodies). The term "antibody" is used in the broadest sense and encompasses a wide variety of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies; monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, and antibody fragments (or antigen-binding fragments, or antigen-binding portions), as long as they exhibit the desired antigen-binding activity. For example, a natural IgG antibody is a heterotetraglycoprotein of approximately 150,000 Daltons, consisting of two identical light chains and two identical heavy chains bound by disulfide bonds. From the N to the C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or heavy chain variable region, followed by three constant domains (CH1, CH2, and CH3). Similarly, from the N to the C-terminus, each light chain has a variable region (VL), also called a variable light domain or light chain variable domain, followed by a constant light domain (light chain constant region, CL). The term "bispecific antibody" refers to an antibody (including the antibody or its antigen-binding fragment, such as a single-chain antibody) that can specifically bind to two different antigens or at least two different antigenic epitopes of the same antigen. Bispecific antibodies with various structures have been disclosed in the prior art. Based on the integrity of the IgG molecule, they can be classified into IgG-like bispecific antibodies and antibody fragment-type bispecific antibodies; based on the number of antigen-binding regions, they can be classified into bivalent, trivalent, tetravalent, or more; and based on whether the structure is symmetrical, they can be classified into symmetrical bispecific antibodies. Bispecific antibodies with asymmetric structures include those based on antibody fragments, such as Fab fragments lacking the Fc fragment. These form bispecific antibodies by combining two or more Fab fragments into one molecule. They exhibit low immunogenicity, small molecular weight, and high tumor tissue penetration. Typical antibody structures of this type include F(ab)2, scFv-Fab, and (scFv)2-Fab. IgG-like bispecific antibodies (e.g., those with an Fc fragment) have a relatively large molecular weight. The Fc fragment facilitates antibody purification and improves its solubility and stability. The Fc portion may also bind to the receptor FcRn, increasing the antibody's serum half-life. Typical bispecific antibody structural models include KiH, CrossMAb, Triomab quadroma, FcΔAdp, ART-Ig, BiMAb, Biclonics, BEAT, DuoBody, Azymetric, XmAb, 2:1TCBs, and 1Fab-IgG. TDB, FynomAb, two-in-one / DAF, scFv-Fab-IgG, DART-Fc, LP-DART, CODV-Fab-TL, HLE-BiTE, F(ab)2-CrossMAb , IgG-(scFv)2, Bs4Ab, DVD-Ig, Tetravalent-DART-Fc, (scFv)4-Fc, CODV-Ig, mAb2, F(ab)4-CrossMAb, etc. (see Aran F. Labrijn et al., Nature Reviews Drug Discovery volume 18, pages 585–608 (2019); Chen S1 et al., J Immunol Res. 2019 Feb 11; 2019:4516041). The term "variable region" or "variable domain" refers to the domain in an antigen-binding molecule that binds to the antigen. In this paper, the heavy chain variable region in the antigen-binding module that specifically binds to PSMA is labeled PSMA-VH, and the light chain variable region is labeled PSMA-VL; the heavy chain variable region in the antigen-binding module that specifically binds to CD28 is labeled CD28-VH, and the light chain variable region is labeled CD28-VL. Both VH and VL contain four conserved frame regions (FRs) and three complementarity-determining regions (CDRs). The term "complementarity-determining region" or "CDR" refers to the region within the variable domain that primarily facilitates antigen binding; "frame" or "FR" refers to the variable domain residues other than the CDR residues. VH contains three CDR regions: HCDR1, HCDR2, and HCDR3; VL contains three CDR regions: LCDR1, LCDR2, and LCDR3. In this study, the three CDR regions in PSMA-VH are labeled PSMA-HCDR1, PSMA-HCDR2, and PSMA-HCDR3; the three CDR regions in PSMA-VL are labeled PSMA-LCDR1, PSMA-LCDR2, and PSMA-LCDR3; the three CDR regions in CD28-VH are labeled CD28-HCDR1, CD28-HCDR2, and CD28-HCDR3; and the three CDR regions in CD28-VL are labeled CD28-LCDR1, CD28-LCDR2, and CD28-LCDR3. Each VH and VL, from N-terminus to C-terminus, is labeled FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. A single VH or VL may be sufficient to confer antigen binding specificity. The amino acid sequence boundaries of CDRs can be determined using various well-known schemes, such as the "Kabat" numbering system (see Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD), the "Chothia" numbering system, the "ABM" numbering system, the "contact" numbering system (see Martin, ACR. Protein Sequence and Structure Analysis of Antibody Variable Domains[J]. 2001), and the ImMunoGenTics (IMGT) numbering system (Lefranc, MP et al., Dev. Comp. Immunol., 27, 55-77(2003); Front Immunol. 2018 Oct 16; 9:2278), etc.; the correspondence between various numbering systems is well known to those skilled in the art. The numbering system disclosed herein is shown in Table 1 below. Table 1. Relationship between CDR numbering systems Unless otherwise stated, the variable regions and CDR sequences in this disclosure embodiment are governed by the "Kabat" numbering rule. Although a numbering system (such as Kabat) is used to define amino acid residues in a specific implementation, the corresponding technical solutions of other numbering systems are considered equivalent. The term "antibody fragment" refers to a molecule that is distinct from the complete antibody but contains a portion of the complete antibody that retains the antigen-binding ability of the complete antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, single-domain antibodies, single-chain Fab (scFab), biantibodies, linear antibodies, single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments. The term "Fc region" or "fragment crystallizable region" is used to define the C-terminal region of an antibody heavy chain, including native and modified Fc regions. In some embodiments, the Fc region comprises two identical or different subunits. In some embodiments, the Fc region of a human IgG heavy chain is defined as an amino acid residue extending from the Cys226 position or from Pro230 to its carboxyl terminus. Suitable native sequence Fc regions for the antibodies described herein include human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4. Unless otherwise stated, Fc regions are numbered using the EU index. The term "Titin chain" refers to a 78-118 amino acid segment of the titin protein containing a titin Ig-like 152 domain or a functional variant thereof, which can bind to the obscurin chain to form a dimerizing complex. The term "Obscurin chain" refers to an 87-117 amino acid segment of the obscurin protein containing an obscurin Ig-like 1 domain or a functional variant thereof, or a 78-118 amino acid segment of the obscurin-like 1 protein containing an obscurin-like Ig-like 1 domain or a functional variant thereof, which can bind to the titin chain to form a dimerizing complex. The titin and obscurin chains disclosed herein can be used to replace CH1 and CL in Fab to form a replaced Fab (Fab-S), which does not affect the binding of antigen-binding molecules to antigens. The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain originates from a specific source or species, while the remainder of the heavy and / or light chain originates from a different source or species. The term "humanized" antibody refers to an antibody that retains the reactivity of a non-human antibody while exhibiting lower immunogenicity in humans. For example, this can be achieved by retaining the non-human CDR region and replacing the rest of the antibody with its human counterpart (i.e., the frame region portion of the constant region and the variable region). The term "affinity" refers to the overall strength of the non-covalent interaction between a single binding site of a molecule (e.g., an antibody) and its binding ligand (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to internal binding affinity, which reflects a 1:1 ratio between members of a binding pair (e.g., antibody and antigen). Interactions. The affinity of molecule X for its ligand Y can typically be represented by the equilibrium dissociation constant (KD). Affinity can be measured using conventional methods known in the art, including those described herein. The terms “kassoc” or “ka” refer to the association rate of a particular antibody-antigen interaction, while the terms “kdis” or “kd” as used herein are intended to refer to the dissociation rate of a particular antibody-antigen interaction. As used herein, the term “KD” refers to the equilibrium dissociation constant, which is derived from the ratio of kd to ka (i.e., kd / ka) and expressed as a molar concentration (M). The KD value of an antibody can be determined using methods known in the art, such as surface plasmon resonance, ELISA, or solution equilibrium titration (SET). The term "monoclonal antibody" refers to a group of antibodies or its members that are substantially homogeneous, meaning that the antibody molecules contained in the group have the same amino acid sequence, except for the possible presence of small amounts of naturally occurring mutations. In contrast, polyclonal antibody formulations typically comprise multiple different antibodies with varying amino acid sequences in their variable structural domains, which are generally specific to different epitopes. "Monoclonal" indicates the characteristic of an antibody obtained from a substantially homogeneous group of antibodies and should not be construed as requiring the antibody to be produced by any particular method. In some embodiments, the antibodies provided in this disclosure are monoclonal antibodies. The term "antigen" refers to a molecule or molecular moiety that can be selectively recognized or bound by antigen-binding molecules (such as antibodies). An antigen may have one or more epitopes that can interact with different antigen-binding molecules (such as antibodies). The term "epitope" refers to a region on an antigen that can specifically bind to an antibody or its antigen-binding fragment. Epitopes can be formed from consecutive amino acids (linear epitopes) or contain non-consecutive amino acids (conformal epitopes), for example, due to the folding of the antigen (i.e., the tertiary folding of the antigen as a protein), which allows non-consecutive amino acids to be spatially close. The difference between conformational and linear epitopes is that antibody binding to a conformational epitope is lost in the presence of a denaturing solvent. Epitopes contain at least 3, at least 4, at least 5, at least 6, at least 7, or 8-10 amino acids in a unique spatial conformation. Screening for antibodies that bind to a specific epitope (i.e., those that bind to the same epitope) can be performed using methods routine in the art, such as, but not limited to, alanine scanning, Western blotting (see Meth. Mol. Biol. 248 (2004) 443-463), peptide cleavage analysis, epitope excision, epitope extraction, chemical modification of the antigen (see Prot. Sci. 9 (2000) 487-496), and cross-blocking (see “Antibodies”, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harb., NY)). The terms "specific binding," "specific binding," or "binding" refer to the ability of an antibody to bind to a specific antigen or epitope with a higher affinity than other antigens or epitopes. Typically, antibodies bind at an affinity of approximately 1 × 10⁻⁶. -7 M or smaller (e.g., about 1×10⁻⁶) -8The equilibrium dissociation constant (KD) of an antibody (M or less) binds to an antigen or epitope. In some embodiments, the KD of an antibody binding to an antigen is 10% or less (e.g., 1%) of the KD of the antibody binding to a nonspecific antigen (e.g., BSA, casein). KD can be measured using known methods, such as by FACS or surface plasmon resonance assays. However, antibodies that specifically bind to an antigen or its epitope may be cross-reactive to other related antigens, for example, to corresponding antigens from other species (homologous) (such as humans or monkeys, e.g., cynomolgus macaques (Macaca fascicularis) (cynomolgus, cyno) or chimpanzees (Pan troglodytes) (chimpanzee, chimp) or marmosets (Callithrix jacchus) (commonmarmoset, marmoset). The term "non-binding" means that the antibody cannot bind to an antigen or its epitope in the manner described above for specific binding. For example, when the antibody binds at approximately 1 × 10⁻⁶... -6 M or a larger equilibrium dissociation constant (KD) binds to the antigen or its epitope. The term "antigen-binding module" refers to a polypeptide molecule that specifically binds to a target antigen or its epitope. Specific antigen-binding modules include the antigen-binding domain of an antibody, such as those containing a heavy chain variable region and a light chain variable region. The term "CD28-specific antigen-binding module" refers to a module capable of binding to CD28 or its epitope with sufficient affinity, such that molecules containing this module can be used as diagnostic and / or therapeutic agents targeting CD28. For example, a CD28-specific antigen-binding module has the following equilibrium dissociation constant (KD): <approximately 2 × 10⁻⁶. -8 M, which is measured by surface plasmon resonance assay. The antigen-binding module includes antibody fragments as defined herein, such as Fab, replaced Fab, or scFv. The term "linker" refers to a connecting unit that links two polypeptide fragments. In this document, linkers appearing in the same structural formula may be the same or different. Linkers may be peptide linkers, containing one or more amino acids, typically about 1-30, 2-24, or 3-15 amino acids. Linkers used in this document may be the same or different. When a "-" appears in the structural formula, it indicates that the units on either side are directly connected by a covalent bond. "Tm" refers to the dissolution and denaturation temperature (intrinsic fluorescence). When a protein denatures (due to heating or the action of a denaturing agent), its tertiary structure opens, and the microenvironment of aromatic amino acids changes, leading to a change in the emission fluorescence spectrum. In this disclosure, Tm1 refers to the temperature at which the fluorescence changes to half of its maximum value. "Tonset" is the denaturation initiation temperature. It refers to the temperature at which a protein begins to denature, that is, the temperature at which its fluorescence value begins to change. "Tagg" refers to the aggregation initiation temperature. Aggregates are detected at two wavelengths, 266 nm and 473 nm, using static light scattering to monitor the temperature at which the sample begins to aggregate. Tagg 266 refers to the aggregation initiation temperature detected at 266 nm. The term “nucleic acid” is used interchangeably with the term “polynucleotide” herein and refers to deoxyribonucleotides or ribonucleotides and their polymers in single-stranded or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, or non-natural, have similar binding properties to a reference nucleic acid, and are metabolized in a manner similar to that of a reference nucleotide. Examples of such analogs include, but are not limited to, thiophosphates, aminophosphates, methylphosphonates, chiral methylphosphonates, 2-O-methylribonucleotides, and peptide-nucleic acids (PNAs). “Isolated” nucleic acid refers to a nucleic acid molecule that has been separated from its components in its natural environment. An isolated nucleic acid encoding the antigen-binding molecule refers to one or more nucleic acid molecules encoding the antibody heavy and light chains (or fragments thereof), including one or more such nucleic acid molecules in a single or separate vector, and one or more such nucleic acid molecules present at one or more locations in the host cell. Unless otherwise stated, a specific nucleic acid sequence also implicitly encompasses variants of its conserved modifications (e.g., degenerate codon substitutions) and complementary sequences, as well as explicitly stated sequences. Specifically, as detailed below, degenerate codon substitution can be obtained by generating sequences in which the third position of one or more selected (or all) codons is substituted with a degenerate base and / or a deoxyinosine residue. The terms “peptide” and “protein” are used interchangeably herein to refer to polymers of amino acid residues. The term applies to amino acid polymers, where one or more amino acid residues are artificial chemical analogs of naturally occurring amino acids, as well as to both naturally occurring and non-naturally occurring amino acid polymers. Unless otherwise stated, a particular peptide sequence also implicitly encompasses variants with conserved modifications. The term "sequence identity" refers to the degree (percentage) to which two sequences share the same amino acids / nucleic acids at equivalent positions when optimally aligned. During alignment, gaps may be introduced where necessary to achieve the maximum percentage of sequence identity, but any conserved substitutions are not considered part of the sequence identity. To determine the percentage of sequence identity, alignment can be performed using techniques known in the art, such as publicly available computer software like BLAST, BLAST-2, ALIGN, ALIGN-2, or Megalign (DNASTAR) software. Those skilled in the art can determine the parameters suitable for measuring alignment, including any algorithms required to achieve maximum alignment across the full length of the sequences being compared. The terms “fusion” or “linkage” refer to the direct or covalent connection of components (such as antigen-binding modules and Fc domains) via linkers. The term "vector" refers to a polynucleotide molecule capable of transporting another polynucleotide linked to it. One type of vector is a "plasmid," which is a circular double-stranded DNA loop in which an additional DNA segment can be attached. Another type of vector is a viral vector, such as an adeno-associated virus vector (AAV or AAV2), in which an additional DNA segment can be attached to the viral genome. Some vectors are capable of autonomous replication in the host cells to which they are introduced (e.g., bacterial vectors with bacterial origins of replication and attachable mammalian vectors). Other vectors (e.g., non-attached mammalian vectors) can integrate into the host cell's genome after introduction into the host cell, thereby replicating along with the host genome. The term "expression vector" or "expression construct" refers to a nucleic acid sequence suitable for transforming host cells and containing a sequence that directs and / or controls (alongside the host cell) the expression of one or more heterologous coding regions operatively linked to it. Expression constructs can include, but are not limited to, sequences that affect or control transcription, translation, and, in the presence of introns, influence RNA splicing of coding regions operatively linked to them. The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acids have been introduced, including the progeny of such cells. Host cells include “transformers” and “transformed cells,” which include primary transformed cells and their derived progeny, regardless of the number of passages. Progeny may not be identical to parental cells in their nucleic acid contents and may contain mutations. In this text, the term includes mutant progeny that have the same function or biological activity as cells screened or selected in primary transformed cells. Host cells include prokaryotic and eukaryotic host cells, with eukaryotic host cells including, but not limited to, mammalian cells, insect cell lines, plant cells, and fungal cells. Mammalian host cells include human, mouse, rat, dog, monkey, pig, goat, cow, horse, and hamster cells, including but not limited to Chinese hamster ovary (CHO) cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, and HEK-293 cells. Fungal cells include yeast and filamentous fungal cells, including, for example, *Pichia pastoris*, *Pichia finlandica*, *Pichia trehalophila*, and *Pichia cocco*. Pichia koclamae, Pichia membranaefaciens, Pichia minuta (Ogataea minuta, Pichia lindneri), Pichia xiaopuntiae, Pichia thermotolerans, Pichia salictaria, Pichia guercuum, Pichia pijperi, Pichia stiptis, Pichia methanolica, Pichia genus, Saccharomyces cerevisiae, Saccharomyces genus, Hansenula polymorpha, Kluyveromyces genus, Kluyveromyces lactis, Candida albicans, Aspergillus nidulans, Aspergillus nidulans *Aspergillus oryzae*, *Trichoderma reesei*, *Chrysosporium lucknowense*, *Fusarium* sp., *Fusarium gramineum*, *Fusarium venenatum*, *Physcomitrella patens*, and *Neurospora crassa*. *Pichia pastoris*, any *Saccharomyces* genus, *Hansenula polymorpha*, any *Kluyveromyces* genus, *Candida albicans*, any *Aspergillus* genus, *Trichoderma reesei*, *Chrysosporium lucknowense*, any *Fusarium* genus, *Yarrowia lipolytica*, and *Neurospora crassa*. The host cells of this patent do not include subject matter not authorized under patent law. "Optional" or "optionally" means that the event or circumstances described below may, but do not have to, occur, including the circumstances in which the event or circumstances may or may not occur. The term "pharmaceutical composition" means a mixture containing one or more antigen-binding molecules or antibodies described herein, along with other chemical components, such as physiological / pharmaceutical carriers and excipients. The term "pharmaceutically acceptable carrier" refers to a component in a pharmaceutical preparation that is different from the active ingredient and is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives. The terms “subject” or “individual” include both humans and non-human animals. Non-human animals include all vertebrates (e.g., mammals and non-mammals) such as non-human primates (e.g., cynomolgus monkeys), sheep, dogs, cattle, chickens, amphibians, and reptiles. Unless explicitly stated otherwise, the terms “patient” or “subject” are used interchangeably herein. As used herein, the term “cynomolgus monkey” refers to the cynomolgus monkey (Macaca fascicularis). In some embodiments, the individual or subject is a human. "Administration" or "giving," when applied to animals, humans, experimental subjects, cells, tissues, organs, or biological fluids, refers to the contact between an exogenous drug, therapeutic agent, diagnostic agent, or composition and the animal, human, subject, cell, tissue, organ, or biological fluid. The term "sample" refers to a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present within the subject's body. Exemplary samples include biological fluids such as blood, serum and serous fluid, plasma, lymph, urine, saliva, cystic fluid, tears, excretions, sputum, mucosal secretions of secretory tissues and organs, vaginal secretions, ascites, pleura, pericardium, peritoneum, fluids in the abdominal cavity and other body cavities, fluids collected from bronchoalveolar lavage fluid, synovial fluid, and liquid solutions that come into contact with the subject or biological sources. Examples include cell and organ culture media (including cell or organ conditioned media), irrigation solutions, tissue biopsy samples, fine needle aspiration, surgically removed tissue, organ cultures, or cell cultures. "Treatment" and "treatment" (and their grammatical variations) refer to a clinical intervention intended to be applied to the individual being treated, and can be implemented for preventative purposes or during a clinicopathological process. The desired effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, reducing / decreasing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and resolving or improving prognosis. In some implementations, the molecules disclosed herein are used to delay the onset of disease or slow its progression. The terms "recurrence," "relapse," and "relapsed" refer to the recovery of cancer or disease after a clinical assessment of disease resolution. A diagnosis of distant metastasis or local recurrence can be considered a recurrence. The terms "refractory" or "resistant" refer to cancers or diseases that do not respond to treatment. An "effective dose" is generally an amount sufficient to reduce the severity and / or frequency of symptoms, eliminate these symptoms and / or underlying causes, prevent the occurrence of symptoms and / or underlying causes, and / or improve or mitigate damage caused by or associated with a disease state. In some embodiments, an effective dose is a therapeutically effective dose or a preventatively effective dose. A "therapeuticly effective dose" is an amount sufficient to treat a disease state or symptom, especially a state or symptom associated with that disease state, or otherwise prevent, inhibit, delay, or reverse the progression of the disease state or any other undesirable symptom associated with that disease. A "preventatively effective dose" is an amount that, when administered to a subject, will have a predetermined preventative effect, such as preventing or delaying the onset (or recurrence) of the disease state, or reducing the likelihood of the onset (or recurrence) of the disease state or related symptoms. A complete therapeutic or preventative effect may not occur after the administration of a single dose, but may occur after the administration of a series of doses. Thus, a therapeutically or preventatively effective dose may be administered in a single or multiple-dose manner. "Therapeutic effective dose" and "preventive effective dose" can vary depending on a number of factors, such as an individual's disease state, age, sex, and weight, as well as the ability of the treatment or combination of treatments to elicit the desired response in the individual. Exemplary indicators of an effective treatment or combination of treatments include, for example, improved health status in the patient. The term "immune checkpoint" refers to a group of molecules on the cell surface of CD4 T cells and CD8 T cells. These molecules can effectively act as "brakes" to downregulate or inhibit anti-tumor immune responses. Immune checkpoint molecules include, but are not limited to, programmed death 1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), B7H1, B7H4, OX-40, CD137, CD40, and LAG-3, which directly inhibit immune cells. The immune checkpoint inhibitors used in this disclosure are substances that inhibit the function of immune checkpoint molecules. There are no particular limitations on the immune checkpoint inhibitors, as long as the inhibitor is a substance capable of inhibiting the function (signaling) of immune checkpoint molecules. Immune checkpoint inhibitors that can be used in the methods disclosed herein include, but are not limited to, inhibitors of PD-1, PD-L2, CTLA-4, TIM-3, LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CEACAM (e.g., CEACAM-1, CEACAM-3, and / or CEACAM-5) and / or TGFRβ. Inhibition of the inhibitory molecule can be implemented at the DNA, RNA, or protein level. In embodiments, inhibitory nucleic acids (e.g., dsRNA, siRNA, or shRNA) can be used to inhibit the expression of the inhibitory molecule. In other embodiments, the inhibitor of the inhibitory signal is a polypeptide that binds to the inhibitory molecule, such as a soluble ligand or antibody. Examples of immune checkpoint inhibitors used in this disclosure include… Including, but not limited to, anti-PD-1 antibodies, anti-PD-L1 antibodies, and anti-CTLA-4 antibodies, with anti-PD-1 antibodies and anti-PD-L1 antibodies being preferred. The antigen-binding molecules disclosed herein This disclosure provides antigen-binding molecules with many advantageous properties, such as good in vitro cytotoxic activity, therapeutic activity, safety, pharmacokinetic properties, and drugability (e.g., yield, purity, and stability). Exemplary antigen-binding molecules The antigen-binding molecules disclosed herein include bispecific antigen-binding molecules (e.g., bispecific antibodies) that specifically bind to CD28 and PSMA, and anti-CD28 antibodies. In particular, the antigen-binding molecules disclosed herein possess any of the following properties: a. High affinity for CD28. In some embodiments, the anti-CD28 antibody binds to human CD28 at an EC50 of less than 1 nM, wherein the EC50... 50 It is measured using ELISA. b. High affinity for CD28 and PSMA on the cell surface. c. In vitro activation activity against T cells. In some embodiments, the antigen-binding molecule activates IL-2-expressing Jurkat cells at an EC50 of less than 0.1 μg / mL in the presence of a first activation signal. d. When used in combination with a PSMA / CD3 bispecific antibody, it induces the release of low levels of cytokines (IL6 and IFNγ). e. Enhanced in vivo therapeutic activity. In some implementations, combination with PSMA / CD3 bispecific antibodies or anti-PD-1 antibodies results in better in vivo therapeutic activity. f. When used in combination with PSMA / CD3 bispecific antibodies, it can significantly increase the killing effect of PSMA / CD3 bispecific antibodies on tumor cells. This disclosure provides an antigen-binding molecule comprising at least one antigen-binding module specifically binding to CD28 and at least one antigen-binding module specifically binding to PSMA, wherein the CD28-binding antigen-binding module comprises CD28-VH and CD28-VL, and the PSMA-binding antigen-binding module comprises PSMA-VH and PSMA-VL. This disclosure also provides an anti-CD28 antibody capable of specifically binding to CD28, wherein the antibody comprises CD28-VH and CD28-VL. Specifically, the embodiments herein disclose antibody series 81, 94, 97, and 129. The antibodies herein are described using antibodies 97 and 94 as examples. Antigen-binding molecules or anti-CD28 antibodies that specifically bind to CD28 and PSMA, wherein: (i) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 19, CD28-HCDR2 as shown in SEQ ID NO: 20, and CD28-HCDR3 as shown in SEQ ID NO: 21, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 22, CD28-LCDR2 as shown in SEQ ID NO: 23, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93, and CD28-LCDR3 as shown in SEQ ID NO: 24; or (ii) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 13, CD28-HCDR2 as shown in SEQ ID NO: 14, and CD28-HCDR3 as shown in SEQ ID NO: 15, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 16, and CD28-LCDR1 as shown in SEQ ID NO: 17, 54, 54, 54, 55, 56, 57, 58, 58, 59 ... CD28-LCDR2 as shown in 55, 56, 57, 58, 59, 60, 61 or 62 and CD28-LCDR3 as shown in SEQ ID NO: 18. Antigen-binding molecules or anti-CD28 antibodies that specifically bind to CD28 and PSMA, wherein: (i) The CD28-VH comprises CD28-HCDR1 as shown in SEQ ID NO: 19, CD28-HCDR2 as shown in SEQ ID NO: 20, and CD28-HCDR3 as shown in SEQ ID NO: 21, and the CD28-VL comprises CD28-LCDR1 as shown in SEQ ID NO: 22, CD28-LCDR2 as shown in SEQ ID NO: 23, and CD28-LCDR3 as shown in SEQ ID NO: 24; or (ii) The CD28-VH includes CD28-HCDR1 as shown in SEQ ID NO: 13, CD28-HCDR2 as shown in SEQ ID NO: 14 and CD28-HCDR3 as shown in SEQ ID NO: 15, and the CD28-VL includes CD28-LCDR1 as shown in SEQ ID NO: 16, CD28-LCDR2 as shown in SEQ ID NO: 62 and CD28-LCDR3 as shown in SEQ ID NO: 18. In some embodiments, the antigen-binding molecule or anti-CD28 antibody as described above, the CD28-VH and / or the CD28-VL are murine or humanized. In some embodiments, the CD28-VH and / or the CD28-VL are humanized. In some embodiments, the FR1, FR2, FR3, and FR4 of the humanized CD28-VH have at least 60%, 70%, 80%, or 90% sequence identity with the FR1, FR2, FR3, and FR4 of SEQ ID NO: 98; and the FR1, FR2, FR3, and FR4 of the humanized CD28-VL have at least 60%, 70%, 80%, or 90% sequence identity with the FR1, FR2, FR3, and FR4 of SEQ ID NO: 102. In some embodiments, the humanized CD28-VH has FR1, FR2, FR3 derived from IGHV1-46*01 and FR4 derived from IGHJ6*01, and is either unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1E, 26A, 29L, 69L, 71V, 78A, and 93S; and / or the humanized CD28-VL has FR1, FR2, FR3 derived from IGKV1-33*01 and FR4 derived from IGKJ4*01, and is either unsubstituted or has one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44I, and 71Y. In some embodiments, the amino acid positions in the variable regions are defined according to the Kabat numbering rules. In some embodiments, the humanized CD28-VH comprises the amino acid sequence of SEQ ID NO: 98 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 26A, 29L, 69L, 71V, 78A, and 93S in the FR region of SEQ ID NO: 98. In some embodiments, the humanized CD28-VL comprises the amino acid sequence of SEQ ID NO: 102 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 41D, 42G, 43T, 44I, and 71Y in the FR region of SEQ ID NO: 102. In some embodiments, the FR1, FR2, FR3, and FR4 of the humanized CD28-VH have at least 60%, 70%, 80%, or 90% sequence identity with the FR1, FR2, FR3, and FR4 of SEQ ID NO: 69; and the FR1, FR2, FR3, and FR4 of the humanized CD28-VL have at least 60%, 70%, 80%, or 90% sequence identity with the FR1, FR2, FR3, and FR4 of SEQ ID NO: 80. In some embodiments, the humanized CD28-VH has FR1 derived from IGHV1-3*01. FR2, FR3, and FR4 derived from IGHJ1*01, wherein the FR4 is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 1E, 28S, 69L, 71V, 73K, and 94S; and / or the humanized CD28-VL has FR1, FR2, FR3 derived from IGKV1-12*01 and FR4 derived from IGKJ4*01, wherein the FR1 is unsubstituted or has one or more amino acid substitutions selected from the group consisting of 43S and 70K. In some embodiments, the amino acid positions in the above-mentioned variable regions are defined according to the Kabat numbering rules. In some embodiments, the humanized CD28-VH comprises the amino acid sequence of SEQ ID NO: 69 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions selected from the group consisting of 28S, 69L, 71V, 73K, and 94S in the FR region of SEQ ID NO: 69. In some embodiments, the humanized CD28-VL comprises the amino acid sequence of SEQ ID NO: 80 or a variant thereof. In some embodiments, the variant comprises one or more amino acid substitutions in the FR region of SEQ ID NO: 80. In some embodiments, such as the antigen-binding molecule or anti-CD28 antibody described in any of the preceding claims, wherein the amino acid sequence of said CD28-VH has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 95, 35, 94, 96, 97, or 98, and the amino acid sequence of said CD28-VL has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 101, 36, 99, 100, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, or 115. In some embodiments, the amino acid sequence of CD28-VH is as shown in SEQ ID NO: 95, 35, 94, 96, 97 or 98, and the amino acid sequence of CD28-VL is as shown in SEQ ID NO: 101, 36, 99, 100, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 or 115. In some embodiments, as described in any of the preceding claims, the amino acid sequence of CD28-VH is as shown in SEQ ID NO: 94, and the amino acid sequence of CD28-VL is as shown in SEQ ID NO: 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 or 115, or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 95, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 or 115, or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 96, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 99 or 100, or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 97, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 99, 100 or 101. In some embodiments, the antigen-binding molecule or anti-CD28 antibody as described in any of the preceding claims, wherein the amino acid sequence of CD28-VH is shown in SEQ ID NO: 95, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 101. In some embodiments, such as the antigen-binding molecule or anti-CD28 antibody described in any of the preceding claims, wherein the amino acid sequence of said CD28-VH is identical to SEQ ID NO: 68, 33, 63, 64, 65, 66, 67 or 69. The CD28-VL has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity, and the amino acid sequence of the CD28-VL has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 80, 34, 70, 71, 72, 73, 74, 75, 76, 77, 78, or 79. In some embodiments, the amino acid sequence of the CD28-VH is as shown in SEQ ID NO: 68, 33, 63, 64, 65, 66, 67, or 69, and the amino acid sequence of the CD28-VL is as shown in SEQ ID NO: 80, 34, 70, 71, 72, 73, 74, 75, 76, 77, 78, or 79. In some embodiments, the antigen-binding molecule or anti-CD28 antibody as described in any of the preceding claims, wherein the amino acid sequence of CD28-VH is as shown in SEQ ID NO: 63, and the amino acid sequence of CD28-VL is as shown in SEQ ID NO: 70 or 71, or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 64, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 70, 71 or 72, or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 65, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 70, 71 or 72, or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 66, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 70, 71, 72, 74, 75, 76 or 79, or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 67, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 72, 74, 75, 76 or 79, or The amino acid sequence of CD28-VH is shown in SEQ ID NO: 68, and the amino acid sequence of CD28-VL is shown in SEQ ID NO: 72, 73, 74, 75, 76, 77, 78, 79 or 80. In some embodiments, such as the antigen-binding molecule or anti-CD28 antibody described in any of the preceding claims, the amino acid sequence of CD28-VH is shown as SEQ ID NO: 68, and the amino acid sequence of CD28-VL is shown as SEQ ID NO: 80. In some implementations, the antigen-binding molecule as described above, wherein: i) The PSMA-VH comprises PSMA-HCDR1 as shown in SEQ ID NO: 164, PSMA-HCDR2 as shown in SEQ ID NO: 165, and PSMA-HCDR3 as shown in SEQ ID NO: 166; and the PSMA-VL comprises PSMA-LCDR1 as shown in SEQ ID NO: 167, PSMA-LCDR2 as shown in SEQ ID NO: 168, and PSMA-LCDR3 as shown in SEQ ID NO: 169; or ii) The PSMA-VH includes PSMA-HCDR1 as shown in SEQ ID NO: 170, PSMA-HCDR2 as shown in SEQ ID NO: 171, and PSMA-HCDR3 as shown in SEQ ID NO: 172; and the PSMA-VL includes PSMA-LCDR1 as shown in SEQ ID NO: 173, PSMA-LCDR2 as shown in SEQ ID NO: 174, and PSMA-LCDR3 as shown in SEQ ID NO: 175. In some embodiments, as described in any of the preceding embodiments, the PSMA-VH and / or the PSMA-VL are murine or humanized. In some embodiments, the PSMA-VH and / or the PSMA-VL are humanized. In some embodiments, as described in any of the preceding embodiments, the antigen-binding molecule wherein: i) The amino acid sequence of the PSMA-VH is shown in SEQ ID NO: 197, 199, 332, 194, 195, 196 or 198, and the amino acid sequence of the PSMA-VL is shown in SEQ ID NO: 201, 202, 333 or 200; or ii) The amino acid sequence of the PSMA-VH is shown in SEQ ID NO: 204, 184 or 203, and the amino acid sequence of the PSMA-VL is shown in SEQ ID NO: 206, 185 or 205. In some embodiments, the antigen-binding molecule as described in the preceding one, wherein: i) The amino acid sequence of PSMA-VH is shown in SEQ ID NO: 204, and the amino acid sequence of PSMA-VL is shown in SEQ ID NO: 206; or ii) The amino acid sequence of PSMA-VH is shown in SEQ ID NO: 197, and the amino acid sequence of PSMA-VL is shown in SEQ ID NO: 201; or The PSMA-VH contains the amino acid sequence of SEQ ID NO: 199, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 202. In some implementations, the aforementioned variable area and CDR are defined according to the Kabat numbering rules. The antibody series 81 and 129 disclosed in the embodiments herein have similar technical scope to the antibody series 97 and 94 described above. Structure of antigen-binding molecules The bispecific antigen-binding molecules disclosed herein are not limited to a specific molecular structure, as long as they possess the desired antigen-binding function. For example, the bispecific antigen-binding molecules described herein can be bivalent (1+1), trivalent (2+1), or tetravalent (2+2). The antigen-binding module in the antigen-binding molecule can be any antibody fragment with antigen-binding activity, fused via a peptide linker. The peptide linkers disclosed herein (e.g., linkers 1 to 11) can be any suitable peptide chain, as long as the antigen-binding molecule can exhibit the desired antigen-binding activity. For example, the peptide linker can be a flexible peptide containing 1-50 or 3-20 amino acid residues. In some embodiments, each of the peptide linkers independently has an L1-(GGGGS)n-L2 structure, wherein L1 is a bond, A, GS, GGS (SEQ ID NO: 399), GGGS (SEQ ID NO: 400), SGGGGS (SEQ ID NO: 294), GGGTKLTVLGGG (SEQ ID NO: 401), n ​​is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and L2 is a bond, G, GG, GGG (SEQ ID NO: 295), or GGGG (SEQ ID NO: 256), and the peptide linker is not a bond. In some embodiments, the peptide linker is 3-15 amino acid residues in length. In some embodiments, each of the peptide linkers independently has a (GGGGS)n structure, wherein n is 1, 2, or 3. In some embodiments, the amino acid sequences of linker 1, linker 2, linker 3, and linker 4 are as shown in SEQ ID NO: 223. For example, the antigen-binding molecule disclosed herein has a first chain with the structure shown in formula (a), a second chain with the structure shown in formula (b), a third chain with the structure shown in formula (c-1), and a fourth chain with the structure shown in formula (d-1). (a)[CD28-VH]-[CH1]-[Fc1], (b)[CD28-VL]-[CL] (c-1)[PSMA-VH]-[GGGGS]-[Titin chain]-[Fc2], (d-1)[PSMA-VL]-[GGGGS]-[Obscurin chain], The structures shown in equations (a), (b), (c-1), and (d-1) are arranged from the N end to the C end. Exemplary antigen-binding molecules have: A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 239, a third strand containing the amino acid sequence SEQ ID NO: 249, and a fourth strand containing the amino acid sequence SEQ ID NO: 250. For example, the antigen-binding molecule comprises a first chain having the structure shown in formula (e-1), a second chain having the structure shown in formula (f-1), a third chain having the structure shown in formula (g), and a fourth chain having the structure shown in formula (h). (e-1)[CD28-VH]-[GGGGS]-[Titin chain]-[Fc1], (f-1)[CD28-VL]-[GGGGS]-[Obscurin chain], (g)[PSMA-VH]-[CH1]-[Fc2], (h)[PSMA-VL]-[CL], The structures shown in equations (e-1), (f-1), (g), and (h) are arranged from the N end to the C end. Exemplary antigen-binding molecules have: A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 272, and a fourth strand containing the amino acid sequence SEQ ID NO: 273; or A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 274, and a fourth strand containing the amino acid sequence SEQ ID NO: 275. Variants of antigen-binding molecules In some embodiments, amino acid sequence variants of the antigen-binding molecules provided herein are included. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of the antibody can be prepared by introducing suitable modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletion, and / or insertion, and / or substitution of residues within the amino acid sequence of the antigen-binding molecule. Any combination of deletions, insertions, and substitutions can be performed to obtain the final construct, provided that the final construct possesses the desired characteristics, such as antigen-binding properties. Replace, insert, and delete variants In some embodiments, antigen-binding molecule variants with one or more amino acid substitutions are provided. Substitutions can be made in CDR and FR. Conservative substitutions are shown in Table 2 under the heading “Preferred Substitutions.” More substantial variations are provided in Table 2 under the heading “Exemplary Substitutions” and are further described below with reference to the amino acid side chain categories. Amino acid substitutions can be introduced into antibodies of interest, and the product can be screened for desired activities, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC. Table 2. Substitution of amino acids Based on common side-chain characteristics, amino acids can be grouped as follows: (1) Hydrophobic: Leucine, Met, Ala, Val, Leu, Ile; (2) Neutral and hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) Alkaline: His, Lys, Arg; (5) Residues that affect chain orientation: Gly, Pro; (6) Aromatic: Trp, Tyr, Phe. Non-conservative substitution refers to replacing a member of one category with a member of another category. One class of substitution variants involves replacing one or more CDR residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variants selected for further research will have alterations (e.g., improvements) to certain biological properties (e.g., increased affinity, decreased immunogenicity) relative to the parent antibody, and / or will substantially retain certain biological properties of the parent antibody. An exemplary substitution variant is an affinity-matured antibody, which can be conveniently generated, for example, using phage display-based affinity maturation techniques (such as those described herein). In short, one or more CDR residues are mutated, the variant antibody is displayed on a phage, and it is screened for specific biological activities (e.g., binding affinity). CDRs can be altered (e.g., substituted), for example, to improve antibody affinity. CDR “hotspots,” i.e., in somatic cells, can be modified. During the maturation process, residues encoded by codons undergo high-frequency mutations, and / or residues that contact the antigen are altered, while binding affinity is tested on the resulting variants VH or VL. In some embodiments of affinity maturation, diversity is introduced into the selected variant gene for maturation using any of a variety of methods, such as error-prone PCR, strand shuffling, or oligonucleotide-directed mutagenesis. A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method for introducing diversity involves CDR-directed approaches, where several CDR residues (e.g., 4-6 residues at a time) are randomized. CDR residues involved in antigen binding can be specifically identified, for example, using alanine scan mutagenesis or modeling. In some embodiments, substitution, insertion, or deletion may occur within one or more CDRs, as long as such changes do not materially reduce the antibody's ability to bind to the antigen. For example, conserved changes (e.g., conserved substitutions, as provided herein) may be made to CDRs that do not materially reduce binding affinity. In some embodiments of the variant VH and VL sequences provided above, each CDR is unchanged or contains no more than one, two, or three amino acid substitutions. One method for identifying residues or regions in an antibody that can serve as mutagenic targets is called "alanine scan mutagenesis." In this method, a residue or group of residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) is identified and substituted with a neutral or negatively charged amino acid (e.g., Ala or polyalanine) to determine if the antibody-antigen interaction is affected. Further substitutions can be introduced at amino acid positions that show functional sensitivity to the initial substitution. Furthermore, the contact points between the antibody and antigen can be identified by studying the crystal structure of the antigen-antibody complex. These contact residues and adjacent residues can be targeted or eliminated as substitution candidates. Variants can be screened to determine if they contain the desired properties. Amino acid sequence insertions include: peptides with one residue fused to the amino and / or carboxyl terminus or with a length of 100 or more residues; and intra-sequence insertions of one or more amino acid residues. Examples of terminal insertions include antibodies having an N-terminal methionyl residue. Other insertion variants of antibody molecules include fusions of an enzyme (or a peptide that prolongs the serum half-life of the antibody) fused to the N or C terminus. Fab transformation In one aspect, in the antigen-binding molecule disclosed herein, one of the antigen-binding modules specifically binding to PSMA and the antigen-binding module specifically binding to CD28 is a replaced Fab, said replaced Fab comprising a heavy chain variable region, a light chain variable region, a titin chain, and an obscurin chain. In the replaced Fab, the original CH1 and CL of the Fab are replaced by the titin chain and the obscurin chain. Exemplarily, the sequences of the titin chain and the obscurin chain are shown in Tables 3-1 and 3-2. Table 3-1. Amino acid sequence of the titin chain Table 3-2. Amino acid sequence of the obscurin chain Renovation of Fc District In one aspect, the Fc region of the antigen-binding molecule disclosed herein contains one or more amino acid substitutions that reduce its binding to an Fc receptor, such as an Fcγ receptor, and reduce or eliminate effector function. The native IgG Fc region, specifically the IgG1 Fc region or the IgG4 Fc region, may cause the antigen-binding molecule disclosed herein to target cells expressing an Fc receptor, rather than cells expressing an antigen. The modified Fc region of this disclosure exhibits reduced binding affinity to the Fc receptor and / or reduced effector function. In some embodiments, the modified Fc region exhibits a 50%, 80%, 90%, or 95% or more reduction in binding affinity to the Fc receptor compared to the native Fc region. In some embodiments, the Fc receptor is an Fcγ receptor. In some embodiments, the Fc receptor is a human Fcγ receptor, such as FcγRI, FcγRIIa, FcγRIIB, or FcγRIIIa. In some embodiments, the modified Fc region also exhibits reduced binding affinity for complement, such as C1q, compared to the natural Fc region. In some embodiments, the modified Fc region does not exhibit reduced binding affinity for neonatal Fc receptors (FcRn) compared to the natural Fc region. In some embodiments, the modified Fc region has reduced effector functions, which may include, but are not limited to, one or more of the following: reduced complement-dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent phagocytosis (ADCP), reduced cytokine secretion, reduced antigen uptake by immune complex-mediated antigen-presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling-induced apoptosis, reduced dendritic cell maturation, or reduced T cell initiation. For the IgG1 Fc region, amino acid residues at positions 238, 265, 269, 270, 297, 327, and 329 replace potentially degraded effector functions. In some embodiments, the Fc region is the human IgG1 Fc region, and amino acid residues at positions 234 and 235 are designated as A, numbered according to the EU index. For the IgG4 Fc region, amino acid residues at positions 228 replace potentially degraded effector functions. Antigen-binding molecules can also contain disulfide bond modifications, such as 354C in the first subunit and 349C in the second subunit. To increase the serum half-life of antigen-binding molecules, mutations in 252Y, 254T, and 256E can be introduced. When an antigen-binding molecule contains different binding modules fused to the two subunits of the Fc region, undesirable homodimerization may occur. To improve yield and purity, it is advantageous to introduce modifications that promote heterodimerization into the Fc region of the antigen-binding molecule disclosed herein. In some embodiments, the Fc region of this disclosure comprises a modification according to the knock-in-hole (KIH) technique, which involves introducing a protrusion (knob) at the interface of the first subunit and a hole (hole) at the interface of the second subunit. This allows the protrusion to be positioned within the hole, promoting heterodimer formation and inhibiting homodimer production. The protrusion is constructed by replacing a small amino acid side chain from the interface of the first subunit with a larger side chain (e.g., tyrosine or tryptophan). The hole is created at the interface of the second subunit by replacing a large amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine). The protrusion and hole structures are prepared by altering the nucleic acid encoding the polypeptide; optional amino acid substitutions are shown in the table below. Table 4. KIH Mutation Combinations Besides the mortar and pestle technique, other techniques for modifying the CH3 domain of heavy chains to achieve heterodimerization are also known in the art, such as WO1996027011A1, WO1998050431, EP1870459, WO2007110205, WO2009089004, WO2010129304, WO201190754, WO2011143545, WO2012058768, WO2013157954 and WO2013096291. The C-terminus of the Fc region can be a complete C-terminus ending with the amino acid residue PGK; or it can be a truncated C-terminus, for example, in which one or two C-terminal amino acid residues have been removed. In a preferred aspect, the C-terminus of the heavy chain is a shortened C-terminus ending with PG. Thus, in some embodiments, the composition of a complete antibody may include an antibody population with all K447 residues and / or G446+K447 residues removed. In some embodiments, the composition of a complete antibody may include an antibody population without the removal of K447 residues and / or G446+K447 residues. In some embodiments, the composition of a complete antibody has an antibody population consisting of a mixture of antibodies with and without K447 residues and / or G446+K447 residues. Recombination method Antigen-binding molecules can be produced using recombinant methods. For these methods, one or more isolated nucleic acids encoding the antigen-binding molecule are provided. In the case of natural antibodies, natural antibody fragments, or bispecific antibodies with homodimeric heavy chains, two nucleic acids are required: one for the light chain or a fragment thereof, and one for the heavy chain or a fragment thereof. These nucleic acids encode the amino acid sequence containing the antibody VL and / or the amino acid sequence containing the antibody VH (e.g., the light and / or heavy chains of the antibody). These nucleic acids can be expressed on the same expression vector or on different expression vectors. In the case of bispecific antibodies with heterodimeric heavy chains, for example, four nucleic acids are required: one for the first light chain, one for the first heavy chain containing the Fc region polypeptide of the first heteromonomer, one for the second light chain, and one for the second heavy chain containing the Fc region polypeptide of the second heteromonomer. These four nucleic acids can be contained in one or more nucleic acid molecules or expression vectors, typically on two or three expression vectors, meaning that one vector can contain more than one of these nucleic acids. In one embodiment, this disclosure provides isolated nucleic acids encoding antibodies as described above. Such nucleic acids can independently encode any of the aforementioned polypeptide chains. In another aspect, this disclosure provides one or more vectors (e.g., expression vectors) comprising such nucleic acids. In yet another aspect, this disclosure provides host cells comprising such nucleic acids. In one embodiment, a method for preparing an antigen-binding molecule is provided, wherein the method includes culturing host cells comprising nucleic acids encoding said antibody, as provided above, under conditions suitable for antibody expression, and optionally recovering said antibody from the host cells (or host cell culture medium). To recombinantly generate antigen-binding molecules, nucleic acids encoding proteins are isolated and inserted into one or more vectors for further cloning and / or expression in host cells. These nucleic acids can be easily processed using standard procedures. They can be isolated and sequenced (e.g., by using oligonucleotide probes that can specifically bind to genes encoding antibody heavy and light chains), or produced by recombinant methods or obtained through chemical synthesis. Suitable host cells for cloning or expressing vectors encoding antibodies include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be produced in bacteria, particularly when glycosylation and Fc effector function are not required. After expression, antibodies can be separated from bacterial cell paste in soluble fractions and can be further purified. Besides prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are also suitable cloning or expression hosts for antibody-encoding vectors, including fungal and yeast strains whose glycosylation pathways have been "humanized," resulting in antibodies with partial or complete human glycosylation patterns. Suitable host cells for expressing (glycosylated) antibodies can also be derived from multicellular organisms (invertebrates and vertebrates); examples of invertebrate cells include plant and insect cells. Many baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfection of fall armyworm (Spodoptera frugiperda) cells; plant cell cultures can also be used as hosts, such as US5959177, US 6040498, US6420548, US 7125978, and US6417429; and vertebrate cells, such as mammalian cell lines adapted for growth in suspension, can also be used as hosts. Other examples of suitable mammalian host cell lines include SV40-transformed monkey kidney CV1 line (COS-7); human embryonic kidney line (293 or 293T cells); young hamster kidney cells (BHK); mouse seltoli cells (TM4 cells); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical cancer cells (HELA); canine kidney cells (MDCK); buffalo rat hepatocytes (BRL3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumors (MMT 060562); TRI cells; MRC 5 cells; and FS4 cells. Other suitable mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells; and myeloma cell lines such as Y0, NSO, and Sp2 / 0. For reviews of certain mammalian host cell lines suitable for antibody production, see, for example, Yazaki, P. and Wu, AM, Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2004), pp. 255-268. Diagnostic and therapeutic compositions In some embodiments, the antigen-binding molecules provided in this disclosure can be used to detect the presence of PSMA and / or CD3 in biological samples. As used herein, the term "detection" encompasses both quantitative and qualitative detection. In some embodiments, the biological sample comprises cells or tissues, such as tumor tissue. In one embodiment, an antigen-binding molecule is provided for use in a diagnostic or detection method. In another aspect, a method is provided for detecting the presence of PSMA and / or CD3 in a biological sample. In some embodiments, the method includes contacting the biological sample with an antigen-binding molecule under suitable conditions and detecting whether a complex is formed between the detection reagent and the antigen. Such methods can be in vitro or in vivo. In one embodiment, antigen-binding molecules are used to select subjects suitable for treatment; for example, PSMA and / or CD3 are biomarkers used for patient selection. Exemplary conditions, such as tumors or cancers, can be diagnosed using the antigen-binding molecules disclosed herein. In some embodiments, a labeled antigen-binding molecule is provided. The label includes, but is not limited to, direct... The modules for direct detection include markers or modules for direct detection (such as fluorescent, chromogenic, electronically dense, chemiluminescent, and radioactive markers) and modules for indirect detection (e.g., modules for indirect detection via enzyme reactions or molecular interactions, such as enzymes or ligands). In another aspect, pharmaceutical compositions comprising the said antigen-binding molecule are provided, for example, for any of the following treatment methods. In one aspect, the pharmaceutical composition comprises any antigen-binding molecule provided herein and a pharmaceutically acceptable carrier. In another aspect, the pharmaceutical composition comprises any antigen-binding molecule provided herein and at least one additional therapeutic agent. The pharmaceutical compositions of antigen-binding molecules described in this disclosure are prepared by mixing such antigen-binding molecules, having the desired purity, with one or more optional pharmaceutically acceptable carriers, wherein the pharmaceutical composition is in the form of a lyophilized composition or an aqueous solution. Formulations intended for in vivo administration are generally sterile. Sterility can be readily achieved, for example, by filtration through a sterile filter membrane. Treatment methods and routes of administration Any antigen-binding molecules provided in this article can be used for treatment. In another aspect, this disclosure provides the use of antigen-binding molecules in the manufacture or preparation of medicaments. In one embodiment, the medicament is used to treat proliferative diseases or tumors. And the medicament is present in an effective amount for the aforementioned diseases. In some embodiments, the effective amount is a daily dose or a weekly dose. In one such embodiment, the use further includes administering to a subject an effective amount of at least one additional therapeutic agent (e.g., one, two, three, four, five, or six additional therapeutic agents). The “subject” according to any of the above embodiments can be a human being. In another aspect, a pharmaceutical composition comprising the said antigen-binding molecule is provided, for example, for any of the pharmaceutical uses or treatment methods described above. In another embodiment, the pharmaceutical composition further comprises at least one additional therapeutic agent. The antigen-binding molecule disclosed herein can be used alone or in combination with other agents for treatment. For example, the antigen-binding molecule disclosed herein can be administered in combination with at least one additional therapeutic agent. In some embodiments, the additional therapeutic agent is a bispecific antibody that specifically binds to PSMA and CD3 or an anti-PD-1 antibody. The antigen-binding molecules (and any other therapeutic agents) disclosed herein may be administered by any suitable means, including parenteral, intrapulmonary, and intranasal administration, and, if local treatment is required, intralesional administration. Parenteral infusion includes intramuscular, intravenous, intra-arterial, intraperitoneal, or subcutaneous administration. Administration may be carried out via any suitable route, such as by injection, such as intravenous or subcutaneous injection, depending in part on whether the administration is short-term or long-term. Various dosing schedules are considered herein, including, but not limited to, single or multiple administrations at multiple time points, bolus administration, and pulsatile infusion. The antigen-binding molecules disclosed herein will be formulated, administered, and applied in accordance with good medical practice. Factors considered in this context include the specific disease being treated, the specific mammal being treated, the individual patient's clinical condition, the cause of the disease, the site of delivery of the reagent, the method of administration, the timing of administration, and other factors known to the medical practitioner. The antigen-binding molecules do not need to be formulated, but optionally may be formulated, with one or more reagents currently used for the prevention or treatment of the stated disease. Other such reagents The effective amount depends on the amount of antigen-binding molecules present in the pharmaceutical composition, the type of disease or treatment, and other factors discussed above. These are generally used at the same dosage and route of administration as described herein, or at about 1 to 99% of the dosage described herein, or at any dosage and any route of administration determined empirically / clinically to be appropriate. For the prevention or treatment of disease, the appropriate dose of the antigen-binding molecule disclosed herein (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of therapeutic molecule, the severity and duration of the disease, whether it is administered for prophylactic or therapeutic purposes, prior treatment, the patient's clinical history and response to the therapeutic molecule, and the judgment of the attending physician. The therapeutic molecule is appropriately administered to the patient either as a single dose or as part of a series of treatments. Depending on the type and severity of the disease, an antigen-binding molecule of about 1 μg / kg to 15 mg / kg may be a candidate initial dose for administration to the patient, whether, for example, by a single or multiple separate administrations or by continuous infusion. A typical daily dose may be in the range of about 1 μg / kg to 100 mg / kg or more, depending on the factors mentioned above. Accordingly, for a body weight of 50 kg, an exemplary unit daily dose is 50 μg to 5 g. Products In another aspect of this disclosure, an article of manufacture is provided comprising materials that can be used to treat, prevent, and / or diagnose the aforementioned conditions. The article of manufacture comprises a container and a label or package insert on or in conjunction with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The container can be formed from various materials such as glass or plastic. The container contains a composition, alone or in combination with another composition, that is effective in treating, preventing, and / or diagnosing the condition, and may have a sterile access port (e.g., the container may be an intravenous solution bag or vial with a stopper puncturable by a hypodermic needle). At least one active agent in the composition is an antigen-binding molecule of this disclosure. The label or package insert indicates that the use of the composition is for the treatment of a selected condition. Furthermore, the article of manufacture may comprise: (a) a first container containing a composition, wherein the composition contains an antigen-binding molecule of this disclosure; and (b) a second container containing a composition, wherein the composition contains additional cytotoxic agents or other therapeutic agents. The article of manufacture in this embodiment of the present disclosure may further comprise a package insert indicating that the composition can be used to treat a specific condition. Alternatively, or additionally, the article may further comprise a second (or third) container containing a pharmaceutically acceptable buffer solution. From a commercial and user perspective, it may further include other materials as needed, including additional buffers, diluents, filters, needles, and syringes. As an example, the article is prepared in the form of a kit. Examples and Test Cases The present disclosure is further described below with reference to examples and test cases, but these examples and test cases are not intended to limit the scope of the disclosure. Experimental methods in the examples and test cases of this disclosure that do not specify specific conditions are generally performed under conventional conditions, such as those described in Cold Spring Harbor's Antibody Technology Manual or Molecular Cloning Manual; or under conditions recommended by the raw material or commercial manufacturer. Reagents whose specific source is not specified are commercially available, conventional reagents. Example 1. Antigen-binding molecules containing Titin / Obscurin chains The Titin / Obscurin chain disclosed herein can be derived from any suitable polypeptide, including polypeptides derived from WO2021139758 (included herein in its entirety by reference) and CN202110527339.7 and the patents prior to which thereof are cited (included herein in its entirety by reference). A bispecific antibody is constructed, wherein CL is the constant region of the kappa light chain in WO2021139758 (sequence can be found in the specification).

[0377] The amino acid sequences of the Titin chain and Obscurin chain are shown in Tables 3-1 and 3-2. The linker sequences include GGGGS (SEQ ID NO: 223), ASTKG (SEQ ID NO: 397) or RTVAS (SEQ ID NO: 398). The amino acid sequences of Fc1, Fc2 and CH1 in this embodiment are shown below. Example 1 - Fc1 (knob, SEQ ID NO: 394) Example 1 - Fc2 (hole, SEQ ID NO: 222) Example 1-CH1 (SEQ ID NO: 219) 1.1 DI Bispecific Antibody Referring to Example 5 of WO2021139758, bispecific antibodies against hNGF and hRANKL, DI-2 to DI-20, were constructed, comprising the first heavy chain, second heavy chain, first light chain, and second light chain as described below: The first chain: from the N end to the C end, it is as follows: [VH1-I]-[connector 1]-[Obscurin chain]-[Fc2], The first light chain, from the N end to the C end, is as follows: [VL1-I] - [connector 2] - [Titin chain]. The second chain: from the N-terminus to the C-terminus, is: [VH2-D]-[CH1]-[Fc1], and The second light chain consists of the following sequence from the N-terminus to the C-terminus: [VL2-D]-[CL]; In this embodiment, VH1-I and VL1-I are the heavy chain variable region and light chain variable region of I0 in WO2021139758, respectively, and VH2-D and VL2-D are the heavy chain variable region and light chain variable region of D0 in WO2021139758, respectively. The structures of Obscurin chain, Titin chain, linker 1, and linker 2 in the DI bispecific antibody are shown in the table below. Table 5. Correspondence between Obscurin chain / Titin chain and linker in DI bispecific antibodies Note: The Titin and Obscurin chain numbers in the table are shown in Tables 3-1 and 3-2. The binding activity of bispecific antibodies DI-2 to DI-20 to their antigens was detected using the method described in Test Example 4 of WO2021139758. Thermostability studies were conducted on the antibodies. Methods: The antibody concentration was diluted to 5 mg / mL with PBS, and its thermostability was determined using a high-throughput differential scanning fluorometer (UNCHAINED, Unit). The results showed that the binding activity of the modified bispecific antibodies to the antigens did not change significantly; furthermore, compared to DI-2, the Tm1 (°C) and Tonset (°C) of DI-4 to DI-8, DI-10 to DI-16, and DI-20 were significantly improved, indicating superior thermostability of the bispecific antibodies. Table 6. Detection of binding activity of DI bispecific antibodies Table 7. Results of thermostability test of DI bispecific antibodies A solution containing DI bispecific antibody was prepared using a buffer solution of 10 mM acetic acid, pH 5.5, and 9% sucrose. The solution was incubated at 40°C for four weeks. After incubation, the antibody concentration was concentrated back to the initial concentration, and precipitation was observed. The results showed that precipitation occurred in the DI-2 bispecific antibody group, and DI-3 to DI-7 exhibited better stability compared to DI-2. Table 8. Precipitation of DI bispecific antibodies 1.2 PL Bispecific Antibody Construct bispecific antibodies against hPDL1 and hCTLA4: PL-1 to PL-19, comprising a first heavy chain, a second heavy chain, a first light chain, and a second light chain as described below: The first chain: from the N end to the C end, it is as follows: [VH1-P]-[connector 1]-[Obscurin chain]-[Fc1] The first light chain, from the N end to the C end, is as follows: [VL1-P]-[connector 2]-[Titin chain]. The second chain: from the N-terminus to the C-terminus, is: [VH2-L]-[CH1]-[Fc2], and The second light chain consists of the following sequence from the N-terminus to the C-terminus: [VL2-L]-[CL]; Among them, VH1-P and VL1-P are the heavy chain variable region and light chain variable region of the h1831K antibody in WO2020177733A1, respectively, and the amino acid sequences of VH2-L and VL2-L are shown below. The structures of the Obscurin chain, Titin chain, linker 1, and linker 2 in the PL bispecific antibody in this embodiment are shown in the table below. Table 9. Correspondence between Obscurin chain / Titin chain and linker in PL bispecific antibody Note: The Titin and Obscurin chain numbers in the table are shown in Tables 3-1 and 3-2. The binding activity of the PL bispecific antibody was detected using the ELISA method described in Test Example 4 of WO2021139758. The hPDL1 and hCTLA4 antigens were purchased from Sino Biology. The thermostability of the antibody was studied. Methods: The antibody concentration was diluted to 1.4-3 mg / mL with PBS, and its thermostability was determined using a high-throughput differential scanning fluorometer (UNCHAINED, Unit). The results showed that the PL bispecific antibody still exhibited good binding activity to the antigen; furthermore, compared with PL-1, the Tm1 (°C), Tagg 266 (°C), and Tonset (°C) of PL-2 to PL-19 were significantly improved, indicating superior thermostability of the bispecific antibody. Table 10. Detection of binding activity of PL bispecific antibody Table 11. Results of thermostability test of PL bispecific antibody 1.3 HJ Bispecific Antibody Construct HJ bispecific antibodies against hIL5 and hTSLP: HJ-3 to HJ11, comprising a first heavy chain, a second heavy chain, a first light chain, and a second light chain as described below: The first chain: from the N end to the C end, it is as follows: [VH1-H]-[connector 1]-[Titin chain]-[Fc1] The first light chain, from N to C, consists of: [VL1-H] - [connector 2] - [Obscurin chain]. The second chain: from the N-terminus to the C-terminus, is: [VH2-J]-[CH1]-[Fc2], and The second light chain consists of the following sequence from the N-terminus to the C-terminus: [VL2-J]-[CL]; In this embodiment, VH1-H and VL1-H are the heavy chain variable region and light chain variable region of H0 in WO2021139758, respectively, and VH2-J and VL2-J are the heavy chain variable region and light chain variable region of J1 in WO2021139758, respectively. The structures of Obscurin chain, Titin chain, linker 1, and linker 2 in the HJ bispecific antibody are shown in the table below. Table 12. Correspondence between Obscurin chain / Titin chain and linker in HJ bispecific antibodies The antigen-binding activity of the HJ bispecific antibody was detected according to the method in Test Example 4 of WO2021139758. The thermostability of the antibody was studied. The method was as follows: A diluted solution of the HJ bispecific antibody was prepared using a 10mM acetic acid pH 5.5 buffer solution containing 9% sucrose. The bispecific antibody was then concentrated by ultrafiltration to obtain HJ bispecific antibody solutions of different concentrations (the concentrations of HJ bispecific antibody are shown in Table 13-2). The concentrated solutions were then incubated at 40°C. The SEC purity of the samples was measured on day 0 (before the start of incubation at 40°C, D0), day 7 (day 7 of incubation at 40°C, D7), day 14 (day 14 of incubation at 40°C, D14), day 21 (day 21 of incubation at 40°C, D21), and day 28 (day 28 of incubation at 40°C, D28). Immediately after 28 days of incubation at 40°C, samples were taken to test the CE-SDS purity. Experimental results show that the binding activity of the HJ bispecific antibodies constructed in this study to the antigen did not change significantly; and, compared with HJ-3, the HJ-5 to HJ-11 bispecific antibodies have better thermal stability. Table 13-1. Detection of binding activity of HJ bispecific antibodies Table 13-2. Results of accelerated stability test of HJ bispecific antibody Example 2. Screening and identification of anti-human CD28 hybridoma antibodies 2.1 Cell line construction CHO-hPSMA, CHO-APC-hPSMA, CHO-hCD28, HEK293-hCD28, CHO-APC-hPSMA-PDL1, and Jurkat-PD1 cell lines were constructed, and the relevant protein sequences are as follows: The full-length gene encoding human PSMA or human CD28 was cloned into the mammalian cell expression vector pCDH. HEK293T cells (ATCC, CRL-11268) were co-transfected with three plasmids: pVSV-G, pCMV-dR8.91, and pCDH-hPSMA to package the virus. Forty-eight hours after transfection, the virus was collected and used to infect HEK293 (ATCC, CRL-1573), CHO-K1 (ATCC, CCL-61), or CHO-APC (Promega, JA9441) cells. After two weeks of selection under pressure, cell subcloning was performed. FACS analysis yielded CHO-hPSMA, CHO-APC-hPSMA, CHO-hCD28, and HEK293-hCD28 cell lines that highly expressed PSMA or CD28. The gene encoding human PDL1 or the full-length human PD1 gene was cloned into the mammalian cell expression vector pCDH, and HEK293T cells were co-transfected with three plasmids: pVSV-G, pCMV-dR8.91, and pCDH-hPSMA. After transfecting the virus with CRL-11268 for 48 hours, the virus was used to infect the CHO-APC-hPSMA or Jurkat (ATCC, TIB-152) cells described above. Cell sorting was performed by pressure screening to obtain CHO-APC-hPSMA-PDL1 and Jurkat-PD1 cell lines that highly express PDL1 or PD1. 2.2 Screening and Identification of Anti-CD28 Hybridoma Antibodies This disclosure describes the preparation of a monoclonal antibody against human CD28 using hybridoma technology. The resulting antibody binds specifically to human CD28 with high affinity and can cross-bind with cynomolgus monkey CD28. It also shows good binding activity to both human CD28 and cynomolgus monkey CD28 on the cell surface. Human CD28-his, human CD28-Fc, CHO-hCD28 cells, or HEK293-hCD28 cells were used as immunogens. The initial immunization was 50 μg of protein, with booster immunizations of 25 μg each time. Gold Adjuvant (Sigma Cat No.T2684) and Thermo Alum (Thermo Cat No. 77161) was used for cross-immunization with adjuvant. Cellular immunization was performed at 5E6 times per cycle. After the primary immunization and 7 booster immunizations, mice with high antibody titers in their serum were selected for spleen cell fusion. The immunogen sequence is as follows: After fusion, the hybridoma culture supernatant was analyzed based on the hybridoma cell growth density. Hybridomas exhibiting good binding activity to human CD28 on the cell surface and good activation function were screened. Monoclonal hybridoma cells were collected, and RNA was extracted using NucleoZol (MN) (following the kit instructions) and reverse transcribed (PrimeScript). TM Reverse Transcriptase (Takara, cat#2680A). The cDNA obtained by reverse transcription was amplified by PCR using a mouse Ig-Primer Set (Novagen, TB326Rev.B 0503) and then sequenced to obtain the CDR and amino acid sequence of the variable region of the antibody in the hybridoma cell line. Table 14. CDR of anti-CD28 antibodies Note: The underlined part is the CDR area obtained according to the Kabat numbering rules. Chimeric antibodies are obtained by combining the variable region sequence of the murine anti-CD28 antibody with the heavy chain and light chain constant regions shown in SEQ ID NO: 144 and SEQ ID NO: 145, respectively. For example, Chi81 represents a chimeric antibody comprising the m81 murine heavy chain variable region, the light chain variable region, and the heavy chain and light chain constant regions shown in SEQ ID NO: 144 and SEQ ID NO: 145. Chi94, Chi97, and Chi129 follow the same pattern. Example 3. Humanization of anti-CD28 monoclonal antibody The humanization of the murine antibody was performed according to methods published in numerous documents in the field. In short, upon obtaining... Based on the typical structure of the mouse antibody VH / VL CDR, homologous sequences of the light chain variable region (VL) and heavy chain variable region (VH) were searched from the human germline database. The sequences were sorted from high to low homology of the FR, and the germline with the highest FR homology was selected as the template. The CDR region of the mouse antibody was transplanted onto the human template, some amino acid mutations were made in the variable region, and the constant region of the mouse antibody was replaced with the human constant region to obtain the final humanized antibody. Humanization of 3-1.m81 antibody The humanized antibody for m81 uses FR1, FR2, and FR3 of IGKV1-12*01 and FR4 of IGKJ4*01 as templates for the light chain framework region; and FR1, FR2, and FR3 of IGHV1-46*01 and FR4 of IGHJ1*01 as templates for the heavy chain framework region. Optionally, amino acid residues at positions 43, 54, and / or 73 of the light chain variable region of the humanized antibody are substituted; and / or amino acid residues at positions 1, 69, 71, 73, 78, 94, 100a, 100b, and / or 100c of the heavy chain variable region of the humanized antibody are substituted. Table 15. Amino acid substitutions in humanized antibody 81 Note: R71V indicates that the 71st R is mutated to V according to the Kabat numbering system; 100a indicates that the Kabat numbering rules are followed. 100A position, and so on for the others. The CDRs of the humanized antibody against m81 are as follows: Table 16. CDRs of humanized antibody 81 The variable region sequence of the humanized antibody h81 is as follows: Note: Single underlined portions indicate CDRs, double underlined portions indicate amino acid substitution sites, and the remaining portions are... FR. Humanization of 3-2.m94 antibody The humanized antibody for m94 uses FR1, FR2, and FR3 of IGKV1-12*01 and FR4 of IGKJ4*01 as templates for the light chain framework region; and FR1, FR2, and FR3 of IGHV1-3*01 and FR4 of IGHJ1*01 as templates for the heavy chain framework region. Optionally, amino acid residues at positions 43, 50, 51, 53, 54, 55, and / or 70 of the light chain variable region of the humanized antibody are substituted; and / or amino acid residues at positions 1, 28, 66, 69, 71, 73, and / or 94 of the heavy chain variable region of the humanized antibody are substituted. Table 17. Amino acid substitutions in humanized antibody 94 Note: R94S indicates that the 94th R is mutated to S according to the Kabat numbering system. The CDR region sequence of the humanized antibody against m94 is as follows: Table 18. CDR of humanized antibody 94 The variable region sequence of the humanized antibody h94 is as follows: Note: Single underlined portions indicate CDRs, double underlined portions indicate amino acid substitution sites, and the remaining portions are... FR. Humanization of 3-3.m97 For the humanized antibody derived from murine antibody 97, FR1, FR2, and FR3 of IGKV1-33*01 and FR4 of IGKJ4*01 were selected as templates for the light chain framework region; FR1, FR2, and FR3 of IGHV1-46*01 and FR4 of IGHJ6*01 were selected as templates for the heavy chain framework region. Optionally, amino acid residues at positions 41, 42, 43, 44, 50, 51, 52, 53, 54, 55, 56, and / or 71 of the light chain variable region of the humanized antibody were substituted; and / or amino acid residues at positions 1, 26, 29, 69, 71, 78, and / or 93 of the heavy chain variable region of the humanized antibody were substituted. Table 19. Amino acid substitutions in humanized antibody 97 Note: F71Y indicates that the 71st F bit was mutated back to Y according to the Kabat numbering system. The CDR region of the m97 humanized antibody is as follows: Table 20. CDR of humanized antibody 97 The variable region sequence of the humanized antibody h97 is as follows: Note: Single underlined portions indicate CDRs, double underlined portions indicate amino acid substitution sites, and the remaining portions are... FR. 3-4.m129 humanization For the humanized antibody m129 derived from murine antibody, FR1, FR2, and FR3 of IGKV1-33*01 and FR4 of IGKJ4*01 were selected as templates for the light chain framework region; FR1, FR2, and FR3 of IGHV1-46*01 and FR4 of IGHJ6*01 were selected as templates for the heavy chain framework region. Optionally, amino acid residues at positions 41, 42, 43, 44, 50, 53, 54, 55, and / or 73 on the variable region of the light chain of the humanized antibody were substituted; and / or human... The amino acid residues at positions 1, 25, 30, 34, 52, 71 and / or 78 on the variable region of the heavy chain of the derived antibody are substituted. Table 21. Amino acid substitutions in human antibody 129 Note: P44V indicates that the 44th P bit was mutated to V according to the Kabat numbering system. The CDRs for the humanized antibody against m129 are as follows: Table 22. CDRs of humanized antibody 129 The variable region sequence of humanized antibody 129 is as follows: The heavy chain variable region and light chain variable region of the anti-CD28 humanized antibody were recombined with the heavy chain constant region hIgG1:CH1-Fc and the light chain constant region CL, respectively, to obtain the full-length humanized antibody. The following humanized antibodies against CD28 are disclosed: Table 23-1. Humanized Antibodies of the 81 Series Table 23-2. Humanized Antibodies of the 94 Series Table 23-3. Humanized Antibodies of the 97 Series Table 23-4. Humanized Antibodies of the 129 Series Table 23-5. Humanized Antibodies of the 129 Series For example, the full-length sequence of the anti-CD28 humanized antibody is as follows: The control antibodies used in this disclosure for the anti-CD28 antibody are as follows: REGN-hIgG1 was constructed with reference to patent US20190389951A1, and its sequence is as follows: The CD28 super agonist TGN1412 was prepared with reference to patent US07585960B2, and its specific sequence is as follows: Example 4. Screening and identification of anti-human PSMA hybridoma antibodies This disclosure describes the preparation of a monoclonal antibody against human PSMA using hybridoma technology. The resulting antibody binds specifically to human PSMA with high affinity and can cross-react with cynomolgus monkey PSMA; the antibody also exhibits good binding activity to both human PSMA and cynomolgus monkey PSMA on cell surfaces. Human PSMA-ECD-his, LnCap cells (ATCC), or CHOK1-hPSMA cells can be used as immunoassay reagents, or human PSMA-ECD-his and LnCap cells can be used as cross-immunoassay reagents. Gold Adjuvant (Sigma Cat No.T2684) and Thermo Alum (Thermo Cat No. 77161) was used as an adjuvant for cross-immunization of mice. Mice with high antibody titers (>307.2K) in their serum were selected after primary immunization and seven booster immunizations for spleen cell fusion. After fusion, the hybridoma culture supernatant was analyzed based on the hybridoma cell growth density. Highly viable monoclonal hybridoma cell lines were screened. Logarithmically growing hybridoma cells were collected, and RNA was extracted using NucleoZol (MN) (following the kit instructions) and subjected to reverse transcription (PrimeScript). TM Reverse Transcriptase (Takara, cat#2680A). The cDNA obtained from reverse transcription was amplified by PCR using a mouse Ig-Primer Set (Novagen, TB326 Rev.B 0503) and then sequenced. The amino acid sequences of the CDR and variable regions of the screened monoclonal hybridoma cell lines are as follows: Table 24. CDR of PSMA Antibody >13. Variable regions of mouse heavy chains: >13 Mouse-derived light chain variable regions: >15 Mouse-derived heavy chain variable regions: >15 Mouse-derived light chain variable regions: >19. Mouse-derived heavy chain variable region: >19. Mouse-derived light chain variable region: >31. Mouse-derived heavy chain variable region: >31. Mouse-derived light chain variable region: Note: The underlined area is the CDR area obtained according to the Kabat numbering rules. Chimeric antibodies are obtained by combining the variable region sequence of a murine anti-PSMA antibody with the heavy and light chain constant regions shown in SEQ ID NO: 144 and SEQ ID NO: 145. For example, Chi13 represents a chimeric antibody comprising 13 murine heavy chain variable regions, light chain variable regions, and the heavy and light chain constant regions shown in SEQ ID NO: 144 and SEQ ID NO: 145. Chi15, Chi19, and Chi31 follow the same pattern. Example 5: Humanization design of anti-human PSMA monoclonal antibody Humanization of murine monoclonal antibodies was performed according to methods published in numerous publications in the field. In short, based on the typical VH / VL CDR structure of the obtained murine antibody, homologous sequences of the light chain variable region (VL) and heavy chain variable region (VH) were searched from human germline databases. The CDR region of the murine antibody was transplanted onto a human template, and some residues of VL and VH were mutated to replace the constant region of the murine antibody with the human constant region, resulting in the final humanized molecule. 5-1. Humanization of Antibody 13 For the humanized antibody of murine antibody 13, FR1, FR2, and FR3 of IGHV2-26*01 and FR4 of IGHJ6*01 were selected as templates for the heavy chain framework region; FR1, FR2, and FR3 of IGKV1-39*01 and FR4 of IGKJ4*01 were selected as templates for the light chain framework region. Optionally, amino acids at positions 1, 30, 44, 49, 73, and / or 89 of the heavy chain variable region of the humanized antibody were substituted; and / or amino acids at positions 41, 42, 43, 44, and / or 71 of the light chain variable region of the humanized antibody were substituted. Table 25-1. Amino acid substitutions in humanized antibody 13 The sequence of the antibody variable region is as follows: Note: The underlined part is CDR, and the rest is FR. 5-2. Humanization of Antibody 15 The humanized antibody of mouse antibody 15 uses FR1, FR2, and FR3 of IGHV1-3*01 and FR4 of IGHJ1*01 as templates for the heavy chain framework region; and FR1, FR2, and FR3 of IGKV1-27*01 and FR4 of IGKJ2*01 as templates for the light chain framework region. Optionally, amino acids at positions 1, 2, 28, 44, 48, 67, 69, 71, 73, and / or 76 of the heavy chain variable region of the humanized antibody are substituted; and / or amino acids at positions 43, 60, and / or 100 of the light chain variable region of the humanized antibody are substituted. Table 25-2. Amino acid substitutions in humanized antibody 15 The sequence of the antibody variable region is as follows: Note: The underlined part is CDR, and the rest is FR. 5-3. Humanization of Antibody 19 For the humanized antibody of murine antibody 19, FR1, FR2, and FR3 of IGHV3-7*01 and FR4 of IGHJ6*01 were selected as templates for the heavy chain framework region; FR1, FR2, and FR3 of IGKV1-39*01 and FR4 of IGKJ4*01 were selected as templates for the light chain framework region. Optionally, the amino acid at position 3 of the heavy chain variable region of the humanized antibody was substituted; and / or the amino acid at position 71 of the light chain variable region of the humanized antibody was substituted. Table 25-3. Amino acid substitutions in humanized antibody 19 The sequence of the antibody variable region is as follows: Note: The underlined part is CDR, and the rest is FR. 5-4. Humanization of Antibody 31 For the humanized antibody of mouse antibody 31, FR1, FR2, and FR3 of IGHV3-7*01 and FR4 of IGHJ1*01 were selected as templates for the heavy chain framework region; FR1, FR2, and FR3 of IGKV1-39*01 and FR4 of IGKJ4*01 were selected as templates for the light chain framework region. Optionally, amino acid position 94 of the heavy chain variable region of the humanized antibody was substituted; and / or amino acids positions 43, 45, 48, and / or 70 of the light chain variable region of the humanized antibody were substituted. Table 25-4. Amino acid substitutions of humanized antibody 31 The sequence of the antibody variable region is as follows: Note: The underlined part is CDR, and the rest is FR. Example 6. Preparation of anti-PSMA / CD28 bispecific antibody The PSMA arm of the PSMA / CD28 bispecific antibody disclosed herein can be derived from any suitable anti-PSMA antibody. For example, the anti-PSMA arm of the bispecific antibody in this disclosure can be the variable region of any anti-PSMA antibody in Example 4, or the variable region of the PSMA arm disclosed in US20190389951A1. The variable region and CDR sequence of the PSMA arm in US20190389951A1 used in this disclosure are as follows: PSMA heavy chain variable region of bs16429D (also known as h20VH): PSMA light chain variable region (also known as h20VL) of bs16429D: Table 26. CDR of PSMA in h20 The structure of the PSMA-CD28 bispecific antibody molecule disclosed herein is as follows: Formula 1 is an asymmetric molecule containing four distinct chains, as detailed below: Chain 1: [CD28-VH]-[IgG1(CH1)]-[IgG1Fc(Knob)]; Chain 2: [CD28-VL]-[CL]; Chain 3: [PSMA-VH]-[linker 1a]-[Titin]-[IgG1Fc(Hole)]; and Chain 4: [PSMA-VL]-[Connector 1a]-[Obscurin]; Its schematic diagram is shown in Figure 1A (where: Ob represents Obscurin). Formula 2 is an asymmetric molecule containing four distinct chains, as detailed below: Chain 1: [CD28-VH]-[linker 1a]-[Titin]-[IgG1Fc(Knob)]; Chain 2: [CD28-VL]-[connector 1a]-[Obscurin]; Chain 3: [PSMA-VH]-[IgG1(CH1)]-[IgG1Fc(Hole)]; Chain 4: [PSMA-VL]-[CL]; Its schematic diagram is shown in Figure 1B (Ob represents Obscurin). The relevant sequences are as follows: Table 27. PSMA-CD28 Bispecific Antibody Disclosed herein The sequence of the bispecific antibody constructed using Formula 1 in this disclosure is as follows: 1. Chi81-F1 Chi81-F1 chain 1: Chi81-F1 chain 2: >Chi81-F1 chain 3; Chi81-F1 chain 4: 2. 81H1L1-F1 >81H1L1-F1 chain 1: >81H1L1-F1 chain 2: >81H1L1-F1 chain 3 (same as Chi81-F1 chain 3, SEQ ID NO: 228) >81H1L1-F1 chain 4 (same as Chi81-F1 chain 4, SEQ ID NO: 229) 3. 81H1L3-F1 >81H1L3-F1 chain 1 (same as 81H1L1-F1 chain 1, SEQ ID NO: 230) >81H1L3-F1 chain 2: >81H1L3-F1 chain 3 (same as Chi81-F1 chain 3, SEQ ID NO: 228) >81H1L3-F1 chain 4 (same as Chi81-F1 chain 4, SEQ ID NO: 229) 4. Chi94-F1 Chi94-F1 Chain 1: Chi94-F1 chain 2: >Chi94-F1 chain 3: (Same as Chi81-F1 chain 3, SEQ ID NO: 228) >Chi94-F1 chain 4: (Same as Chi81-F1 chain 4, SEQ ID NO: 229) 5. 94H3L2-F1 >94H3L2-F1 chain 1: >94H3L2-F1 chain 2: >94H3L2-F1 chain 3: (Same as Chi81-F1 chain 3, SEQ ID NO: 228) >94H3L2-F1 chain 4: (Same as Chi81-F1 chain 4, SEQ ID NO: 229) 6. 94H6L9-F1 >94H6L9-F1 chain 1: >94H6L9-F1 chain 2: >94H6L9-F1 chain 3: (Same as Chi81-F1 chain 3, SEQ ID NO: 228) >94H6L9-F1 chain 4: (Same as Chi81-F1 chain 4, SEQ ID NO: 229) 7. 94H6L12-F1 >94H6L12-F1 chain 1 (same as 94H6L9-F1 chain 1, SEQ ID NO: 237) >94H6L12-F1 chain 2: >94H6L12-F1 chain 3: (Same as Chi81-F1 chain 3, SEQ ID NO: 228) >94H6L12-F1 chain 4: (Same as Chi81-F1 chain 4, SEQ ID NO: 229) 8. 97H2L3-F1 >97H2L3-F1 chain 1: >97H2L3-F1 chain 2: >97H2L3-F1 chain 3: (Same as Chi81-F1 chain 3, SEQ ID NO: 228) >97H2L3-F1 chain 4: (Same as Chi81-F1 chain 4, SEQ ID NO: 229) 9. 97H2L1-4-F1 >97H2L1-4-F1 chain 1: (Same as 97H2L3-F1 chain 1, SEQ ID NO: 240) >97H2L1-4-F1 chain 2: >97H2L1-4-F1 chain 3: (Same as Chi81-F1 chain 3, SEQ ID NO: 228) >97H2L1-4-F1 chain 4: (Same as Chi81-F1 chain 4, SEQ ID NO: 229) 10.Chi129-F1 Chi129-F1 chain 1: Chi129-F1 chain 2: >Chi129-F1 chain 3: (Same as Chi81-F1 chain 3, SEQ ID NO: 228) >Chi129-F1 chain 4: (Same as Chi81-F1 chain 4, SEQ ID NO: 229) 11. 129H4L1-F1 >129H4L1-F1 chain 1: >129H4L1-F1 chain 2: >129H4L1-F1 chain 3: (Same as Chi81-F1 chain 3, SEQ ID NO: 228) >129H4L1-F1 chain 4: (Same as Chi81-F1 chain 4, SEQ ID NO: 229) 12. 81H1L3-15-F1 >81H1L3-15-F1 chain 1 (same as 81H1L1-F1 chain 1, SEQ ID NO: 230) >81H1L3-15-F1 chain 2 (same as 81H1L3-F1 chain 2, SEQ ID NO: 232) >81H1L3-15-F1 chain 3: >81H1L3-15-F1 chain 4: 13. 81H1L3-19-F1 >81H1L3-19-F1 chain 1: (Same as 81H1L1-F1 chain 1, SEQ ID NO: 230) >81H1L3-19-F1 chain 2: (Same as 81H1L3-F1 chain 2, SEQ ID NO: 232) >81H1L3-19-F1 chain 3: >81H1L3-19-F1 chain 4: 14. 81H3L3-15-F1 >81H3L3-15-F1 chain 1: >81H3L3-15-F1 chain 2 (same as 81H1L3-F1 chain 2, SEQ ID NO: 232) >81H3L3-15-F1 chain 3 (same as 81H1L3-15-F1 chain 3, SEQ ID NO: 247) >81H3L3-15-F1 chain 4 (81H1L3-15-F1 chain 4, SEQ ID NO: 248) 15. 81H3L3-19-F1 >81H3L3-19-F1 chain 1: (Same as 81H3L3-15-F1 chain 1, SEQ ID NO: 251) >81H3L3-19-F1 chain 2: (Same as 81H1L3-F1 chain 2, SEQ ID NO: 232) >81H3L3-19-F1 chain 3: (Same as 81H1L3-19-F1 chain 3, SEQ ID NO: 249) >81H3L3-19-F1 chain 4: (Same as 81H1L3-19-F1 chain 4, SEQ ID NO: 250) 16. 81H3L3-13-F1 >81H3L3-13-F1 chain 1: (Same as 81H3L3-15-F1 chain 1, SEQ ID NO: 251) >81H3L3-13-F1 chain 2: (Same as 81H1L3-F1 chain 2, SEQ ID NO: 232) >81H3L3-13-F1 chain 3: >81H3L3-13-F1 chain 4: 17. 81H3L3-31-F1 >81H3L3-31-F1 chain 1: ((same as 81H3L3-15-F1 chain 1, SEQ ID NO: 251) >81H3L3-31-F1 chain 2: (Same as 81H1L3-F1 chain 2, SEQ ID NO: 232) >81H3L3-31-F1 chain 3: >81H3L3-31-F1 chain 4: 18. 94H6L12-15-F1 >94H6L12-15-F1 chain 1: (Same as 94H6L9-F1 chain 1, SEQ ID NO: 237) >94H6L12-15-F1 chain 2: (Same as 94H6L12-F1 chain 2, SEQ ID NO: 239) >94H6L12-15-F1 chain 3: (Same as 81H1L3-15-F1 chain 3, SEQ ID NO: 247) >94H6L12-15-F1 chain 4: (81H1L3-15-F1 chain 4, SEQ ID NO: 248) 19. 94H6L12-19-F1 >94H6L12-19-F1 chain 1: (Same as 94H6L9-F1 chain 1, SEQ ID NO: 237) >94H6L12-19-F1 chain 2: (Same as 94H6L12-F1 chain 2, SEQ ID NO: 239) >94H6L12-19-F1 chain 3: (Same as 81H1L3-19-F1 chain 3, SEQ ID NO: 249) >94H6L12-19-F1 chain 4: (Same as 81H1L3-19-F1 chain 4, SEQ ID NO: 250) 20. 94H6L12-13-F1 >94H6L12-13-F1 chain 1: (Same as 94H6L9-F1 chain 1, SEQ ID NO: 237) >94H6L12-13-F1 chain 2: (Same as 94H6L12-F1 chain 2, SEQ ID NO: 239) >94H6L12-13-F1 chain 3: (Same as 81H3L3-13-F1 chain 3, SEQ ID NO: 252) >94H6L12-13-F1 chain 4: (Same as 81H3L3-13-F1 chain 4, SEQ ID NO: 253) 21. 94H6L12-31-F1 >94H6L12-31-F1 chain 1: (Same as 94H6L9-F1 chain 1, SEQ ID NO: 237) >94H6L12-31-F1 chain 2: (Same as 94H6L12-F1 chain 2, SEQ ID NO: 239) >94H6L12-31-F1 chain 3: (Same as 81H3L3-31-F1 chain 3, SEQ ID NO: 254) >94H6L12-31-F1 chain 4: (Same as 81H3L3-31-F1 chain 4, SEQ ID NO: 255) 22. 97H2L1-4-15-F1 >97H2L1-4-15-F1 chain 1: (Same as 97H2L3-F1 chain 1, SEQ ID NO: 240) >97H2L1-4-15-F1 chain 2: (Same as 97H2L1-4-F1 chain 2, SEQ ID NO: 242) >97H2L1-4-15-F1 chain 3: (Same as 81H1L3-15-F1 chain 3, SEQ ID NO: 247) >97H2L1-4-15-F1 chain 4 (81H1L3-15-F1 chain 4, SEQ ID NO: 248) 23. 97H2L1-4-19-F1 >97H2L1-4-19-F1 chain 1: (Same as 97H2L1-4-15-F1 chain 1, SEQ ID NO: 240) >97H2L1-4-19-F1 chain 2: (Same as 97H2L1-4-15-F1 chain 2, SEQ ID NO: 242) >97H2L1-4-19-F1 chain 3: (Same as 81H1L3-19-F1 chain 3, SEQ ID NO: 249) >97H2L1-4-19-F1 chain 4: (Same as 81H1L3-19-F1 chain 4, SEQ ID NO: 250) 24. 97H2L1-4-13-F1 >97H2L1-4-13-F1 chain 1: (Same as 97H2L1-4-15-F1 chain 1, SEQ ID NO: 240) >97H2L1-4-13-F1 chain 2: (Same as 97H2L1-4-15-F1 chain 2, SEQ ID NO: 242) >97H2L1-4-13-F1 chain 3: (Same as 81H3L3-13-F1 chain 3, SEQ ID NO: 252) >97H2L1-4-13-F1 chain 4: (Same as 81H3L3-13-F1 chain 4, SEQ ID NO: 253) 25. 97H2L1-4-31-F1 >97H2L1-4-31-F1 chain 1: (Same as 97H2L1-4-15-F1 chain 1, SEQ ID NO: 240) >97H2L1-4-31-F1 chain 2: (Same as 97H2L1-4-15-F1 chain 2, SEQ ID NO: 242) >97H2L1-4-31-F1 chain 3: (Same as 81H3L3-31-F1 chain 3, SEQ ID NO: 254) >97H2L1-4-31-F1 chain 4: (Same as 81H3L3-31-F1 chain 4, SEQ ID NO: 255) For example, the sequence of the PSMA / CD28 bispecific antibody constructed using Formula 2 is as follows: 26. 81H1L3-F2 >81H1L3-F2 chain 1: >81H1L3-F2 chain 2: >81H1L3-F2 chain 3: >81H1L3-F2 chain 4: 27. 97H2L3-F2 >97H2L3-F2 chain 1: >97H2L3-F2 chain 2: >97H2L3-F2 chain 3: (Same as 81H1L3-F2 chain 3, SEQ ID NO: 259) >97H2L3-F2 chain 4: (Same as 81H1L3-F2 chain 4, SEQ ID NO: 260) 28. 97H2L1-4-F2 >97H2L1-4-F2 chain 1: (Same as 97H2L3-F2 chain 1, SEQ ID NO: 261) >97H2L1-4-F2 chain 2: >97H2L1-4-F2 chain 3: (Same as 81H1L3-F2 chain 3, SEQ ID NO: 259) >97H2L1-4-F2 chain 4: (Same as 81H1L3-F2 chain 4, SEQ ID NO: 260) 29. 97H1L3-F2 >97H1L3-F2 chain 1: >97H1L3-F2 chain 2: >97H1L3-F2 chain 3: (Same as 81H1L3-F2 chain 3, SEQ ID NO: 259) >97H1L3-F2 chain 4: (Same as 81H1L3-F2 chain 4, SEQ ID NO: 260) 30.Chi129-F2 Chi129-F2 chain 1: Chi129-F2 chain 2: >Chi129-F2 chain 3: (Same as 81H1L3-F2 chain 3, SEQ ID NO: 259) >Chi129-F2 chain 4: (Same as 81H1L3-F2 chain 4, SEQ ID NO: 260) 31. 129H4L1-F2 >129H4L1-F2 chain 1: >129H4L1-F2 chain 2: >129H4L1-F2 chain 3: (Same as 81H1L3-F2 chain 3, SEQ ID NO: 259) >129H4L1-F2 chain 4: (Same as 81H1L3-F2 chain 4, SEQ ID NO: 260) 32. 129H7L5-F2 >129H7L5-F2 chain 1: >129H7L5-F2 chain 2: >129H7L5-F2 chain 3: (Same as 81H1L3-F2 chain 3, SEQ ID NO: 259) >129H7L5-F2 chain 4: (Same as 81H1L3-F2 chain 4, SEQ ID NO: 260) 33. 97H2L3-15-F2 >97H2L3-15-F2 chain 1: (Same as 97H2L3-F2 chain 1, SEQ ID NO: 261) >97H2L3-15-F2 chain 2: (Same as 97H2L3-F2 chain 2, SEQ ID NO: 262) >97H2L3-15-F2 chain 3: >97H2L3-15-F2 chain 4: 34. 97H2L3-19-F2 >97H2L3-19-F2 chain 1: (Same as 97H2L3-F2 chain 1, SEQ ID NO: 261) >97H2L3-19-F2 chain 2: (Same as 97H2L3-F2 chain 2, SEQ ID NO: 262) >97H2L3-19-F2 chain 3: >97H2L3-19-F2 chain 4: 35. 97H2L3-13-F2 >97H2L3-13-F2 chain 1 (same as 97H2L3-F2 chain 1, SEQ ID NO: 261) >97H2L3-13-F2 chain 2: (Same as 97H2L3-F2 chain 2, SEQ ID NO: 262) >97H2L3-13-F2 chain 3: >97H2L3-13-F2 chain 4: 36. 97H2L3-31-F2 >97H2L3-31-F2 chain 1: (Same as 97H2L3-F2 chain 1, SEQ ID NO: 261) >97H2L3-31-F2 chain 2: (Same as 97H2L3-F2 chain 2, SEQ ID NO: 262) >97H2L3-31-F2 chain 3: >97H2L3-31-F2 chain 4: 37. 129H4L1-15-F2 >129H4L1-15-F2 chain 1: (Same as 129H4L1-F2 chain 1, SEQ ID NO: 268) >129H4L1-15-F2 chain 2: (Same as 129H4L1-F2 chain 2, SEQ ID NO: 269) >129H4L1-15-F2 chain 3: (Same as 97H2L3-15-F2 chain 3, SEQ ID NO: 272) >129H4L1-15-F2 chain 4: (Same as 97H2L3-15-F2 chain 4, SEQ ID NO: 273) 38. 129H4L1-19-F2 >129H4L1-19-F2 chain 1: (Same as 129H4L1-F2 chain 1, SEQ ID NO: 268) >129H4L1-19-F2 chain 2: (Same as 129H4L1-F2 chain 2, SEQ ID NO: 269) >129H4L1-19-F2 chain 3: (Same as 97H2L3-19-F2 chain 3, SEQ ID NO: 274) >129H4L1-19-F2 chain 4: (Same as 97H2L3-19-F2 chain 4, SEQ ID NO: 275) 39. 129H4L1-13-F2 >129H4L1-13-F2 chain 1: (Same as 129H4L1-F2 chain 1, SEQ ID NO: 268) >129H4L1-13-F2 chain 2: (Same as 129H4L1-F2 chain 2, SEQ ID NO: 269) >129H4L1-13-F2 chain 3: (Same as 97H2L3-13-F2 chain 3, SEQ ID NO: 276) >129H4L1-13-F2 chain 4: (Same as 97H2L3-13-F2 chain 4, SEQ ID NO: 277) 40. 129H4L1-31-F2 >129H4L1-31-F2 chain 1: (Same as 129H4L1-F2 chain 1, SEQ ID NO: 268) >129H4L1-31-F2 chain 2: (Same as 129H4L1-F2 chain 2, SEQ ID NO: 269) >129H4L1-31-F2 chain 3: (Same as 97H2L3-31-F2 chain 3, SEQ ID NO: 278) >129H4L1-31-F2 chain 4: (Same as 97H2L3-31-F2 chain 4, SEQ ID NO: 279) Note: Double-underlined regions are Titin or Obscurin sequences, and italics indicate constant regions. The control molecule for the PSMA / CD28 bispecific antibody disclosed herein is REGN5678V. It was constructed based on bs16429D (also known as REGN-5678) in US20190389951A1, by replacing its Fc with the disclosed IgG1Fc (Knob) and IgG1Fc (Hole) to obtain REGN5678V, which shares a common light chain structure. The specific sequence is as follows: REGN5678V First Chain: REGN5678V Second Chain: REGN5678V Third Chain: Example 7: Preparation of anti-PSMA / CD3 bispecific antibody The CD3-binding molecule disclosed herein can be derived from any suitable antibody. Specifically, the embodiments disclosed herein use S107E. Table 28. CDR of S107E The S107E variable region sequence is as follows: The PSMA / CD3 bispecific antibody disclosed herein has the molecular structures of Formulas 1 and 5 as follows: Formula 1 is an asymmetric molecule, comprising: Chain 1: VH(anti-PSMA)-IgG1(CH1)-IgG1Fc(Knob, L234A / L235A / S354C / T366W); Chain 2: VL (anti-PSMA)-CL; Chain 3 (Ob-hole): VH(S107E)-linker 1a-Obscurin-IgG1Fc(Hole,L234A / L235A / Y349C / T366S / L368A / Y407V); and Chain 4 (VL-Titin): VL(S107E)-connector 1a-Titin. Its schematic diagram is shown in Figure 1C. >IgG1(CH1)(SEQ ID NO: 219) >CL(SEQ ID NO: 145) >IgG1Fc(Knob,L234A / L235A / S354C / T366W)(SEQ ID NO: 220) >Ob-hole (SEQ ID NO: 291) VL-Titin: VL(S107E)-connector 1a-Titin (SEQ ID NO: 292) Connector 1a (SEQ ID NO: 223) Note: The single-underline marked area is the CDR area of ​​the CD3 combined structural domain obtained according to the Kabat numbering rules. Double-underlined regions indicate Titin or Obscurin sequences, while italics indicate constant regions. The same applies below. Formula 5 is an asymmetric molecule, containing Chain 1: VH (anti-PSMA)-linker 2a-VL (anti-PSMA)-linker 3a-VH(S107E)-linker 2a-VL(S107E)-linker 4a-IgG1Fc(Hole,L234A / L235A / Y349C / T366S / L368A / Y407V); and Chain 3 (Fc(Knob)): IgG1Fc(Knob,L234A / L235A / S354C / T366W), the schematic diagram of which is shown in Figure 1D. >IgG1Fc(Knob,L234A / L235A / S354C / T366W)(SEQ ID NO: 220) >IgG1Fc(Hole,Y349C / T366S / L368A / Y407V)(SEQ ID NO: 221) Connector 2a: (SEQ ID NO: 293) Connector 3a: (SEQ ID NO: 294) Connector 4a: (SEQ ID NO: 295) Based on the amino acid sequences of the humanized antibodies 15 and 19, bispecific antibodies as shown below were constructed. Table 29. PSMA-CD3 Bispecific Antibody Disclosed herein In this designation, 15-F5-1 indicates that the molecule uses the variable region of antibody 15 and its humanized antibody as the PSMA-binding domain, and adopts Formula 5 as the molecular structure. hu15H4L2-F5-1 indicates that the chain uses hu15H4 as the heavy chain variable region, hu15L2 as the light chain variable region, and so on. The specific amino acid sequence is as follows: In addition, this disclosure also uses the PSMA-CD3 bispecific antibody CC-1, prepared with reference to patent WO2017121905A1, which has an IgG-scFv structure. The complete molecule contains two first chains and two second chains, as detailed below: Chain 1: [PSMA-VH]-[IgG constant region]-[linker 1b]-[CD3-VL]-[linker 2a]-[CD3-VH]; Chain 2: [PSMA-VL]-CL; The specific sequence is as follows: Table 30. Sequence of CC1 IgG constant region: CL: SEQ ID NO: 145 Connector 1b: SG Connector 2a: GGGGSGGGGSGGGGS SEQ ID NO: 293 The control molecule of the PSMA / CD3 bispecific antibody used in this disclosure is Aca-Mab, whose amino acid sequence is shown in SEQ ID NO: 382 in WO2017134158A1. This disclosure also relates to the combination of PSMA / CD28 bispecific antibody and anti-PD-1 antibody. The anti-PD-1 antibody used is prepared with reference to patent WO2020156509A1, and its specific sequence is as follows: Table 31. CDR region of anti-PD-1 antibody >PD-1VH PD-1VL: PD-1 heavy chain constant region: >PD-1 light chain constant region: PD-1 heavy chain: PD-1 light chain: In addition, the anti-CD3 antibody TNB383B-H was also used in the test examples disclosed herein, prepared according to WO2018052503A1, with the specific sequence as follows: TNB383B-H heavy chain: TNB383B-H Light Chain: Test case Test Example 1. Activation effect of CD28 monoclonal antibody on T cells To test the co-stimulatory effect of the CD28 antibody disclosed herein, this test case used Jurkat-NFAT lum (Promega, J133A) cells to detect the activation of Jurkat cells by the CD28 monoclonal antibody in solution. The method is as follows: Jurkat-NFAT lum cells were passaged in complete culture medium. Antibody was serially diluted with 1640 + 10% FBS, and 50 μL was added to each well of a 96-well ELISA plate. Jurkat-NFAT lum cells were collected by centrifugation, resuspended in 1640 + 10% FBS, and counted to 1E6 cells / mL. 50 μL (5E4 / well) of cells was added to each well of the antibody-containing 96-well ELISA plate. After incubation at 37°C for 6 hours, 50 μL of firefly-glo luciferase reporter gene assay reagent (Meilun Biotechnology Cat.#MA0519-2) was added to each well. After incubation at room temperature for 8 minutes, the liquid was transferred to a white plate and read using a multi-functional microplate reader (BMG Cat.#PHERAstar). The results are shown in Tables 32-1 to 32-4 below. Table 32-1. T-cell activation effect of humanized antibody 81 (bioluminescence value) Table 32-2. T cell activation effect of antibody 94 (bioluminescence value) Table 32-3. T-cell activation effect of humanized antibody 97 (bioluminescence value) Table 32-4. T-cell activation effect of humanized antibody 129 (bioluminescence value) The results showed that all the humanized antibodies (81, 94, 97, and 129) activated the T cell NFAT signaling pathway to a much lesser extent than the super agonist TGN1412. Test Example 2. Activation effect of CD28 monoclonal antibody combined with CD3 monoclonal antibody on T cells. To test the co-stimulatory effect of the disclosed CD28 antibody, this test case used Jurkat-IL2 lum cells (Promega, J129A) to detect the activation of Jurkat-IL2 lum cells by CD28 and CD3 monoclonal antibodies (TNB383B-H) in solution. The method is as follows: Jurkat-IL2 lum cells were cultured in 1640 complete medium and passaged every 2 days. Before the experiment, cells were pipetted and centrifuged, the supernatant was removed, and the cells were resuspended in PBS and centrifuged again. Cells were resuspended in 1640 complete medium again, counted, and the cell density was adjusted to 3E4 cells / 50μL / well. Cells were coated with 2μg / mL Anti-hu(H+L) onto a high-absorption cell culture plate and incubated for 2 hours. The supernatant was discarded, and 30ng / mL TNB383B-H was added, incubating for 0.5–1 hour. The supernatant was discarded, and diluted CD28 humanized antibody (starting from 3μg / mL, 3-fold diluted to 8 concentrations) was added, incubating for 1 hour. The supernatant was discarded. Add Jurkat-IL2-lum cells to a density of 3E4 cells / 50μL / well and culture overnight. For plate reading, add 50μL / well of firefly-glo luciferase reporter gene assay reagent (Meilun Bio Cat.#MA0519-2), incubate at room temperature in the dark for 10 minutes, and then use PheraStar to read the lumin signal. The results showed that TNB383B-H alone had a weak IL2 activation signal, but when used in combination with CD28 monoclonal antibody, it could enhance the IL2 activation signal. All antibodies 81, 94, 97, and 129 could activate the IL2 signaling pathway of T cells. Table 33. Activation results of various CD28 antibodies on the T cell IL2 signaling pathway after combination with CD3 monoclonal antibody. Test Example 3. Binding activity of anti-CD28 humanized monoclonal antibody to CD28 antigen To test the ability of the disclosed CD28-targeting humanized antibody to bind to the CD28 antigen, this test case used ELISA to detect the binding activity of the CD28 humanized antibody to human CD28 antigen (purchased from SinoBiological, 11524-HCCH) or monkey CD28 antigen (purchased from SinoBiological, 90182-C08H). Details are as follows: CD28 antigen was coated onto 96-well plates at a rate of 0.5 μg / well and incubated overnight at 4°C. After discarding the supernatant, the plates were blocked with 5% skim milk for 2 hours. Different concentrations of humanized antibodies were prepared using 1% BSA, starting at 200 nM and diluted 5-fold to obtain eight different concentrations. After washing the blocked 96-well plates twice, the humanized antibodies were added, and the plates were incubated at 4°C for 1 hour. After washing four times, the plates were incubated with anti-human IgG Fc-HRP secondary antibody (1:10000) at 4°C for 1 hour. The reaction was terminated with 0.1M sulfuric acid after TMB color development. The ELISA results are shown in Tables 34 and 35 below. Table 34. Binding interaction between humanized CD28 monoclonal antibodies and human CD28 antigen Table 35. Binding effect ...

Claims

1. An antigen-binding molecule that specifically binds CD28 and PSMA, said antigen-binding molecule comprising at least one antigen-binding module specifically binding CD28 and at least one antigen-binding module specifically binding PSMA, said antigen-binding module specifically binding CD28 comprising a heavy chain variable region CD28-VH and a light chain variable region CD28-VL, said antigen-binding module specifically binding PSMA comprising a heavy chain variable region PSMA-VH and a light chain variable region PSMA-VL; wherein: i) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 19, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 20, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 22, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 23, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 24; or ii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 13, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 14, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 15; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 16, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 62, 17, 54, 55, 56, 57, 58, 59, 60, or 61, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 18; or iii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25 or 117, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26 or 116, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, 118, 119, 120, 121, or 122, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or iv) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9, 39, 40, 41 or 42; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 43 or 11, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12; Preferably, i) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 19, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 20, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 21; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 22, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 23, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 24; or ii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 13, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 14, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 15; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 16, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 62, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 18; or iii) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 25, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 26, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 27; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 28, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 29, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 30; or iv) The CD28-VH comprises: CD28-HCDR1 containing the amino acid sequence of SEQ ID NO: 7, CD28-HCDR2 containing the amino acid sequence of SEQ ID NO: 8, and CD28-HCDR3 containing the amino acid sequence of SEQ ID NO: 9; and the CD28-VL comprises: CD28-LCDR1 containing the amino acid sequence of SEQ ID NO: 10, CD28-LCDR2 containing the amino acid sequence of SEQ ID NO: 43, and CD28-LCDR3 containing the amino acid sequence of SEQ ID NO: 12; More preferably, The antigen-binding molecule was subjected to a concentration of less than 2 × 10⁻⁶ at 25°C. -8 M binds to human CD28 via KD, which is measured by surface plasmon resonance.

2. The antigen-binding molecule according to claim 1, wherein: i) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 170, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 171, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 172; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 173, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 174, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 175; or ii) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 164, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 165, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 166; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 167, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 168, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 169; or iii) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 158, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 159, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 160; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 161, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 162, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 163; or iv) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 176, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 177, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 178; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 179, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 180, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 181; or v) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 213, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 214, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 215; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 216, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 217, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO:

218.

3. The antigen-binding molecule according to claim 1 or 2, wherein: i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, 35, 94, 96, 97 or 98, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101, 36, 99, 100, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 or 115; or ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, 33, 63, 64, 65, 66, 67 or 69, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80, 34, 70, 71, 72, 73, 74, 75, 76, 77, 78 or 79; or iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, 37, 123, 124, 125, 127, 128, 129, 130, 131, 132 or 133, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 38, 135, 136, 137, 138, 139, 140, 141, 142 or 143; or iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, 31, 45, 46, 47, 48, 49 or 53, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52, 32, 50 or 51; Preferably, i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, 94, 96, 97 or 98, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101, 99, 100 or 102, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101, 99, 100, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114 or 115, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 94, and the CD28-VL contains the amino acid sequences of SEQ ID NO: 99, 100, 101, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, or 115, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 96, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 99 or 100, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 97, and the CD28-VL contains the amino acid sequence of SEQ ID NO:

97. The amino acid sequence of ID NO: 99, 100 or 101, or ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80, 72, 73, 74, 75, 76, 77, 78, or 79, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 63, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70 or 71, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 64, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70, 71, or 72, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 65, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70, 71, or 72, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 66, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 70, 71, 72, 74, 75, 76, or 79, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 67, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 72, 74, 75, 76, or 79, or iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 135, 136, 137, 138, or 139, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 123, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 135, or 136, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 124, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 135; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 125, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134 or 135, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 127, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 137, 138, or 139; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 128, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 137, 138, 139, or 142; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 129, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134, 138, 139, 140, 141, 142, or 143, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 130, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 138, 140, 141, 142, or 143, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 131, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 138, 140, 141, 142, or 143, or iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52, 50, or 51, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 45, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO:

46. The amino acid sequence of ID NO: 50 or 52, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 47, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51, or The CD28-VH contains the amino acid sequence of SEQ ID NO: 48, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50 or 51; More preferably: i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; or ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; or iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; or iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO:

52.

4. The antigen-binding molecule according to any one of claims 1 to 3, wherein: i) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, 184 or 203, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206, 185 or 205; or ii) The PSMA-VH comprises the amino acid sequence of SEQ ID NO: 197, 332, 194, 195, 196, 198 or 199, and the PSMA-VL comprises the amino acid sequence of SEQ ID NO: 201, 333, 200 or 202; or iii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, 182, 189 or 190, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191, 183, 192 or 193; or iv) The PSMA-VH comprises the amino acid sequence of SEQ ID NO: 207 or 186, and the PSMA-VL comprises the amino acid sequence of SEQ ID NO: 208, 187, 209, or 210; or v) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; Preferably, i) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or ii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or iii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or iv) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO:

208.

5. The antigen-binding molecule according to any one of claims 1 to 4, wherein the antigen-binding module that specifically binds to CD28 or the antigen-binding module that specifically binds to PSMA comprises a Titin chain and an Obscurin chain capable of forming a dimer. Preferably, The titin chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 334 to SEQ ID NO: 352, and the obscurin chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 353 to SEQ ID NO: 393; More preferably, The titin chain contains the amino acid sequence of SEQ ID NO: 350, and the obscurin chain contains the amino acid sequence of SEQ ID NO:

388.

6. The antigen-binding molecule according to any one of claims 1 to 5, wherein the antigen-binding molecule further comprises an Fc region, wherein the Fc region is preferably an IgG Fc region, more preferably an IgG1 Fc region; More preferably, the Fc region contains one or more amino acid substitutions that can reduce the binding of the Fc region to the Fcγ receptor; Most preferably, the Fc region is the human IgG1 Fc region, and the amino acids at positions 234 and 235 are A, numbered according to the EU index.

7. The antigen-binding molecule of claim 6, wherein the Fc region comprises a first subunit Fc1 and a second subunit Fc2 capable of associating with each other, wherein Fc1 and Fc2 each independently have one or more amino acid substitutions that reduce homodimerization of the Fc region; Preferably, Fc1 has a protruding structure according to the pestle and mortar technique, and Fc2 has a hole structure according to the pestle and mortar technique; More preferably, the amino acid at position 366 of Fc1 is W; and the amino acid at position 366 of Fc2 is S, the amino acid at position 368 is A, and the amino acid at position 407 is V, with the numbering based on the EU index. Most preferably, Fc1 contains the amino acid sequence of SEQ ID NO: 220; and Fc2 contains the amino acid sequence of SEQ ID NO: 221 or 222.

8. The antigen-binding molecule of claim 7, wherein the antigen-binding molecule comprises an antigen-binding module that specifically binds to CD28 and an antigen-binding module that specifically binds to PSMA, wherein the antigen-binding module that specifically binds to CD28 is Fab; and the antigen-binding module that specifically binds to PSMA is a replaced Fab comprising a Titin chain and an Obscurin chain capable of forming a dimer. Preferably, The antigen-binding molecule comprises a first chain having the structure shown in formula (a) and a chain having the structure shown in formula (b). The structure includes a second chain, a third chain with the structure shown in equation (c), and a fourth chain with the structure shown in equation (d). (a)[CD28-VH]-[CH1]-[Fc1], (b)[CD28-VL]-[CL] (c)[PSMA-VH]-[Connector 1]-[Titin Chain]-[Fc2], (d) [PSMA-VL]-[Connector 2]-[Obscurin Chain] in: Linker 1 and linker 2 may be the same or different peptide linkers; or linker 1 and / or linker 2 may not exist; The structures shown in equations (a), (b), (c), and (d) are arranged from the N end to the C end; More preferably, wherein: i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 33, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 34; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 65, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 71; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 78; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 68, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 80; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 208; or ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 31, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 32; and the PSMA-VH contains the amino acid sequence of SEQ ID NO:

211. The amino acid sequence, and the amino acid sequence of the PSMA-VL containing SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 50; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 46, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 208; or iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO:

211. The amino acid sequence, and the amino acid sequence of the PSMA-VL containing SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 208; or iv) The CD28-VH contains the amino acid sequence of SEQ ID NO: 37, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 38; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO:

212. Most preferably, the antigen-binding molecule has: A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 239, a third strand containing the amino acid sequence SEQ ID NO: 249, and a fourth strand containing the amino acid sequence SEQ ID NO: 250; or A first strand containing the amino acid sequence SEQ ID NO: 226, a second strand containing the amino acid sequence SEQ ID NO: 227, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence of SEQ ID NO: 230, a second strand containing the amino acid sequence of SEQ ID NO: 231, a third strand containing the amino acid sequence of SEQ ID NO: 228, and a fourth strand containing the amino acid sequence of SEQ ID NO: 229; or A first strand containing the amino acid sequence of SEQ ID NO: 230, a second strand containing the amino acid sequence of SEQ ID NO: 232, a third strand containing the amino acid sequence of SEQ ID NO: 228, and a fourth strand containing the amino acid sequence of SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 233, a second strand containing the amino acid sequence SEQ ID NO: 234, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 235, a second strand containing the amino acid sequence SEQ ID NO: 236, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 238, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 237, and a strand containing the amino acid sequence SEQ ID NO: A second strand containing the amino acid sequence 239, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 240, a second strand containing the amino acid sequence SEQ ID NO: 241, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence of SEQ ID NO: 240, a second strand containing the amino acid sequence of SEQ ID NO: 242, a third strand containing the amino acid sequence of SEQ ID NO: 228, and a fourth strand containing the amino acid sequence of SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 243, a second strand containing the amino acid sequence SEQ ID NO: 244, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence SEQ ID NO: 245, a second strand containing the amino acid sequence SEQ ID NO: 246, a third strand containing the amino acid sequence SEQ ID NO: 228, and a fourth strand containing the amino acid sequence SEQ ID NO: 229; or A first strand containing the amino acid sequence of SEQ ID NO: 230, a second strand containing the amino acid sequence of SEQ ID NO: 232, a third strand containing the amino acid sequence of SEQ ID NO: 247, and a fourth strand containing the amino acid sequence of SEQ ID NO: 248; or A first strand containing the amino acid sequence SEQ ID NO: 230, a second strand containing the amino acid sequence SEQ ID NO: 232, a third strand containing the amino acid sequence SEQ ID NO: 249, and a fourth strand containing the amino acid sequence SEQ ID NO: 250; or A first strand containing the amino acid sequence SEQ ID NO: 251, a second strand containing the amino acid sequence SEQ ID NO: 232, a third strand containing the amino acid sequence SEQ ID NO: 247, and a fourth strand containing the amino acid sequence SEQ ID NO: 248; or A first strand containing the amino acid sequence SEQ ID NO: 251, a second strand containing the amino acid sequence SEQ ID NO: 232, a third strand containing the amino acid sequence SEQ ID NO: 249, and a fourth strand containing the amino acid sequence SEQ ID NO: 250; or A first strand containing the amino acid sequence SEQ ID NO: 251, a second strand containing the amino acid sequence SEQ ID NO: 232, a third strand containing the amino acid sequence SEQ ID NO: 252, and a fourth strand containing the amino acid sequence SEQ ID NO: 253; or A first strand containing the amino acid sequence SEQ ID NO: 251, a second strand containing the amino acid sequence SEQ ID NO: 232, a third strand containing the amino acid sequence SEQ ID NO: 254, and a fourth strand containing the amino acid sequence SEQ ID NO: 255; or A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 239, a third strand containing the amino acid sequence SEQ ID NO: 247, and a fourth strand containing the amino acid sequence SEQ ID NO: 248; or A first strand containing the amino acid sequence SEQ ID NO: 237, and a strand containing the amino acid sequence SEQ ID NO: A second strand containing the amino acid sequence 239, a third strand containing the amino acid sequence SEQ ID NO: 252, and a fourth strand containing the amino acid sequence SEQ ID NO: 253; or A first strand containing the amino acid sequence SEQ ID NO: 237, a second strand containing the amino acid sequence SEQ ID NO: 239, a third strand containing the amino acid sequence SEQ ID NO: 254, and a fourth strand containing the amino acid sequence SEQ ID NO: 255; or A first strand containing the amino acid sequence of SEQ ID NO: 240, a second strand containing the amino acid sequence of SEQ ID NO: 242, a third strand containing the amino acid sequence of SEQ ID NO: 247, and a fourth strand containing the amino acid sequence of SEQ ID NO: 248; or A first strand containing the amino acid sequence SEQ ID NO: 240, a second strand containing the amino acid sequence SEQ ID NO: 242, a third strand containing the amino acid sequence SEQ ID NO: 249, and a fourth strand containing the amino acid sequence SEQ ID NO: 250; or A first strand containing the amino acid sequence SEQ ID NO: 240, a second strand containing the amino acid sequence SEQ ID NO: 242, a third strand containing the amino acid sequence SEQ ID NO: 252, and a fourth strand containing the amino acid sequence SEQ ID NO: 253; or A first strand containing the amino acid sequence of SEQ ID NO: 240, a second strand containing the amino acid sequence of SEQ ID NO: 242, a third strand containing the amino acid sequence of SEQ ID NO: 254, and a fourth strand containing the amino acid sequence of SEQ ID NO:

255.

9. The antigen-binding molecule of claim 7, wherein the antigen-binding molecule comprises an antigen-binding module that specifically binds to CD28 and an antigen-binding module that specifically binds to PSMA, wherein the antigen-binding module that specifically binds to PSMA is Fab; and the antigen-binding module that specifically binds to CD28 is a replaced Fab comprising a Titin chain and an Obscurin chain capable of forming a dimer. Preferably, The antigen-binding molecule comprises a first chain having the structure shown in formula (e), a second chain having the structure shown in formula (f), a third chain having the structure shown in formula (g), and a fourth chain having the structure shown in formula (h). (e)[CD28-VH]-[Connector 3]-[Titin Chain]-[Fc1], (f) [CD28-VL]-[Connector 4]-[Obscurin Chain] (g)[PSMA-VH]-[CH1]-[Fc2], (h)[PSMA-VL]-[CL], in: Linker 3 and linker 4 may be the same or different peptide linkers; or linker 3 and / or linker 4 may not exist. The structures shown in equations (e), (f), (g), and (h) are arranged from the N end to the C end; More preferably, wherein: i) The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: The amino acid sequence of SEQ ID NO: 204, and the PSMA-VL containing the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 106; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 94, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 95, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 101; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 208; or ii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 44, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 52; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or iii) The CD28-VH contains the amino acid sequence of SEQ ID NO: 37, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 38; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 129, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 138; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 211, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 212; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: The amino acid sequence of SEQ ID NO: 204, and the PSMA-VL containing the amino acid sequence of SEQ ID NO: 206; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or The CD28-VH contains the amino acid sequence of SEQ ID NO: 126, and the CD28-VL contains the amino acid sequence of SEQ ID NO: 134; and the PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO:

208. Most preferably, the antigen-binding molecule has: A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 274, and a fourth strand containing the amino acid sequence SEQ ID NO: 275; or A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 272, and a fourth strand containing the amino acid sequence SEQ ID NO: 273; or A first strand containing the amino acid sequence SEQ ID NO: 257, a second strand containing the amino acid sequence SEQ ID NO: 258, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 263, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 264, a second strand containing the amino acid sequence SEQ ID NO: 265, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 266, a second strand containing the amino acid sequence SEQ ID NO: 267, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 268, a second strand containing the amino acid sequence SEQ ID NO: 269, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 270, a second strand containing the amino acid sequence SEQ ID NO: 271, a third strand containing the amino acid sequence SEQ ID NO: 259, and a fourth strand containing the amino acid sequence SEQ ID NO: 260; or A first strand containing the amino acid sequence SEQ ID NO: 261, and a strand containing the amino acid sequence SEQ ID NO: A second strand containing the amino acid sequence 262, a third strand containing the amino acid sequence SEQ ID NO: 276, and a fourth strand containing the amino acid sequence SEQ ID NO: 277; or A first strand containing the amino acid sequence SEQ ID NO: 261, a second strand containing the amino acid sequence SEQ ID NO: 262, a third strand containing the amino acid sequence SEQ ID NO: 278, and a fourth strand containing the amino acid sequence SEQ ID NO: 279; or A first strand containing the amino acid sequence SEQ ID NO: 268, a second strand containing the amino acid sequence SEQ ID NO: 269, a third strand containing the amino acid sequence SEQ ID NO: 272, and a fourth strand containing the amino acid sequence SEQ ID NO: 273; or A first strand containing the amino acid sequence SEQ ID NO: 268, a second strand containing the amino acid sequence SEQ ID NO: 269, a third strand containing the amino acid sequence SEQ ID NO: 274, and a fourth strand containing the amino acid sequence SEQ ID NO: 275; or A first strand containing the amino acid sequence SEQ ID NO: 268, a second strand containing the amino acid sequence SEQ ID NO: 269, a third strand containing the amino acid sequence SEQ ID NO: 276, and a fourth strand containing the amino acid sequence SEQ ID NO: 277; or A first strand containing the amino acid sequence SEQ ID NO: 268, a second strand containing the amino acid sequence SEQ ID NO: 269, a third strand containing the amino acid sequence SEQ ID NO: 278, and a fourth strand containing the amino acid sequence SEQ ID NO:

279.

10. A pharmaceutical composition comprising: The antigen-binding molecule according to any one of claims 1 to 9, and one or more pharmaceutically acceptable carriers, diluents, buffers or excipients; Preferably, the pharmaceutical composition further comprises a second therapeutic agent; More preferably, the second therapeutic agent is an antibody capable of specifically binding to CD3.

11. An isolated nucleic acid that encodes the antigen-binding molecule according to any one of claims 1 to 9.

12. A host cell comprising the isolated nucleic acid as described in claim 11.

13. A method of treating a disease, the method comprising administering to a subject a therapeutically effective amount of the antigen-binding molecule of any one of claims 1 to 9, or the pharmaceutical composition of claim 10; Preferably, the disease is a tumor; more preferably, the tumor is prostate cancer, kidney cancer, urothelial carcinoma, breast cancer, bladder cancer, primary liver cancer, pancreatic cancer, melanoma, glioblastoma, osteosarcoma, ovarian cancer, esophageal cancer, cervical squamous cell carcinoma, lung cancer, colorectal cancer, endometrial cancer, skin cancer, head and neck squamous cell carcinoma, brain cancer, gastroesophageal cancer, metastatic liver cancer, multiple myeloma, lymphoma, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or B-cell lymphoma; most preferably, the tumor cells or blood vessels near the tumor... Endothelial cells express PSMA.

14. The method of claim 13, further comprising using a second therapeutic agent; preferably, the second therapeutic agent comprises an antitumor agent, radiotherapy, an antibody-drug conjugate, a bispecific antibody, a bispecific antibody conjugated with an antitumor agent, an immune checkpoint inhibitor, or a combination thereof.

15. The method of claim 14, wherein the second therapeutic agent is a bispecific antibody that specifically binds to PSMA and CD3, comprising at least one antigen-binding module that specifically binds to PSMA and at least one antigen-binding module that specifically binds to CD3, wherein the antigen-binding module that specifically binds to PSMA comprises a heavy chain variable region PSMA-VH and a light chain variable region PSMA-VL, and the antigen-binding module that specifically binds to CD3 comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL; Preferably, i) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 164, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 165, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 166; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 167, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 168, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 169; or ii) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 170, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 171, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 172; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 173, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 174, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 175; or iii) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 158, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 159, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 160; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 161, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 162, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 163; or iv) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 176, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 177, and PSMA-HCDR3 containing the amino acid sequence of SEQ ID NO: 178; and the PSMA-VL comprises: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 179, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 180, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO: 181; or v) The PSMA-VH comprises: PSMA-HCDR1 containing the amino acid sequence of SEQ ID NO: 301, PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO: 302, and PSMA-HCDR2 containing the amino acid sequence of SEQ ID NO:

303. The PSMA-HCDR3 has the amino acid sequence of SEQ ID NO: 304; and the PSMA-VL has: PSMA-LCDR1 containing the amino acid sequence of SEQ ID NO: 305, PSMA-LCDR2 containing the amino acid sequence of SEQ ID NO: 306, and PSMA-LCDR3 containing the amino acid sequence of SEQ ID NO:

306. More preferably, i) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, 199, 332, 194, 195, 196 or 198, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201, 202, 333 or 200; or ii) The PSMA-VH comprises the amino acid sequence of SEQ ID NO: 204, 184 or 203, and the PSMA-VL comprises the amino acid sequence of SEQ ID NO: 206, 185 or 205; or iii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, 182, 189 or 190, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191, 183, 192 or 193; or iv) The PSMA-VH comprises the amino acid sequence of SEQ ID NO: 207 or 186, and the PSMA-VL comprises the amino acid sequence of SEQ ID NO: 208, 187, 209, or 210; or v) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 313, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 314; Most preferably, i) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 197, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 201; or The PSMA-VH contains the amino acid sequence of SEQ ID NO: 199, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 202; or ii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 204, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 206; or iii) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 188, and the PSMA-VL contains the amino acid sequence of SEQ ID NO: 191; or iv) The PSMA-VH contains the amino acid sequence of SEQ ID NO: 207, and the PSMA-VL contains the amino acid sequence of SEQ ID NO:

208.

16. The method of claim 15, wherein the CD3-specific antigen-binding module comprises a heavy chain variable region CD3-VH and a light chain variable region CD3-VL, wherein: i) The CD3-VH comprises: CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 283, CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 284, and CD3-HCDR3 containing the amino acid sequence of SEQ ID NO: 285; and the CD3-VL comprises: CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 286, CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 287, and CD3-LCDR3 containing the amino acid sequence of SEQ ID NO: 288; or ii) The CD3-VH comprises: CD3-HCDR1 containing the amino acid sequence of SEQ ID NO: 307, CD3-HCDR2 containing the amino acid sequence of SEQ ID NO: 308, and CD3-HCDR2 containing the amino acid sequence of SEQ ID NO:

309. The CD3-HCDR3 has an amino acid sequence; and the CD3-VL has: a CD3-LCDR1 containing the amino acid sequence of SEQ ID NO: 310, a CD3-LCDR2 containing the amino acid sequence of SEQ ID NO: 311, and a CD3-LCDR3 containing the amino acid sequence of SEQ ID NO:

312. More preferably, The CD3-VH contains the amino acid sequence of SEQ ID NO: 289, and the CD3-VL contains the amino acid sequence of SEQ ID NO: 290; or The CD3-VH contains the amino acid sequence of SEQ ID NO: 315, and the CD3-VL contains the amino acid sequence of SEQ ID NO:

316.

17. The method of claim 15 or 16, wherein the bispecific antibody that specifically binds to PSMA and CD3 comprises an Fc region; Preferably, the Fc region includes a first subunit Fc1 and a second subunit Fc2 that can associate with each other, wherein Fc1 has a protrusion structure according to the pestle and mortar technique, and Fc2 has a hole structure according to the pestle and mortar technique; More preferably, the amino acid at position 366 of Fc1 is W; and the amino acid at position 366 of Fc2 is S, the amino acid at position 368 is A, and the amino acid at position 407 is V, with the numbering based on the EU index. Most preferably, Fc1 contains the amino acid sequence of SEQ ID NO: 220; and Fc2 contains the amino acid sequence of SEQ ID NO: 221 or 222.

18. The method according to any one of claims 15 to 17, wherein the bispecific antibody that specifically binds PSMA and CD3 comprises an antigen-binding module that specifically binds PSMA and an antigen-binding module that specifically binds CD3, wherein both the antigen-binding module that specifically binds PSMA and the antigen-binding module that specifically binds CD3 are scFv. Preferably, The bispecific antibody that specifically binds to PSMA and CD3 comprises a first chain having the structure shown in formula (a) and a second chain having the structure shown in formula (b). (a)[PSMA-VH]-[Connector 6]-[PSMA-VL]-[Connector 7]-[CD3-VH]-[Connector 8]-[CD3-VL]-[Connector 9]-[Fc2], (b)[Fc1], in, The structures shown in formulas (a) and (b) are arranged from the N-terminus to the C-terminus, and the linkers 6, 7, 8 and 9 are the same or different peptide linkers; Most preferably, The bispecific antibody that specifically binds to PSMA and CD3 has: a first chain containing the amino acid sequence of SEQ ID NO: 296 and a second chain containing the amino acid sequence of SEQ ID NO: 220; or The bispecific antibody that specifically binds to PSMA and CD3 has: one containing SEQ ID NO: The first strand contains the amino acid sequence 297 and the second strand contains the amino acid sequence SEQ ID NO:

220.

19. The method according to any one of claims 15 to 17, wherein the bispecific antibody that specifically binds PSMA and CD3 comprises an antigen-binding module that specifically binds PSMA and an antigen-binding module that specifically binds CD3, wherein the antigen-binding module that specifically binds PSMA is a Fab; and the antigen-binding module that specifically binds CD3 is a replaced Fab comprising a Titin chain and an Obscurin chain capable of forming a dimer. Preferably, The bispecific antibody that specifically binds to PSMA and CD3 comprises a first chain having the structure shown in formula (c), a second chain having the structure shown in formula (d), a third chain having the structure shown in formula (e), and a fourth chain having the structure shown in formula (f). (c)[PSMA-VH]-[CH1]-[Fc1], (d)[PSMA-VL]-[CL], (e)[CD3-VH]-[Connector 10]-[Obscurin Chain]-[Fc2], (f) [CD3-VL]-[Connector 11]-[Titin Chain] in: The structures shown in formulas (c), (d), (e) and (f) are arranged from the N-terminus to the C-terminus, and the linkers 10 and 11 are the same or different peptide linkers; More preferably, The bispecific antibody that specifically binds to PSMA and CD3 has: a first chain containing the amino acid sequence of SEQ ID NO: 298, a second chain containing the amino acid sequence of SEQ ID NO: 275, a third chain containing the amino acid sequence of SEQ ID NO: 291, and a fourth chain containing the amino acid sequence of SEQ ID NO:

292.

20. The method according to any one of claims 15 to 17, wherein the bispecific antibody that specifically binds to PSMA and CD3 comprises two first chains of the structure shown in formula (a) and two second chains of the structure shown in formula (b): (a) [PSMA-VH]-[IgG constant region]-[linker 12]-[CD3-VL]-[linker 13]-[CD3-VH]; (b)[PSMA-VL]-CL; The structures shown in formulas (a) and (b) are arranged from the N-terminus to the C-terminus, and linkers 12 and 13 are the same or different peptide linkers; preferably, The bispecific antibody that specifically binds to PSMA and CD3 has two first strands containing the amino acid sequence of SEQ ID NO: 299 and two second strands containing the amino acid sequence of SEQ ID NO:

300.

21. The method of claim 14, wherein the second therapeutic agent is an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor targets PD-1 or CTLA4; preferably, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

22. The method of claim 21, wherein the anti-PD-1 antibody comprises a heavy chain variable region PD-1-VH and a light chain variable region PD-1-VL, wherein: The PD-1-VH comprises: PD-1-HCDR1 containing the amino acid sequence of SEQ ID NO: 319, PD-1-HCDR2 containing the amino acid sequence of SEQ ID NO: 320, and PD-1-HCDR3 containing the amino acid sequence of SEQ ID NO: 321; and the PD-1-VL comprises: PD-1-LCDR1 containing the amino acid sequence of SEQ ID NO: 322, PD-1-LCDR2 containing the amino acid sequence of SEQ ID NO: 323, and PD-1-LCDR3 containing the amino acid sequence of SEQ ID NO: 324; Preferably, The PD-1-VH contains the amino acid sequence of SEQ ID NO: 325, and the PD-1-VL contains the amino acid sequence of SEQ ID NO: 326; More preferably, The anti-PD-1 antibody comprises a heavy chain of the amino acid sequence of SEQ ID NO: 328 and a light chain of the amino acid sequence of SEQ ID NO: 329.